###begin article-title 0
###xml 70 79 <span type="species:ncbi:7955">zebrafish</span>
Transcriptome analysis of the response to chronic constant hypoxia in zebrafish hearts
###end article-title 0
###begin p 1
Communicated by G. Heldmaier.
###end p 1
###begin p 2
###xml 556 568 556 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Danio rerio)</italic>
###xml 582 605 582 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(Haplochromis piceatus)</italic>
###xml 545 554 <span type="species:ncbi:7955">zebrafish</span>
###xml 556 567 <span type="species:ncbi:7955">Danio rerio</span>
###xml 583 604 <span type="species:ncbi:143508">Haplochromis piceatus</span>
###xml 739 748 <span type="species:ncbi:7955">zebrafish</span>
Insufficient blood supply during acute infarction and chronic ischemia leads to tissue hypoxia which can significantly alter gene expression patterns in the heart. In contrast to most mammals, some teleost fishes are able to adapt to extremely low oxygen levels. We describe here that chronic constant hypoxia (CCH) leads to a smaller ventricular outflow tract, reduced lacunae within the central ventricular cavity and around the trabeculae and an increase in the number of cardiac myocyte nuclei per area in the hearts of two teleost species, zebrafish (Danio rerio) and cichlids (Haplochromis piceatus). In order to identify the molecular basis for the adaptations to CCH, we profiled the gene expression changes in the hearts of adult zebrafish. We have analyzed over 15,000 different transcripts and found 376 differentially regulated genes, of which 260 genes showed increased and 116 genes decreased expression levels. Two notch receptors (notch-2 and notch-3) as well as regulatory genes linked to cell proliferation were transcriptionally upregulated in hypoxic hearts. We observed a simultaneous increase in expression of IGF-2 and IGFbp1 and upregulation of several genes important for the protection against reactive oxygen species (ROS). We have identified here many novel genes involved in the response to CCH in the heart, which may have potential clinical implications in the future.
###end p 2
###begin title 3
Electronic supplementary material
###end title 3
###begin p 4
The online version of this article (doi:10.1007/s00360-007-0201-4) contains supplementary material, which is available to authorized users.
###end p 4
###begin title 5
Keywords
###end title 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2001</xref>
Low oxygen levels (hypoxia) play important roles in clinical conditions such as stroke and heart failure. Insufficient blood supply leads to tissue hypoxia in the heart during acute infarction and chronic ischemia (Semenza 2001).
###end p 7
###begin p 8
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2003</xref>
###xml 789 793 789 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2003</xref>
###xml 813 817 813 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2007</xref>
###xml 821 825 821 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP </sub>
###xml 1074 1078 1070 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2003</xref>
###xml 1259 1263 1255 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2005</xref>
###xml 1242 1246 <span type="species:ncbi:10090">mice</span>
Effective protection of the heart against ischemia/reperfusion injury is one of the most important goals of experimental and clinical research in cardiology. Besides ischemic preconditioning as a powerful temporal protective phenomenon, adaptation to chronic hypoxia also increases cardiac tolerance to all major deleterious consequences of acute oxygen deprivation such as myocardial infarction, contractile dysfunction and ventricular arrhythmias (Kolar and Ostadal 2003). Although many factors have been proposed to play potential roles, the detailed mechanism of this long-term protection remains poorly understood. Some of the molecular mechanisms of cardiac protection by adaptation to chronic hypoxia and chronic high-altitude hypoxia have recently been reviewed (Kolar and Ostadal 2003; Ostadal and Kolar 2007). KATP channels, PKCdelta as well as the different MAPK pathways were shown to be involved in the mechanism of increased tolerance of chronically hypoxic hearts and further the controversial role of ROS in hypoxia tolerance is discussed (Kolar and Ostadal 2003). Furthermore, a recent study has profiled the gene expression changes induced by chronic constant hypoxia (CCH) and chronic intermittent hypoxia (CIH) in newborn mice (Fan et al. 2005).
###end p 8
###begin p 9
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2004</xref>
In contrast to most mammals (with the exception of some marine mammals), some teleosts, have developed the ability to withstand extreme chronic hypoxia (Stecyk et al. 2004). It is well assumed that these vertebrate species possess unique adaptations in order to survive short and long term oxygen deprivation. However, the molecular basis of these adaptations in fish has so far not been extensively investigated.
###end p 9
###begin p 10
###xml 145 166 145 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gillichthys mirabilis</italic>
###xml 450 454 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2001</xref>
###xml 670 674 670 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2005</xref>
###xml 145 166 <span type="species:ncbi:8222">Gillichthys mirabilis</span>
###xml 172 192 <span type="species:ncbi:8222">long-jawed mudsucker</span>
###xml 639 648 <span type="species:ncbi:7955">zebrafish</span>
Several studies have profiled gene expression changes in teleosts exposed to hypoxia. Gracey et al. showed in adults of the euryoxic gobiid fish Gillichthys mirabilis (the long-jawed mudsucker), that 5 days of hypoxia induced a complex transcriptional response, including a shut down of energy requiring pathways like protein synthesis and locomotion, and an induction of genes needed for anaerobic ATP production in different tissues (Gracey et al. 2001). Recently, we described phenotypic and behavioral adaptations to long-term hypoxia and described the gene expression changes induced by chronic constant hypoxia in the gills of adult zebrafish (van der Meer et al. 2005).
###end p 10
###begin p 11
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2003</xref>
###xml 56 65 <span type="species:ncbi:7955">zebrafish</span>
###xml 75 84 <span type="species:ncbi:7955">Zebrafish</span>
Ton et al. identified global gene expression changes in zebrafish embryos. Zebrafish embryos at 48 h post fertilization were exposed to water with 5% oxygen content for 24 h. The authors identified 138 genes responsive to short-term hypoxia and could also show that transcriptional changes indicated metabolic depression, a switch from aerobic to anaerobic metabolism and energy conservation (Ton et al. 2003).
###end p 11
###begin p 12
###xml 77 86 <span type="species:ncbi:7955">zebrafish</span>
###xml 124 133 <span type="species:ncbi:7955">zebrafish</span>
In this study, we have identified CCH-induced gene expression changes in the zebrafish heart by looking at over half of the zebrafish genome. We have compared several of these novel changes described in other species and tissues. We have here identified the heart-specific molecular adaptations to CCH. Future functional experiments are warranted to determine whether some of the findings can be used to better adapt mammalian hearts to CCH.
###end p 12
###begin title 13
Material and methods
###end title 13
###begin title 14
Animal handling
###end title 14
###begin p 15
###xml 27 38 27 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Danio rerio</italic>
###xml 111 132 111 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haplochromis piceatus</italic>
###xml 16 25 <span type="species:ncbi:7955">zebrafish</span>
###xml 27 38 <span type="species:ncbi:7955">Danio rerio</span>
###xml 111 132 <span type="species:ncbi:143508">Haplochromis piceatus</span>
###xml 462 471 <span type="species:ncbi:7955">Zebrafish</span>
Adult wild-type zebrafish (Danio rerio) around 3 month of age, were obtained from a local pet store. Cichlids (Haplochromis piceatus) have been collected in the Mwanza Gulf of Lake Victoria in 1984 and were bred in our laboratory for about 20 generations. All animals were handled in compliance with animal care regulations. Our animal protocols were approved by the review board of Leiden University in accordance with the requirements of the Dutch government. Zebrafish were kept at 25degreesC in aquaria with day/night light cycles (12 h dark vs. 12 h light). Cichlids were kept at 25degreesC with the same day/night light cycles.
###end p 15
###begin title 16
Hypoxia treatment
###end title 16
###begin p 17
###xml 272 273 272 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink">.</sub>
###xml 318 320 312 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 350 352 344 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 616 617 610 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 906 908 900 902 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
For gradual hypoxia treatment, oxygen levels were gradually decreased in 4 days from 100% air saturated water to 40% (day 1), 30% (day 2), 20% (day 3) and the final 10% air saturation (day 4). After day 4, the fish were kept for an additional 21 days at 10% air saturation. (at 100% air saturation and 28degreesC the O2 concentration is 8 mg/l and pO2 is 15 Torr). In parallel, a control group was kept at 100% air saturated water. Both groups were kept in identical aquaria of 100 l. The oxygen level on the hypoxia group was kept constant by a controller (Applikon Biotechnology, The Netherlands) connected to an O2-electrode and solenoid valve in line with an air diffuser. The oxygen level in the tank was kept constant by adding oxygen via the diffuser and thereby compensating the oxygen consumption of the fish. In case of immediate hypoxia exposure, tanks were pre-equilibrated to the respective pO2 concentration and fish were then directly set in the equilibrated aquaria.
###end p 17
###begin title 18
Perfusion of cichlid hearts
###end title 18
###begin p 19
In order to minimize blood clotting, a perfusion protocol was developed in which the whole blood volume of clinically dead animals was initially replaced with isotonic buffer and with a fixative solution secondarily.
###end p 19
###begin title 20
Heart dissection
###end title 20
###begin p 21
The fish were killed with an overdose of anesthetic (MS-222; Tricaine Methanesulfonate from Argent Chemical Laboratories, USA). Hearts were dissected from the fish immediately after the anesthetic worked. For RNA preparation the hearts were immediately shock-freezed in liquid nitrogen. For histology and microscopy, the hearts were left intact and fixed immediately in Karnovsky fixative (4% paraformaldehyde (PFA) and 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.2) for 4 h at 4degreesC. After three washes in 0.1 M phosphate buffer, pH 7.2, they were transferred to 70% ethanol.
###end p 21
###begin title 22
Histology of adult fish hearts, statistical analysis and scanning electron microscopy
###end title 22
###begin p 23
###xml 1254 1258 1241 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2006</xref>
###xml 1872 1876 1853 1857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2005</xref>
###xml 1997 1998 1978 1979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2007 2008 1988 1989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 12 21 <span type="species:ncbi:7955">zebrafish</span>
Hearts from zebrafish and cichlids raised either under normoxic or hypoxic conditions, were dissected from the fish and fixed for 24 h in 4% PFA in PBS. After fixation, hearts were washed with 1 x PBS, cut in halfs (sagittal through the midline) and then dehydrated through ethanol series starting at 70% ethanol, followed by 80, 90, 96 and 100% ethanol, each step was done once for 1 h except the last one which was done twice. After dehydration the hearts were embedded in increasing gradients of Historesin (Technovit 7100, Heraus Kulzer, Germany) (25, 50, 75 and 100% Historesin in ethanol, for 2 h at room temperature; 100% Historesin, 24 h at 4degreesC). Afterwards the plastic with the hearts was polymerized at 40degreesC (overnight). A 5 mum sagittal sections were made using the Ultramicrotome (Reichter-Jung) and a glass knife. Approximately 500 sections on each side of the midline were visually analyzed per heart (1,000 sections in total per heart). Sections were left to dry and later stained with hematoxylin-eosin staining. Pictures were taken with Axioplan 2 imaging, (Carl Zeiss, Jena). Azan staining of histological sections were done as follows. Paraffin sections of the hearts were prepared as described before (van der Meer et al. 2006). Sections were incubated with Azokarmine solution, for 30 min at 60degreesC. Afterwards they were washed in water and differentiated in 0.2% Anilin alcohol. They were then rinsed in 1% acetic acid in 95% alcohol, followed by 45 min incubation period, in 5% phosphotungstic acid. After that, sections were rinsed in distilled water and incubated for 45 min with aniline blue. Finally, they were rinsed with distilled water, differentiated and dehydrated in 95% alcohol followed by absolute, cleared in xylene and mounted in Entallan. The protocols used here for SEM had been described before (van der Meer et al. 2005). The statistical analysis of cardiac myocyte nuclei per section was done using Statistica by performing an independent t test. A P value of less than 0.05 was considered significant.
###end p 23
###begin title 24
Immunohistochemistry and statistical analysis
###end title 24
###begin p 25
###xml 1371 1373 1352 1354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 2551 2552 2526 2527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2665 2666 2640 2641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 0 9 <span type="species:ncbi:7955">Zebrafish</span>
###xml 630 635 <span type="species:ncbi:9823">swine</span>
###xml 1113 1119 <span type="species:ncbi:9986">rabbit</span>
###xml 2077 2082 <span type="species:ncbi:3750">Apple</span>
Zebrafish, raised either under normoxic or hypoxic conditions, were killed with an overdose of anesthetic MS-222 and frozen in liquid nitrogen. Subsequently, transversal cross-sections (10 mum thick) of the body, were cut using a cryostat at -20degreesC and mounted on glass slides coated with Vectabond (Vector Laboratories, Burlingame, USA). Sections were fixed in 4% formaldehyde in Tris-buffered saline (TBS; 50 mM Tris and 150 mM NaCl, pH 7.5) for 10 min and subsequently washed in TBS with 0.05% Tween-20 (TBST) (Sigma-Aldrich, Zwijndrecht, The Netherlands). Subsequently, sections were incubated for 10 min with 10% normal swine serum (Vector laboratories) in TBST after which sections were incubated for 24 h at 4degreesC with anti-phospho Akt polyclonal antibody (Santa-Cruz Biotechnology, USA) diluted 1:50 in TBST. After incubation with primary antibody, the slides were washed in TBST and subsequently placed in 0.25% (v/v) acetic anhydride in 0.1 M triethanolamine buffer (pH 8) for 10 min followed by rinsing in TBST. After this, sections were incubated for 60 min at 20degreesC with secondary anti-rabbit immunoglobulin G (IgG) antibody covalently coupled to alkaline phosphatase (Vector Laboaratories) diluted 1:100 and washed in TBST. After this, sections were incubated for 5 min with alkaline phosphatase (AP) buffer (0.1 M NaCl, 0.1 M Tris, 50 mM MgCl2 and 0.1% Tween-20, pH 9.5) followed by incubation with BM Purple AP substrate (Roche Applied Sciences, Almere, The Netherlands) for 30, 45 or 60 min which was followed by rinsing in TBST. All sections were mounted in glycerine-gelatin and stored at 4degreesC in the dark until staining intensity was measured. The absorbance values of the BM Purple in the sections were determined using a Leica DMRB microscope (Wetzlar, Germany) fitted with calibrated gray filters using different interference filters. Absorbances for BM Purple were determined at 550 nm. Images were recorded with a x20 objective and a Sony XC-77CE camera (Towada, Japan) connected to a LG-3 frame grabber (Scion; Frederick, MD) in an Apple Power Macintosh computer. Recorded images were analysed with the public domain program NIH-Image V1.61 (US National Institutes of Health, available at ). Gray values were converted to absorbance values per pixel using the gray filters and a third-degree polynomial fit in the calibrate option of NIH-image programme. Morphometry was calibrated using a slide micrometer and the set scale option in NIH-image, taking the pixel-aspect ration into account. An independent t test was used to test for differences in phospho-Akt levels in cardiac myocytes of normoxic and hypoxic fish. A P value of less than 0.05 was considered significant. Values are means +/- S.E.M.
###end p 25
###begin title 26
RNA preparation and biological sampling
###end title 26
###begin p 27
After dissection hearts were homogenized in a Dounce homogenizer using 1 ml Trizol solution (GibcoBrl, Life technologies). The whole heart was used and for each biological sample hearts were pooled from five different animals. After Trizol extraction, total RNA was further purified using RNAeasy columns (Qiagen). RNA samples were analyzed for quality control by Lab-on-a-chip analysis (Agilent) and on agarose gels. For the array experiment five arrays were done for normoxic and 5 arrays for the hypoxic condition. Biological samples (BS) came from two independent experiments and one technical replicate (TR) was included (2BS + 2BS + TR for normoxia and 2BS + 2BS + TR for hypoxia). As mentioned above for each BS, hearts from five different animals were pooled.
###end p 27
###begin title 28
Microarray analysis
###end title 28
###begin p 29
###xml 23 26 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 554 560 552 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;&#8804;&#160;</italic>
###xml 890 891 886 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 893 900 889 896 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 970 981 965 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Danio rerio</italic>
###xml 996 1017 991 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haplochromis piceatus</italic>
###xml 900 1025 896 1020 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Statistical analysis of histological sections (5 &#956;m) from zebrafish (<italic>Danio rerio</italic>) and cichlid (<italic>Haplochromis piceatus</italic>) hearts</p>
###xml 900 1025 896 1020 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Statistical analysis of histological sections (5 &#956;m) from zebrafish (<italic>Danio rerio</italic>) and cichlid (<italic>Haplochromis piceatus</italic>) hearts</p></caption>
###xml 1025 1067 1020 1062 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Number of cardiomyocyte nuclei per section</th>
###xml 1025 1067 1020 1062 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="5">Number of cardiomyocyte nuclei per section</th></tr>
###xml 1067 1067 1062 1062 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"/>
###xml 1096 1097 1090 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1067 1098 1062 1092 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Zebrafish (nuclei per 900&#160;&#956;m<sup>2</sup>)</th>
###xml 1128 1129 1121 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1098 1130 1092 1123 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Cichlid (nuclei per 10,000&#160;&#956;m<sup>2</sup>)</th>
###xml 1067 1130 1062 1123 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2"/><th align="left" colspan="2">Zebrafish (nuclei per 900&#160;&#956;m<sup>2</sup>)</th><th align="left" colspan="2">Cichlid (nuclei per 10,000&#160;&#956;m<sup>2</sup>)</th></tr>
###xml 1130 1138 1123 1131 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Normoxia</th>
###xml 1138 1145 1131 1138 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hypoxia</th>
###xml 1145 1153 1138 1146 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Normoxia</th>
###xml 1153 1160 1146 1153 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hypoxia</th>
###xml 1130 1160 1123 1153 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Normoxia</th><th align="left">Hypoxia</th><th align="left">Normoxia</th><th align="left">Hypoxia</th></tr>
###xml 1025 1160 1020 1153 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" colspan="5">Number of cardiomyocyte nuclei per section</th></tr><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Zebrafish (nuclei per 900&#160;&#956;m<sup>2</sup>)</th><th align="left" colspan="2">Cichlid (nuclei per 10,000&#160;&#956;m<sup>2</sup>)</th></tr><tr><th align="left">Normoxia</th><th align="left">Hypoxia</th><th align="left">Normoxia</th><th align="left">Hypoxia</th></tr></thead>
###xml 1160 1164 1153 1157 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean</td>
###xml 1164 1168 1157 1161 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.81</td>
###xml 1168 1173 1161 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13.67</td>
###xml 1173 1177 1166 1170 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14.7</td>
###xml 1177 1179 1170 1172 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 1160 1179 1153 1172 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean</td><td char="." align="char">9.81</td><td char="." align="char">13.67</td><td char="." align="char">14.7</td><td char="." align="char">24</td></tr>
###xml 1179 1181 1172 1174 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SD</td>
###xml 1181 1185 1174 1178 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.30</td>
###xml 1185 1189 1178 1182 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.39</td>
###xml 1189 1193 1182 1186 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.50</td>
###xml 1193 1197 1186 1190 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.68</td>
###xml 1179 1197 1172 1190 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">SD</td><td char="." align="char">0.30</td><td char="." align="char">0.39</td><td char="." align="char">0.50</td><td char="." align="char">0.68</td></tr>
###xml 1197 1198 1190 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1197 1204 1190 1197 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic> value</td>
###xml 1212 1215 1205 1208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;17</sup>
###xml 1204 1215 1197 1208 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.9&#160;&#215;&#160;10<sup>&#8722;17</sup></td>
###xml 1223 1226 1216 1219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;12</sup>
###xml 1215 1226 1208 1219 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.6&#160;&#215;&#160;10<sup>&#8722;12</sup></td>
###xml 1226 1226 1219 1219 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1226 1226 1219 1219 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1197 1226 1190 1219 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>P</italic> value</td><td char="." align="char">9.9&#160;&#215;&#160;10<sup>&#8722;17</sup></td><td char="." align="char">7.6&#160;&#215;&#160;10<sup>&#8722;12</sup></td><td char="." align="char"/><td char="." align="char"/></tr>
###xml 1160 1226 1153 1219 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Mean</td><td char="." align="char">9.81</td><td char="." align="char">13.67</td><td char="." align="char">14.7</td><td char="." align="char">24</td></tr><tr><td align="left">SD</td><td char="." align="char">0.30</td><td char="." align="char">0.39</td><td char="." align="char">0.50</td><td char="." align="char">0.68</td></tr><tr><td align="left"><italic>P</italic> value</td><td char="." align="char">9.9&#160;&#215;&#160;10<sup>&#8722;17</sup></td><td char="." align="char">7.6&#160;&#215;&#160;10<sup>&#8722;12</sup></td><td char="." align="char"/><td char="." align="char"/></tr></tbody>
###xml 1025 1226 1020 1219 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5">Number of cardiomyocyte nuclei per section</th></tr><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Zebrafish (nuclei per 900&#160;&#956;m<sup>2</sup>)</th><th align="left" colspan="2">Cichlid (nuclei per 10,000&#160;&#956;m<sup>2</sup>)</th></tr><tr><th align="left">Normoxia</th><th align="left">Hypoxia</th><th align="left">Normoxia</th><th align="left">Hypoxia</th></tr></thead><tbody><tr><td align="left">Mean</td><td char="." align="char">9.81</td><td char="." align="char">13.67</td><td char="." align="char">14.7</td><td char="." align="char">24</td></tr><tr><td align="left">SD</td><td char="." align="char">0.30</td><td char="." align="char">0.39</td><td char="." align="char">0.50</td><td char="." align="char">0.68</td></tr><tr><td align="left"><italic>P</italic> value</td><td char="." align="char">9.9&#160;&#215;&#160;10<sup>&#8722;17</sup></td><td char="." align="char">7.6&#160;&#215;&#160;10<sup>&#8722;12</sup></td><td char="." align="char"/><td char="." align="char"/></tr></tbody></table>
###xml 1374 1382 1367 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. rerio</italic>
###xml 1423 1424 1415 1416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1452 1463 1444 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. piceatus</italic>
###xml 1481 1482 1472 1473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2080 2081 2071 2072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2129 2130 2120 2121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1226 2249 1219 2240 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Midline sections of zebrafish and cichlids raised under normoxic and hypoxic conditions were chosen and subdivided in smaller areas. In the case of <italic>D. rerio</italic>, each subarea of the section was 900&#160;&#956;m<sup>2</sup> whereas in the case of the <italic>H. piceatus</italic> it was 10,000&#160;&#956;m<sup>2</sup>. Then, subareas were randomly picked and the amount of cardiac myocyte nuclei were counted. The vast majority of cardiac myocytes were mononucleated cells. Hundred subareas per section were counted per specimen. Three sections per heart were visually analyzed (with a magnification of 20&#215;). In total 6 different zebrafish hearts (from three independent experiments) were investigated for hypoxic conditions and 6 for normoxic condition. In total 1,800 subareas were quantified per heart and condition used. The same was done for the cichlids (for which bigger subareas were counted). A two-tailed <italic>t</italic> test was applied and a significant difference (<italic>P</italic>&#160;&lt;&#160;0.001) in the amount of nuclei present in the hearts of normoxia versus hypoxia groups was observed for both species</p>
###xml 1226 2249 1219 2240 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Midline sections of zebrafish and cichlids raised under normoxic and hypoxic conditions were chosen and subdivided in smaller areas. In the case of <italic>D. rerio</italic>, each subarea of the section was 900&#160;&#956;m<sup>2</sup> whereas in the case of the <italic>H. piceatus</italic> it was 10,000&#160;&#956;m<sup>2</sup>. Then, subareas were randomly picked and the amount of cardiac myocyte nuclei were counted. The vast majority of cardiac myocytes were mononucleated cells. Hundred subareas per section were counted per specimen. Three sections per heart were visually analyzed (with a magnification of 20&#215;). In total 6 different zebrafish hearts (from three independent experiments) were investigated for hypoxic conditions and 6 for normoxic condition. In total 1,800 subareas were quantified per heart and condition used. The same was done for the cichlids (for which bigger subareas were counted). A two-tailed <italic>t</italic> test was applied and a significant difference (<italic>P</italic>&#160;&lt;&#160;0.001) in the amount of nuclei present in the hearts of normoxia versus hypoxia groups was observed for both species</p></table-wrap-foot>
###xml 893 2249 889 2240 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="30">Statistical analysis of histological sections (5 &#956;m) from zebrafish (<italic>Danio rerio</italic>) and cichlid (<italic>Haplochromis piceatus</italic>) hearts</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5">Number of cardiomyocyte nuclei per section</th></tr><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Zebrafish (nuclei per 900&#160;&#956;m<sup>2</sup>)</th><th align="left" colspan="2">Cichlid (nuclei per 10,000&#160;&#956;m<sup>2</sup>)</th></tr><tr><th align="left">Normoxia</th><th align="left">Hypoxia</th><th align="left">Normoxia</th><th align="left">Hypoxia</th></tr></thead><tbody><tr><td align="left">Mean</td><td char="." align="char">9.81</td><td char="." align="char">13.67</td><td char="." align="char">14.7</td><td char="." align="char">24</td></tr><tr><td align="left">SD</td><td char="." align="char">0.30</td><td char="." align="char">0.39</td><td char="." align="char">0.50</td><td char="." align="char">0.68</td></tr><tr><td align="left"><italic>P</italic> value</td><td char="." align="char">9.9&#160;&#215;&#160;10<sup>&#8722;17</sup></td><td char="." align="char">7.6&#160;&#215;&#160;10<sup>&#8722;12</sup></td><td char="." align="char"/><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p textid="31">Midline sections of zebrafish and cichlids raised under normoxic and hypoxic conditions were chosen and subdivided in smaller areas. In the case of <italic>D. rerio</italic>, each subarea of the section was 900&#160;&#956;m<sup>2</sup> whereas in the case of the <italic>H. piceatus</italic> it was 10,000&#160;&#956;m<sup>2</sup>. Then, subareas were randomly picked and the amount of cardiac myocyte nuclei were counted. The vast majority of cardiac myocytes were mononucleated cells. Hundred subareas per section were counted per specimen. Three sections per heart were visually analyzed (with a magnification of 20&#215;). In total 6 different zebrafish hearts (from three independent experiments) were investigated for hypoxic conditions and 6 for normoxic condition. In total 1,800 subareas were quantified per heart and condition used. The same was done for the cichlids (for which bigger subareas were counted). A two-tailed <italic>t</italic> test was applied and a significant difference (<italic>P</italic>&#160;&lt;&#160;0.001) in the amount of nuclei present in the hearts of normoxia versus hypoxia groups was observed for both species</p></table-wrap-foot></table-wrap>
###xml 27 36 <span type="species:ncbi:7955">Zebrafish</span>
###xml 69 80 <span type="species:ncbi:7955">Danio rerio</span>
###xml 959 968 <span type="species:ncbi:7955">zebrafish</span>
###xml 970 981 <span type="species:ncbi:7955">Danio rerio</span>
###xml 996 1017 <span type="species:ncbi:143508">Haplochromis piceatus</span>
###xml 1246 1255 <span type="species:ncbi:7955">zebrafish</span>
###xml 1374 1382 <span type="species:ncbi:7955">D. rerio</span>
###xml 1452 1463 <span type="species:ncbi:143508">H. piceatus</span>
###xml 1795 1804 <span type="species:ncbi:7955">zebrafish</span>
The Affymetrix GeneChip(R) Zebrafish Genome Arrays containing 15,509 Danio rerio gene transcripts were used. Probe sets on the arrays were designed with 16 oligonucleotide pairs to detect each transcript and procedures were in full support of MIAME standards. Labeling and microarray hybridization were performed by ServiceXS (Leiden, The Netherlands), including prior a standard round of RNA amplification according to standard Affymetrix protocols. The criteria used for differential expression were greater or equal than 2-fold induced or reduced and P </= 0.02. Data analysis was done using Rosetta Resolver. All expression data was submitted to the NCBI Gene Expression Omnibus (). The series entry number is GSE4989 and the following 10 accession numbers were assigned: GSM112796 and GSM112798-GSM112806. A complete list of differential regulated genes is shown in Supplemental Table 1. Table 1Statistical analysis of histological sections (5 mum) from zebrafish (Danio rerio) and cichlid (Haplochromis piceatus) heartsNumber of cardiomyocyte nuclei per sectionZebrafish (nuclei per 900 mum2)Cichlid (nuclei per 10,000 mum2)NormoxiaHypoxiaNormoxiaHypoxiaMean9.8113.6714.724SD0.300.390.500.68P value9.9 x 10-177.6 x 10-12Midline sections of zebrafish and cichlids raised under normoxic and hypoxic conditions were chosen and subdivided in smaller areas. In the case of D. rerio, each subarea of the section was 900 mum2 whereas in the case of the H. piceatus it was 10,000 mum2. Then, subareas were randomly picked and the amount of cardiac myocyte nuclei were counted. The vast majority of cardiac myocytes were mononucleated cells. Hundred subareas per section were counted per specimen. Three sections per heart were visually analyzed (with a magnification of 20x). In total 6 different zebrafish hearts (from three independent experiments) were investigated for hypoxic conditions and 6 for normoxic condition. In total 1,800 subareas were quantified per heart and condition used. The same was done for the cichlids (for which bigger subareas were counted). A two-tailed t test was applied and a significant difference (P < 0.001) in the amount of nuclei present in the hearts of normoxia versus hypoxia groups was observed for both species
###end p 29
###begin p 30
###xml 70 81 69 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Danio rerio</italic>
###xml 96 117 95 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haplochromis piceatus</italic>
###xml 59 68 <span type="species:ncbi:7955">zebrafish</span>
###xml 70 81 <span type="species:ncbi:7955">Danio rerio</span>
###xml 96 117 <span type="species:ncbi:143508">Haplochromis piceatus</span>
Statistical analysis of histological sections (5 mum) from zebrafish (Danio rerio) and cichlid (Haplochromis piceatus) hearts
###end p 30
###begin p 31
###xml 148 156 148 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. rerio</italic>
###xml 197 198 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 226 237 225 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. piceatus</italic>
###xml 255 256 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 854 855 852 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 903 904 901 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 20 29 <span type="species:ncbi:7955">zebrafish</span>
###xml 148 156 <span type="species:ncbi:7955">D. rerio</span>
###xml 226 237 <span type="species:ncbi:143508">H. piceatus</span>
###xml 569 578 <span type="species:ncbi:7955">zebrafish</span>
Midline sections of zebrafish and cichlids raised under normoxic and hypoxic conditions were chosen and subdivided in smaller areas. In the case of D. rerio, each subarea of the section was 900 mum2 whereas in the case of the H. piceatus it was 10,000 mum2. Then, subareas were randomly picked and the amount of cardiac myocyte nuclei were counted. The vast majority of cardiac myocytes were mononucleated cells. Hundred subareas per section were counted per specimen. Three sections per heart were visually analyzed (with a magnification of 20x). In total 6 different zebrafish hearts (from three independent experiments) were investigated for hypoxic conditions and 6 for normoxic condition. In total 1,800 subareas were quantified per heart and condition used. The same was done for the cichlids (for which bigger subareas were counted). A two-tailed t test was applied and a significant difference (P < 0.001) in the amount of nuclei present in the hearts of normoxia versus hypoxia groups was observed for both species
###end p 31
###begin title 32
Gene ontology analysis
###end title 32
###begin p 33
###xml 488 491 488 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;&lt;</italic>
###xml 159 168 <span type="species:ncbi:7955">zebrafish</span>
The Gene ontology analysis was performed using eGOn and the database of the Norwegian Microarray Consortium () and the most recent updated Unigene numbers for zebrafish (May 2007). 13414 Unigene numbers were annotated to the Affymetrix gene chip used. eGOn Enrichment analysis was used for the entire Affymetrix set versus the identified 376 gene set based on the new Unigene numbers. A master target test was performed (using Fishers exact test) and the cut off for positives was set to P < 0.05. The available three categories, molecular function, biological process and cellular component were all tested and are shown in this dataset (Supplemental Data 1). The fold enrichment was based on the percentage found within the differentially expressed genes divided by the percentage on the total chip. A list of all Unigene numbers found in the different categories is given in Supplemental Data 2.
###end p 33
###begin title 34
Real-time quantitative RT-PCR
###end title 34
###begin p 35
For verification of gene expression data, we used quantitative real-time RT-PCR. Biological RNA samples were obtained from a third independent experiment and as mentioned above for the microarrays, for each BS hearts from five different animals were pooled. The Roche Master SYBR Green kit was used for the RT-PCR reactions. The annealing and synthesis temperature was 55degreesC alternating with 96degreesC for 45 cycles. Dissociation protocols were used to measure melting curves and control for unspecific signals from the primers. A measure of 100 ng of total RNA was used per reaction. A standard curve for beta-actin using 1, 5, 10, 100 and 500 ng of total RNA was used for normalization. Samples were measured in the Roche LightCycler. The primer3 software () was used to design primers for short amplicons between 50 and 100 bases. The primers used are shown in Supplemental Table 2.
###end p 35
###begin title 36
Results
###end title 36
###begin p 37
###xml 106 107 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 148 149 148 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 163 165 163 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 375 392 375 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Hypoxia treatment</xref>
###xml 443 445 443 445 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 698 699 698 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 775 795 775 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Material and methods</xref>
###xml 928 934 928 934 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1154 1155 1154 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1489 1490 1483 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1646 1647 1640 1641 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 934 1851 934 1845 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38">Survival of zebrafish embryos after immediate exposure to hypoxia. Zebrafish were immediately exposed to hypoxia (15&#160;Torr; 0.8&#160;mg/ml; 10% air saturated water). Results are derived from three independent experiments with <italic>n</italic>&#160;=&#160;30 in each experiment (adding to a total of 90 fish tested). After 24, 48 and 72&#160;h, dead and alive fish were counted. Shown here is the percentage of dead fish at the respective time points and the standard deviation. At 24&#160;h 53.3%(&#177;4.4) of fish were dead, at 48&#160;hours 85.3% (&#177;5.1) and at 72&#160;hours 100% (&#177;0). Control groups (<italic>n</italic>&#160;=&#160;30), which were in parallel exposed to normoxic conditions showed no mortality (not shown). None of the zebrafish survived the immediate exposure to an O<sub>2</sub> concentration of 0.8&#160;mg/l (10% air saturation) over the 3-day period. In contrast, fishes gradually exposed to hypoxia showed no induced mortality for even the 25&#160;day time periods used in our experiments</p>
###xml 934 1851 934 1845 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38">Survival of zebrafish embryos after immediate exposure to hypoxia. Zebrafish were immediately exposed to hypoxia (15&#160;Torr; 0.8&#160;mg/ml; 10% air saturated water). Results are derived from three independent experiments with <italic>n</italic>&#160;=&#160;30 in each experiment (adding to a total of 90 fish tested). After 24, 48 and 72&#160;h, dead and alive fish were counted. Shown here is the percentage of dead fish at the respective time points and the standard deviation. At 24&#160;h 53.3%(&#177;4.4) of fish were dead, at 48&#160;hours 85.3% (&#177;5.1) and at 72&#160;hours 100% (&#177;0). Control groups (<italic>n</italic>&#160;=&#160;30), which were in parallel exposed to normoxic conditions showed no mortality (not shown). None of the zebrafish survived the immediate exposure to an O<sub>2</sub> concentration of 0.8&#160;mg/l (10% air saturation) over the 3-day period. In contrast, fishes gradually exposed to hypoxia showed no induced mortality for even the 25&#160;day time periods used in our experiments</p></caption>
###xml 1851 1851 1845 1845 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="360_2007_201_Fig1_HTML" id="MO1"/>
###xml 928 1851 928 1845 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="38">Survival of zebrafish embryos after immediate exposure to hypoxia. Zebrafish were immediately exposed to hypoxia (15&#160;Torr; 0.8&#160;mg/ml; 10% air saturated water). Results are derived from three independent experiments with <italic>n</italic>&#160;=&#160;30 in each experiment (adding to a total of 90 fish tested). After 24, 48 and 72&#160;h, dead and alive fish were counted. Shown here is the percentage of dead fish at the respective time points and the standard deviation. At 24&#160;h 53.3%(&#177;4.4) of fish were dead, at 48&#160;hours 85.3% (&#177;5.1) and at 72&#160;hours 100% (&#177;0). Control groups (<italic>n</italic>&#160;=&#160;30), which were in parallel exposed to normoxic conditions showed no mortality (not shown). None of the zebrafish survived the immediate exposure to an O<sub>2</sub> concentration of 0.8&#160;mg/l (10% air saturation) over the 3-day period. In contrast, fishes gradually exposed to hypoxia showed no induced mortality for even the 25&#160;day time periods used in our experiments</p></caption><graphic position="anchor" xlink:href="360_2007_201_Fig1_HTML" id="MO1"/></fig>
###xml 45 54 <span type="species:ncbi:7955">zebrafish</span>
###xml 244 253 <span type="species:ncbi:7955">zebrafish</span>
###xml 395 404 <span type="species:ncbi:7955">zebrafish</span>
###xml 479 488 <span type="species:ncbi:7955">zebrafish</span>
###xml 668 677 <span type="species:ncbi:7955">zebrafish</span>
###xml 946 955 <span type="species:ncbi:7955">zebrafish</span>
###xml 1001 1010 <span type="species:ncbi:7955">Zebrafish</span>
###xml 1597 1606 <span type="species:ncbi:7955">zebrafish</span>
We describe here the survival rates of adult zebrafish upon immediate and gradual exposure to different pO2 concentrations. Immediate exposure to pO2 of 15 Torr (O2 concentration of 0.8 mg/l or 10% air saturated water) was lethal for the adult zebrafish and none survived for longer than 72 h (Fig. 1). If lowered gradually (see experimental procedures for regimen in Sect. "Hypoxia treatment") zebrafish were able to grow and gain weight at O2 levels of 10% air saturation. The zebrafish were able to survive for longer than 6 months and no mortality was observed, demonstrating that they can well adapt to these conditions (data not shown). For the experiments with zebrafish and cichlids, the pO2 concentration was gradually lowered to 10% air saturation (0.8 mg/l) (see "Material and methods") and fishes were kept under 10% air saturation for 3 weeks. Control groups were always kept in parallel under normoxic conditions. Fig. 1Survival of zebrafish embryos after immediate exposure to hypoxia. Zebrafish were immediately exposed to hypoxia (15 Torr; 0.8 mg/ml; 10% air saturated water). Results are derived from three independent experiments with n = 30 in each experiment (adding to a total of 90 fish tested). After 24, 48 and 72 h, dead and alive fish were counted. Shown here is the percentage of dead fish at the respective time points and the standard deviation. At 24 h 53.3%(+/-4.4) of fish were dead, at 48 hours 85.3% (+/-5.1) and at 72 hours 100% (+/-0). Control groups (n = 30), which were in parallel exposed to normoxic conditions showed no mortality (not shown). None of the zebrafish survived the immediate exposure to an O2 concentration of 0.8 mg/l (10% air saturation) over the 3-day period. In contrast, fishes gradually exposed to hypoxia showed no induced mortality for even the 25 day time periods used in our experiments
###end p 37
###begin p 38
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 555 556 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 712 713 706 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 12 21 <span type="species:ncbi:7955">zebrafish</span>
###xml 67 76 <span type="species:ncbi:7955">Zebrafish</span>
###xml 663 672 <span type="species:ncbi:7955">zebrafish</span>
Survival of zebrafish embryos after immediate exposure to hypoxia. Zebrafish were immediately exposed to hypoxia (15 Torr; 0.8 mg/ml; 10% air saturated water). Results are derived from three independent experiments with n = 30 in each experiment (adding to a total of 90 fish tested). After 24, 48 and 72 h, dead and alive fish were counted. Shown here is the percentage of dead fish at the respective time points and the standard deviation. At 24 h 53.3%(+/-4.4) of fish were dead, at 48 hours 85.3% (+/-5.1) and at 72 hours 100% (+/-0). Control groups (n = 30), which were in parallel exposed to normoxic conditions showed no mortality (not shown). None of the zebrafish survived the immediate exposure to an O2 concentration of 0.8 mg/l (10% air saturation) over the 3-day period. In contrast, fishes gradually exposed to hypoxia showed no induced mortality for even the 25 day time periods used in our experiments
###end p 38
###begin title 39
Phenotypic changes in the heart of adult teleosts under chronic constant hypoxia (CCH)
###end title 39
###begin p 40
###xml 257 268 257 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Danio rerio</italic>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 294 315 294 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haplochromis piceatus</italic>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 956 957 956 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1503 1504 1503 1504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1872 1873 1872 1873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1989 1995 1989 1995 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 2092 2093 2092 2093 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2199 2200 2199 2200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 2202 2203 2202 2203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 2208 2209 2208 2209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 2236 2237 2236 2237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 2239 2240 2239 2240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 2245 2246 2245 2246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 2291 2295 2291 2295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dark</italic>
###xml 2295 2306 2295 2306 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> (dark blue</italic>
###xml 2348 2354 2348 2354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">light </italic>
###xml 2354 2359 2354 2359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(pink</italic>
###xml 2389 2390 2389 2390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 2392 2393 2392 2393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 2395 2396 2395 2396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 2401 2402 2401 2402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 2445 2446 2445 2446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 2451 2452 2451 2452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 2502 2503 2502 2503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 2530 2531 2530 2531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 2540 2541 2540 2541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">v</italic>
###xml 2553 2556 2553 2556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vo </italic>
###xml 2586 2588 2586 2588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ca</italic>
###xml 2607 2608 2607 2608 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2610 2613 2610 2613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;F</italic>
###xml 2727 2728 2727 2728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 2733 2734 2733 2734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 2848 2851 2848 2851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;F</italic>
###xml 2856 2865 2856 2865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Azan blue</italic>
###xml 2867 2868 2867 2868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 2870 2871 2870 2871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 2877 2878 2877 2878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 2880 2881 2880 2881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 2883 2884 2883 2884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 2889 2890 2889 2890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 2937 2938 2937 2938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 2940 2941 2940 2941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 2943 2944 2943 2944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 2949 2950 2949 2950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1995 3107 1995 3107 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Histological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. <bold>a</bold> shows zebrafish hearts that were dissected, sectioned and stained with a hematoxylin&#8211;eosin staining with <italic>A</italic>, <italic>B</italic> and <italic>E</italic> representing normoxic and <italic>C</italic>, <italic>D</italic> and <italic>F</italic> hypoxic conditions. Cell nuclei are seen in <italic>dark</italic><italic> (dark blue</italic> in online version) and cell cytoplasm in <italic>light </italic><italic>(pink</italic> in online version). Pictures <italic>A</italic>, <italic>C</italic>, <italic>E</italic> and <italic>F</italic> have the same magnification (10&#215;). Images <italic>B</italic> and <italic>D</italic> represent a 20&#215; magnification of cardiac muscle (<italic>D</italic>). Abbreviations used are: <italic>a</italic> atrium; <italic>v</italic> ventricle; <italic>vo </italic>ventricular outflow tract and <italic>ca</italic> conus arteriosus. <bold>b</bold> (<italic>A&#8211;F</italic>) corresponds to sections of cichlid hearts, which were treated the same way as the ones above from zebrafish and <italic>G</italic> and <italic>H</italic> show cichlid hearts which have been perfused prior to dissection and were stained with either hematoxylin&#8211;eosin (<italic>A&#8211;F</italic>) or <italic>Azan blue</italic> (<italic>G</italic>, <italic>H</italic>). In <italic>A</italic>, <italic>B</italic>, <italic>C</italic> and <italic>G</italic> pictures of normoxic conditions are shown and <italic>D</italic>, <italic>E</italic>, <italic>F</italic> and <italic>H</italic> represent the corresponding hypoxic conditions. Similar results for both the zebrafish and the cichlid hearts were observed in three independent experiments</p>
###xml 1995 3107 1995 3107 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Histological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. <bold>a</bold> shows zebrafish hearts that were dissected, sectioned and stained with a hematoxylin&#8211;eosin staining with <italic>A</italic>, <italic>B</italic> and <italic>E</italic> representing normoxic and <italic>C</italic>, <italic>D</italic> and <italic>F</italic> hypoxic conditions. Cell nuclei are seen in <italic>dark</italic><italic> (dark blue</italic> in online version) and cell cytoplasm in <italic>light </italic><italic>(pink</italic> in online version). Pictures <italic>A</italic>, <italic>C</italic>, <italic>E</italic> and <italic>F</italic> have the same magnification (10&#215;). Images <italic>B</italic> and <italic>D</italic> represent a 20&#215; magnification of cardiac muscle (<italic>D</italic>). Abbreviations used are: <italic>a</italic> atrium; <italic>v</italic> ventricle; <italic>vo </italic>ventricular outflow tract and <italic>ca</italic> conus arteriosus. <bold>b</bold> (<italic>A&#8211;F</italic>) corresponds to sections of cichlid hearts, which were treated the same way as the ones above from zebrafish and <italic>G</italic> and <italic>H</italic> show cichlid hearts which have been perfused prior to dissection and were stained with either hematoxylin&#8211;eosin (<italic>A&#8211;F</italic>) or <italic>Azan blue</italic> (<italic>G</italic>, <italic>H</italic>). In <italic>A</italic>, <italic>B</italic>, <italic>C</italic> and <italic>G</italic> pictures of normoxic conditions are shown and <italic>D</italic>, <italic>E</italic>, <italic>F</italic> and <italic>H</italic> represent the corresponding hypoxic conditions. Similar results for both the zebrafish and the cichlid hearts were observed in three independent experiments</p></caption>
###xml 3107 3107 3107 3107 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="360_2007_201_Fig2_HTML" id="MO2"/>
###xml 1989 3107 1989 3107 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="41">Histological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. <bold>a</bold> shows zebrafish hearts that were dissected, sectioned and stained with a hematoxylin&#8211;eosin staining with <italic>A</italic>, <italic>B</italic> and <italic>E</italic> representing normoxic and <italic>C</italic>, <italic>D</italic> and <italic>F</italic> hypoxic conditions. Cell nuclei are seen in <italic>dark</italic><italic> (dark blue</italic> in online version) and cell cytoplasm in <italic>light </italic><italic>(pink</italic> in online version). Pictures <italic>A</italic>, <italic>C</italic>, <italic>E</italic> and <italic>F</italic> have the same magnification (10&#215;). Images <italic>B</italic> and <italic>D</italic> represent a 20&#215; magnification of cardiac muscle (<italic>D</italic>). Abbreviations used are: <italic>a</italic> atrium; <italic>v</italic> ventricle; <italic>vo </italic>ventricular outflow tract and <italic>ca</italic> conus arteriosus. <bold>b</bold> (<italic>A&#8211;F</italic>) corresponds to sections of cichlid hearts, which were treated the same way as the ones above from zebrafish and <italic>G</italic> and <italic>H</italic> show cichlid hearts which have been perfused prior to dissection and were stained with either hematoxylin&#8211;eosin (<italic>A&#8211;F</italic>) or <italic>Azan blue</italic> (<italic>G</italic>, <italic>H</italic>). In <italic>A</italic>, <italic>B</italic>, <italic>C</italic> and <italic>G</italic> pictures of normoxic conditions are shown and <italic>D</italic>, <italic>E</italic>, <italic>F</italic> and <italic>H</italic> represent the corresponding hypoxic conditions. Similar results for both the zebrafish and the cichlid hearts were observed in three independent experiments</p></caption><graphic position="anchor" xlink:href="360_2007_201_Fig2_HTML" id="MO2"/></fig>
###xml 3107 3113 3107 3113 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 3292 3293 3292 3293 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 3295 3296 3295 3296 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 3301 3302 3301 3302 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 3335 3336 3335 3336 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 3338 3339 3338 3339 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 3344 3345 3344 3345 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 3352 3365 3352 3365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bigger images</italic>
###xml 3428 3442 3428 3442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">smaller images</italic>
###xml 3499 3504 3499 3504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">scale</italic>
###xml 3569 3570 3569 3570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">v</italic>
###xml 3585 3587 3585 3587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vo</italic>
###xml 3113 3613 3113 3613 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Morphological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. Scanning electron microscopy pictures of hearts from normoxia control zebrafish (<bold>a</bold>, <bold>c</bold> and <bold>d</bold>) and hypoxia-treated zebrafish (<bold>b</bold>, <bold>e</bold> and <bold>f</bold>). The <italic>bigger images</italic> show half of a heart ventricle, sectioned longitudinally. The <italic>smaller images</italic> represent a higher magnification of cardiac muscle. The <italic>scale</italic> is given at the bottom of each picture. Abbreviations used are: <italic>v</italic> ventricle and <italic>vo</italic> ventricular outflow tract</p>
###xml 3113 3613 3113 3613 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Morphological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. Scanning electron microscopy pictures of hearts from normoxia control zebrafish (<bold>a</bold>, <bold>c</bold> and <bold>d</bold>) and hypoxia-treated zebrafish (<bold>b</bold>, <bold>e</bold> and <bold>f</bold>). The <italic>bigger images</italic> show half of a heart ventricle, sectioned longitudinally. The <italic>smaller images</italic> represent a higher magnification of cardiac muscle. The <italic>scale</italic> is given at the bottom of each picture. Abbreviations used are: <italic>v</italic> ventricle and <italic>vo</italic> ventricular outflow tract</p></caption>
###xml 3613 3613 3613 3613 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="360_2007_201_Fig3_HTML" id="MO3"/>
###xml 3107 3613 3107 3613 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="42">Morphological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. Scanning electron microscopy pictures of hearts from normoxia control zebrafish (<bold>a</bold>, <bold>c</bold> and <bold>d</bold>) and hypoxia-treated zebrafish (<bold>b</bold>, <bold>e</bold> and <bold>f</bold>). The <italic>bigger images</italic> show half of a heart ventricle, sectioned longitudinally. The <italic>smaller images</italic> represent a higher magnification of cardiac muscle. The <italic>scale</italic> is given at the bottom of each picture. Abbreviations used are: <italic>v</italic> ventricle and <italic>vo</italic> ventricular outflow tract</p></caption><graphic position="anchor" xlink:href="360_2007_201_Fig3_HTML" id="MO3"/></fig>
###xml 246 255 <span type="species:ncbi:7955">zebrafish</span>
###xml 257 268 <span type="species:ncbi:7955">Danio rerio</span>
###xml 294 315 <span type="species:ncbi:143508">Haplochromis piceatus</span>
###xml 1217 1226 <span type="species:ncbi:7955">zebrafish</span>
###xml 1453 1462 <span type="species:ncbi:7955">zebrafish</span>
###xml 1849 1858 <span type="species:ncbi:7955">zebrafish</span>
###xml 2019 2028 <span type="species:ncbi:7955">zebrafish</span>
###xml 2100 2109 <span type="species:ncbi:7955">zebrafish</span>
###xml 2713 2722 <span type="species:ncbi:7955">zebrafish</span>
###xml 3028 3037 <span type="species:ncbi:7955">zebrafish</span>
###xml 3138 3147 <span type="species:ncbi:7955">zebrafish</span>
###xml 3281 3290 <span type="species:ncbi:7955">zebrafish</span>
###xml 3324 3333 <span type="species:ncbi:7955">zebrafish</span>
In comparison to the normoxic control groups, we observed a significantly smaller ventricular outflow tract and reduced lacunae within the central ventricular cavity and reduced lacunae around the trabeculae in midline sections of hearts of both zebrafish (Danio rerio) (Fig. 2a) and cichlids (Haplochromis piceatus) (Fig. 2b) exposed to CCH. In addition to the midline sections, none of the sections investigated from hypoxia treated fishes showed a ventricular outflow tract in comparable size to the normoxic controls (data not shown). In addition to the midline sections, none of the lateral sections (to both sides of the midline) investigated from hypoxia treated fishes showed a ventricular outflow tract as well as lacunae in a comparable size to the normoxic controls (data not shown). The larger cichlid hearts were also perfused and midline sectioned and showed similar results with a smaller ventricular outflow tract and reduced lacunae (Fig. 2b-H). This might represent ventricular hypertrophy or hyperplasia in both walls and trabeculae, which could lead to the observed cavity obliteration in these sections. We quantified the number of cardiac myocyte nuclei per area in the midline sections of both zebrafish and cichlids under normoxic, as well as hypoxic conditions. A significant difference in both species was observed and showed that hypoxia led to a 1.4- and 1.6-fold increase in the number of cardiac myocyte nuclei per area in zebrafish and cichlid hearts, respectively (Table 1). Cardiac myocyte nuclei in sections were clearly distinguishable from nuclei of other cells like erythrocytes and fibroblasts and only centralized nuclei in cardiac myocytes (which are more elongated than nuclei from erythrocytes) were counted. Furthermore, scanning electron microscopy (SEM) was used to confirm these findings in the smaller zebrafish hearts (Fig. 3). Future research is warranted in order to assess further how the cardiac myocytes adapt to CCH in the fish heart. Fig. 2Histological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. a shows zebrafish hearts that were dissected, sectioned and stained with a hematoxylin-eosin staining with A, B and E representing normoxic and C, D and F hypoxic conditions. Cell nuclei are seen in dark (dark blue in online version) and cell cytoplasm in light (pink in online version). Pictures A, C, E and F have the same magnification (10x). Images B and D represent a 20x magnification of cardiac muscle (D). Abbreviations used are: a atrium; v ventricle; vo ventricular outflow tract and ca conus arteriosus. b (A-F) corresponds to sections of cichlid hearts, which were treated the same way as the ones above from zebrafish and G and H show cichlid hearts which have been perfused prior to dissection and were stained with either hematoxylin-eosin (A-F) or Azan blue (G, H). In A, B, C and G pictures of normoxic conditions are shown and D, E, F and H represent the corresponding hypoxic conditions. Similar results for both the zebrafish and the cichlid hearts were observed in three independent experimentsFig. 3Morphological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. Scanning electron microscopy pictures of hearts from normoxia control zebrafish (a, c and d) and hypoxia-treated zebrafish (b, e and f). The bigger images show half of a heart ventricle, sectioned longitudinally. The smaller images represent a higher magnification of cardiac muscle. The scale is given at the bottom of each picture. Abbreviations used are: v ventricle and vo ventricular outflow tract
###end p 40
###begin p 41
###xml 97 98 97 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 204 205 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 207 208 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 244 245 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 250 251 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dark</italic>
###xml 300 311 300 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> (dark blue</italic>
###xml 353 359 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">light </italic>
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(pink</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 400 401 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 450 451 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 456 457 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 535 536 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 545 546 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">v</italic>
###xml 558 561 558 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vo </italic>
###xml 591 593 591 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ca</italic>
###xml 612 613 612 613 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 615 618 615 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;F</italic>
###xml 732 733 732 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 738 739 738 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 853 856 853 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;F</italic>
###xml 861 870 861 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Azan blue</italic>
###xml 872 873 872 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 875 876 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 882 883 882 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 885 886 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 888 889 888 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 894 895 894 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 942 943 942 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 945 946 945 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 948 949 948 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 954 955 954 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 24 33 <span type="species:ncbi:7955">zebrafish</span>
###xml 105 114 <span type="species:ncbi:7955">zebrafish</span>
###xml 718 727 <span type="species:ncbi:7955">zebrafish</span>
###xml 1033 1042 <span type="species:ncbi:7955">zebrafish</span>
Histological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. a shows zebrafish hearts that were dissected, sectioned and stained with a hematoxylin-eosin staining with A, B and E representing normoxic and C, D and F hypoxic conditions. Cell nuclei are seen in dark (dark blue in online version) and cell cytoplasm in light (pink in online version). Pictures A, C, E and F have the same magnification (10x). Images B and D represent a 20x magnification of cardiac muscle (D). Abbreviations used are: a atrium; v ventricle; vo ventricular outflow tract and ca conus arteriosus. b (A-F) corresponds to sections of cichlid hearts, which were treated the same way as the ones above from zebrafish and G and H show cichlid hearts which have been perfused prior to dissection and were stained with either hematoxylin-eosin (A-F) or Azan blue (G, H). In A, B, C and G pictures of normoxic conditions are shown and D, E, F and H represent the corresponding hypoxic conditions. Similar results for both the zebrafish and the cichlid hearts were observed in three independent experiments
###end p 41
###begin p 42
###xml 179 180 179 180 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 182 183 182 183 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 188 189 188 189 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 222 223 222 223 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 225 226 225 226 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 231 232 231 232 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 239 252 239 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bigger images</italic>
###xml 315 329 315 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">smaller images</italic>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">scale</italic>
###xml 456 457 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">v</italic>
###xml 472 474 472 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vo</italic>
###xml 25 34 <span type="species:ncbi:7955">zebrafish</span>
###xml 168 177 <span type="species:ncbi:7955">zebrafish</span>
###xml 211 220 <span type="species:ncbi:7955">zebrafish</span>
Morphological changes of zebrafish and cichlid hearts after exposure to chronic constant hypoxia. Scanning electron microscopy pictures of hearts from normoxia control zebrafish (a, c and d) and hypoxia-treated zebrafish (b, e and f). The bigger images show half of a heart ventricle, sectioned longitudinally. The smaller images represent a higher magnification of cardiac muscle. The scale is given at the bottom of each picture. Abbreviations used are: v ventricle and vo ventricular outflow tract
###end p 42
###begin title 43
###xml 46 55 <span type="species:ncbi:7955">zebrafish</span>
Gene expression changes in the heart of adult zebrafish under chronic constant hypoxia (CCH)
###end title 43
###begin p 44
###xml 129 138 <span type="species:ncbi:7955">zebrafish</span>
In this study, we used microarrays for the transcriptional profiling of up and downregulated genes in response to hypoxia in the zebrafish heart. We identified 376 genes that were differentially expressed under hypoxic conditions, out of which 116 genes showed a decrease in gene expression (30.9%) in comparison to 260 genes which showed increased expression levels (69.1%).
###end p 44
###begin p 45
###xml 165 174 <span type="species:ncbi:7955">zebrafish</span>
All 376 differentially expressed genes, including the ones with oligo sequences which could not be annotated so far (referred therein either as transcribed locus or zebrafish clone) are shown in the complete file (Supplemental Table 1). Functional groups are color coded and if possible, gene functions are briefly summarized and OMIM links given.
###end p 45
###begin title 46
Functional groups of differentially expressed genes in the heart
###end title 46
###begin p 47
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 435 442 435 442 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 442 493 442 493 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">Functional groups of differentially expressed genes</p>
###xml 442 493 442 493 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">Functional groups of differentially expressed genes</p></caption>
###xml 493 500 493 500 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">UniGene</th>
###xml 500 508 500 508 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GeneBank</th>
###xml 508 512 508 512 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fold</th>
###xml 512 521 512 521 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gene name</th>
###xml 493 521 493 521 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">UniGene</th><th align="left">GeneBank</th><th align="left">Fold</th><th align="left">Gene name</th></tr>
###xml 493 521 493 521 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">UniGene</th><th align="left">GeneBank</th><th align="left">Fold</th><th align="left">Gene name</th></tr></thead>
###xml 521 538 521 538 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Upregulated genes</td>
###xml 521 538 521 538 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Upregulated genes</td></tr>
###xml 538 550 538 550 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Angiogenesis</td>
###xml 538 550 538 550 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Angiogenesis</td></tr>
###xml 550 558 550 558 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.11575</td>
###xml 558 567 558 567 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_173244</td>
###xml 567 570 567 570 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 570 611 570 611 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">T-cell acute lymphocytic leukemia 1; TAL1</td>
###xml 550 611 550 611 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.11575</td><td align="left">NM_173244</td><td char="." align="char">2.3</td><td align="left">T-cell acute lymphocytic leukemia 1; TAL1</td></tr>
###xml 611 617 611 617 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.845</td>
###xml 617 625 617 625 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BG729013</td>
###xml 625 628 625 628 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.8</td>
###xml 628 659 628 659 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibrinogen alpha/alpha-E chain </td>
###xml 611 659 611 659 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.845</td><td align="left">BG729013</td><td char="." align="char">2.8</td><td align="left">Fibrinogen alpha/alpha-E chain </td></tr>
###xml 659 666 659 666 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4907</td>
###xml 666 674 666 674 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC045868</td>
###xml 674 677 674 677 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.2</td>
###xml 677 706 677 706 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibrinogen, gamma polypeptide</td>
###xml 659 706 659 706 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4907</td><td align="left">BC045868</td><td char="." align="char">4.2</td><td align="left">Fibrinogen, gamma polypeptide</td></tr>
###xml 706 715 706 715 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Apoptosis</td>
###xml 706 715 706 715 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Apoptosis</td></tr>
###xml 715 723 715 723 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.15862</td>
###xml 723 731 723 731 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AF493987</td>
###xml 731 734 731 734 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.1</td>
###xml 734 776 734 776 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BCL2adenovirus E1b 19 interacting protein3</td>
###xml 715 776 715 776 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.15862</td><td align="left">AF493987</td><td char="." align="char">2.1</td><td align="left">BCL2adenovirus E1b 19 interacting protein3</td></tr>
###xml 776 787 776 787 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DrAffx.1.39</td>
###xml 787 795 787 795 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AF302789</td>
###xml 795 798 795 798 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 798 812 798 812 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Death receptor</td>
###xml 776 812 776 812 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">DrAffx.1.39</td><td align="left">AF302789</td><td char="." align="char">2.3</td><td align="left">Death receptor</td></tr>
###xml 812 820 812 820 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.20106</td>
###xml 820 828 820 828 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI722277</td>
###xml 828 831 828 831 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.8</td>
###xml 831 852 831 852 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Apoptosis inhibitor 5</td>
###xml 812 852 812 852 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.20106</td><td align="left">AI722277</td><td char="." align="char">2.8</td><td align="left">Apoptosis inhibitor 5</td></tr>
###xml 852 859 852 859 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4039</td>
###xml 859 867 859 867 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ480688</td>
###xml 867 871 867 871 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21.8</td>
###xml 871 886 871 886 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BAX inhibitor 1</td>
###xml 852 886 852 886 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4039</td><td align="left">BQ480688</td><td char="." align="char">21.8</td><td align="left">BAX inhibitor 1</td></tr>
###xml 886 899 886 899 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Cell adhesion</td>
###xml 886 899 886 899 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Cell adhesion</td></tr>
###xml 899 906 899 906 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.6007</td>
###xml 906 915 906 915 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131820</td>
###xml 915 918 915 918 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.9</td>
###xml 918 928 918 928 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cadherin 1</td>
###xml 899 928 899 928 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.6007</td><td align="left">NM_131820</td><td char="." align="char">2.9</td><td align="left">Cadherin 1</td></tr>
###xml 928 936 928 936 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.25140</td>
###xml 936 944 936 944 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ262802</td>
###xml 944 947 944 947 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.3</td>
###xml 947 990 947 990 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tumor-associated calcium signal transducer </td>
###xml 928 990 928 990 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.25140</td><td align="left">BQ262802</td><td char="." align="char">3.3</td><td align="left">Tumor-associated calcium signal transducer </td></tr>
###xml 990 997 990 997 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4409</td>
###xml 997 1005 997 1005 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC049036</td>
###xml 1005 1008 1005 1008 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.4</td>
###xml 1008 1019 1008 1019 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD9 antigen</td>
###xml 990 1019 990 1019 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4409</td><td align="left">BC049036</td><td char="." align="char">4.4</td><td align="left">CD9 antigen</td></tr>
###xml 1019 1027 1019 1027 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.25140</td>
###xml 1027 1035 1027 1035 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ262802</td>
###xml 1035 1038 1035 1038 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.7</td>
###xml 1038 1093 1038 1093 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tumor-associated calcium signal transducer glycoprotein</td>
###xml 1019 1093 1019 1093 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.25140</td><td align="left">BQ262802</td><td char="." align="char">7.7</td><td align="left">Tumor-associated calcium signal transducer glycoprotein</td></tr>
###xml 1093 1104 1093 1104 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Development</td>
###xml 1093 1104 1093 1104 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Development</td></tr>
###xml 1104 1112 1104 1112 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.11575</td>
###xml 1112 1119 1112 1119 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_1732</td>
###xml 1119 1122 1119 1122 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 1122 1164 1122 1164 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">T-cell acute lymphocyte leukemia 1 (tal 1)</td>
###xml 1104 1164 1104 1164 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.11575</td><td align="left">NM_1732</td><td char="." align="char">2.3</td><td align="left">T-cell acute lymphocyte leukemia 1 (tal 1)</td></tr>
###xml 1164 1172 1164 1172 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.23348</td>
###xml 1172 1180 1172 1180 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE201653</td>
###xml 1180 1183 1180 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.6</td>
###xml 1183 1221 1183 1221 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Bone morphogenetic protein 3b; (bmp 3)</td>
###xml 1164 1221 1164 1221 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.23348</td><td align="left">BE201653</td><td char="." align="char">2.6</td><td align="left">Bone morphogenetic protein 3b; (bmp 3)</td></tr>
###xml 1221 1228 1221 1228 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr25405</td>
###xml 1228 1236 1228 1236 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC013923</td>
###xml 1236 1239 1236 1239 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.8</td>
###xml 1239 1253 1239 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SOX2 SRY-box 2</td>
###xml 1221 1253 1221 1253 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr25405</td><td align="left">BC013923</td><td char="." align="char">2.8</td><td align="left">SOX2 SRY-box 2</td></tr>
###xml 1253 1260 1253 1260 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.6382</td>
###xml 1260 1268 1260 1268 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW165053</td>
###xml 1268 1271 1268 1271 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.9</td>
###xml 1271 1299 1271 1299 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hedgehog-interacting protein</td>
###xml 1253 1299 1253 1299 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.6382</td><td align="left">AW165053</td><td char="." align="char">2.9</td><td align="left">Hedgehog-interacting protein</td></tr>
###xml 1299 1307 1299 1307 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.10879</td>
###xml 1307 1313 1307 1313 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">U97669</td>
###xml 1313 1316 1313 1316 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.0</td>
###xml 1340 1350 1340 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 1316 1351 1316 1351 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NOTCH3 Notch homolog 3 (<italic>Drosophila</italic>)</td>
###xml 1299 1351 1299 1351 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.10879</td><td align="left">U97669</td><td char="." align="char">3.0</td><td align="left">NOTCH3 Notch homolog 3 (<italic>Drosophila</italic>)</td></tr>
###xml 1351 1359 1351 1359 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.15055</td>
###xml 1359 1367 1359 1367 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC050172</td>
###xml 1367 1370 1367 1370 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.6</td>
###xml 1370 1391 1370 1391 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Chemokine receptor 4a</td>
###xml 1351 1391 1351 1391 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.15055</td><td align="left">BC050172</td><td char="." align="char">3.6</td><td align="left">Chemokine receptor 4a</td></tr>
###xml 1391 1398 1391 1398 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.6787</td>
###xml 1398 1406 1398 1406 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI533426</td>
###xml 1406 1409 1406 1409 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.5</td>
###xml 1409 1415 1409 1415 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Noelin</td>
###xml 1391 1415 1391 1415 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.6787</td><td align="left">BI533426</td><td char="." align="char">5.5</td><td align="left">Noelin</td></tr>
###xml 1415 1423 1415 1423 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.16720</td>
###xml 1423 1431 1423 1431 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI980847</td>
###xml 1431 1434 1431 1434 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.3</td>
###xml 1434 1441 1434 1441 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">notch 2</td>
###xml 1415 1441 1415 1441 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.16720</td><td align="left">BI980847</td><td char="." align="char">6.3</td><td align="left">notch 2</td></tr>
###xml 1441 1456 1441 1456 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Disease related</td>
###xml 1441 1456 1441 1456 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Disease related</td></tr>
###xml 1456 1463 1456 1463 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.6349</td>
###xml 1463 1471 1463 1471 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW116668</td>
###xml 1471 1474 1471 1474 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.4</td>
###xml 1474 1492 1474 1492 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Eparin cofactor II</td>
###xml 1456 1492 1456 1492 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.6349</td><td align="left">AW116668</td><td char="." align="char">2.4</td><td align="left">Eparin cofactor II</td></tr>
###xml 1492 1500 1492 1500 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.21064</td>
###xml 1500 1508 1500 1508 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC046075</td>
###xml 1508 1511 1508 1511 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.5</td>
###xml 1511 1549 1511 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4hydroxyphenylpyruvate dioxygenase HPD</td>
###xml 1492 1549 1492 1549 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.21064</td><td align="left">BC046075</td><td char="." align="char">4.5</td><td align="left">4hydroxyphenylpyruvate dioxygenase HPD</td></tr>
###xml 1549 1557 1549 1557 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12584</td>
###xml 1557 1566 1557 1566 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131211</td>
###xml 1566 1569 1566 1569 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.4</td>
###xml 1569 1599 1569 1599 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gata binding protein 3 (GATA3)</td>
###xml 1549 1599 1549 1599 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12584</td><td align="left">NM_131211</td><td char="." align="char">5.4</td><td align="left">Gata binding protein 3 (GATA3)</td></tr>
###xml 1599 1606 1599 1606 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3530</td>
###xml 1606 1614 1606 1614 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI497545</td>
###xml 1614 1618 1614 1618 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">79.3</td>
###xml 1618 1642 1618 1642 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Prion protein (prp) gene</td>
###xml 1599 1642 1599 1642 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3530</td><td align="left">AI497545</td><td char="." align="char">79.3</td><td align="left">Prion protein (prp) gene</td></tr>
###xml 1642 1659 1642 1659 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Growth regulation</td>
###xml 1642 1659 1642 1659 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Growth regulation</td></tr>
###xml 1659 1666 1659 1666 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.8145</td>
###xml 1666 1674 1666 1674 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_13143</td>
###xml 1674 1677 1674 1677 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.2</td>
###xml 1677 1713 1677 1713 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Insulin like growth factor 2 (IGF-2)</td>
###xml 1659 1713 1659 1713 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.8145</td><td align="left">NM_13143</td><td char="." align="char">2.2</td><td align="left">Insulin like growth factor 2 (IGF-2)</td></tr>
###xml 1713 1720 1713 1720 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.7609</td>
###xml 1720 1728 1720 1728 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI475857</td>
###xml 1728 1731 1728 1731 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.4</td>
###xml 1731 1749 1731 1749 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Prolactin receptor</td>
###xml 1713 1749 1713 1749 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.7609</td><td align="left">BI475857</td><td char="." align="char">2.4</td><td align="left">Prolactin receptor</td></tr>
###xml 1749 1756 1749 1756 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.8285</td>
###xml 1756 1764 1756 1764 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_13136</td>
###xml 1764 1767 1764 1767 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.4</td>
###xml 1767 1781 1767 1781 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mad homolog 2 </td>
###xml 1749 1781 1749 1781 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.8285</td><td align="left">NM_13136</td><td char="." align="char">2.4</td><td align="left">Mad homolog 2 </td></tr>
###xml 1781 1788 1781 1788 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.8947</td>
###xml 1788 1796 1788 1796 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD594735</td>
###xml 1796 1799 1796 1799 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.5</td>
###xml 1799 1806 1799 1806 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Spint 2</td>
###xml 1781 1806 1781 1806 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.8947</td><td align="left">CD594735</td><td char="." align="char">2.5</td><td align="left">Spint 2</td></tr>
###xml 1806 1812 1806 1812 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.822</td>
###xml 1812 1820 1812 1820 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM184127</td>
###xml 1820 1823 1820 1823 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.5</td>
###xml 1823 1830 1823 1830 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Spint 2</td>
###xml 1806 1830 1806 1830 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.822</td><td align="left">BM184127</td><td char="." align="char">2.5</td><td align="left">Spint 2</td></tr>
###xml 1830 1837 1830 1837 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3563</td>
###xml 1837 1845 1837 1845 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD014488</td>
###xml 1845 1848 1845 1848 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.8</td>
###xml 1848 1881 1848 1881 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tetraspan membrane protein IL-TMP</td>
###xml 1830 1881 1830 1881 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3563</td><td align="left">CD014488</td><td char="." align="char">2.8</td><td align="left">Tetraspan membrane protein IL-TMP</td></tr>
###xml 1881 1888 1881 1888 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.8587</td>
###xml 1888 1896 1888 1896 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_17328</td>
###xml 1896 1899 1896 1899 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.9</td>
###xml 1899 1944 1899 1944 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Insulin-like growth factor binding protein 1 </td>
###xml 1881 1944 1881 1944 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.8587</td><td align="left">NM_17328</td><td char="." align="char">2.9</td><td align="left">Insulin-like growth factor binding protein 1 </td></tr>
###xml 1944 1951 1944 1951 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.2596</td>
###xml 1951 1959 1951 1959 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM342901</td>
###xml 1959 1962 1959 1962 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.2</td>
###xml 1962 1970 1962 1970 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cyclin I</td>
###xml 1944 1970 1944 1970 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.2596</td><td align="left">BM342901</td><td char="." align="char">3.2</td><td align="left">Cyclin I</td></tr>
###xml 1970 1977 1970 1977 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.8587</td>
###xml 1977 1985 1977 1985 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AL910822</td>
###xml 1985 1988 1985 1988 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.4</td>
###xml 1988 2032 1988 2032 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Insulin-like growth factor binding protein 1</td>
###xml 1970 2032 1970 2032 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.8587</td><td align="left">AL910822</td><td char="." align="char">3.4</td><td align="left">Insulin-like growth factor binding protein 1</td></tr>
###xml 2032 2040 2032 2040 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.26458</td>
###xml 2040 2048 2040 2048 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC053206</td>
###xml 2048 2051 2048 2051 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.6</td>
###xml 2051 2056 2051 2056 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">m-ras</td>
###xml 2032 2056 2032 2056 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.26458</td><td align="left">BC053206</td><td char="." align="char">5.6</td><td align="left">m-ras</td></tr>
###xml 2056 2069 2056 2069 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Heart related</td>
###xml 2056 2069 2056 2069 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Heart related</td></tr>
###xml 2069 2077 2069 2077 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.15088</td>
###xml 2077 2085 2077 2085 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM181749</td>
###xml 2085 2088 2085 2088 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.3</td>
###xml 2088 2145 2088 2145 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Lectin galactoside-binding soluble 1; (galectin10-like 3)</td>
###xml 2069 2145 2069 2145 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.15088</td><td align="left">BM181749</td><td char="." align="char">4.3</td><td align="left">Lectin galactoside-binding soluble 1; (galectin10-like 3)</td></tr>
###xml 2145 2152 2145 2152 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4867</td>
###xml 2152 2160 2152 2160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI496840</td>
###xml 2160 2163 2160 2163 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.5</td>
###xml 2163 2174 2163 2174 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Haptoglobin</td>
###xml 2145 2174 2145 2174 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4867</td><td align="left">AI496840</td><td char="." align="char">5.5</td><td align="left">Haptoglobin</td></tr>
###xml 2174 2181 2174 2181 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3585</td>
###xml 2181 2189 2181 2189 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AY049731</td>
###xml 2189 2192 2189 2192 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.6</td>
###xml 2192 2208 2192 2208 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Angiotensinogen </td>
###xml 2174 2208 2174 2208 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3585</td><td align="left">AY049731</td><td char="." align="char">6.6</td><td align="left">Angiotensinogen </td></tr>
###xml 2208 2215 2208 2215 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.2452</td>
###xml 2215 2223 2215 2223 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ284848</td>
###xml 2223 2226 2223 2226 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.3</td>
###xml 2226 2250 2226 2250 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement component C9 </td>
###xml 2208 2250 2208 2250 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9 </td></tr>
###xml 2250 2258 2250 2258 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.18453</td>
###xml 2258 2266 2258 2266 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC044525</td>
###xml 2266 2269 2266 2269 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.8</td>
###xml 2269 2290 2269 2290 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Uridine phosphorylase</td>
###xml 2250 2290 2250 2290 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.18453</td><td align="left">BC044525</td><td char="." align="char">4.8</td><td align="left">Uridine phosphorylase</td></tr>
###xml 2290 2297 2290 2297 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3025</td>
###xml 2297 2305 2297 2305 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BG738204</td>
###xml 2305 2308 2305 2308 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.7</td>
###xml 2308 2336 2308 2336 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alpha-2 macro-globulin; A2MG</td>
###xml 2290 2336 2290 2336 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3025</td><td align="left">BG738204</td><td char="." align="char">2.7</td><td align="left">Alpha-2 macro-globulin; A2MG</td></tr>
###xml 2336 2348 2336 2348 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Inflammation</td>
###xml 2336 2348 2336 2348 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Inflammation</td></tr>
###xml 2348 2356 2348 2356 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12491</td>
###xml 2356 2364 2356 2364 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI672168</td>
###xml 2364 2367 2364 2367 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.1</td>
###xml 2367 2382 2367 2382 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement C4&#8211;2</td>
###xml 2348 2382 2348 2382 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12491</td><td align="left">BI672168</td><td char="." align="char">2.1</td><td align="left">Complement C4&#8211;2</td></tr>
###xml 2382 2389 2382 2389 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4047</td>
###xml 2389 2398 2389 2398 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131627</td>
###xml 2398 2401 2398 2401 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 2401 2435 2401 2435 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Small inducible cytokine A (scyba)</td>
###xml 2382 2435 2382 2435 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4047</td><td align="left">NM_131627</td><td char="." align="char">2.3</td><td align="left">Small inducible cytokine A (scyba)</td></tr>
###xml 2435 2442 2435 2442 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.5053</td>
###xml 2442 2451 2442 2451 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131723</td>
###xml 2451 2454 2451 2454 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 2454 2476 2454 2476 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kruppel-like factor 4 </td>
###xml 2435 2476 2435 2476 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.5053</td><td align="left">NM_131723</td><td char="." align="char">2.3</td><td align="left">Kruppel-like factor 4 </td></tr>
###xml 2476 2483 2476 2483 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr25207</td>
###xml 2483 2489 2483 2489 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X06465</td>
###xml 2489 2492 2489 2492 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.5</td>
###xml 2492 2533 2492 2533 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement component 8, gamma polypeptide</td>
###xml 2476 2533 2476 2533 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr25207</td><td align="left">X06465</td><td char="." align="char">2.5</td><td align="left">Complement component 8, gamma polypeptide</td></tr>
###xml 2533 2540 2533 2540 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.6845</td>
###xml 2540 2546 2540 2546 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">K02765</td>
###xml 2546 2549 2546 2549 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.9</td>
###xml 2549 2574 2549 2574 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C3 complement component 3</td>
###xml 2533 2574 2533 2574 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.6845</td><td align="left">K02765</td><td char="." align="char">2.9</td><td align="left">C3 complement component 3</td></tr>
###xml 2574 2581 2574 2581 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.5741</td>
###xml 2581 2589 2581 2589 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BU710482</td>
###xml 2589 2592 2589 2592 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.2</td>
###xml 2592 2617 2592 2617 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement component b fb</td>
###xml 2574 2617 2574 2617 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.5741</td><td align="left">BU710482</td><td char="." align="char">3.2</td><td align="left">Complement component b fb</td></tr>
###xml 2617 2624 2617 2624 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.7722</td>
###xml 2624 2632 2624 2632 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI878414</td>
###xml 2632 2635 2632 2635 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.5</td>
###xml 2635 2651 2635 2651 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement C3-H1</td>
###xml 2617 2651 2617 2651 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.7722</td><td align="left">BI878414</td><td char="." align="char">3.5</td><td align="left">Complement C3-H1</td></tr>
###xml 2651 2659 2651 2659 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.22244</td>
###xml 2659 2667 2659 2667 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW019781</td>
###xml 2667 2670 2667 2670 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.6</td>
###xml 2670 2684 2670 2684 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement C1s</td>
###xml 2651 2684 2651 2684 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.22244</td><td align="left">AW019781</td><td char="." align="char">3.6</td><td align="left">Complement C1s</td></tr>
###xml 2684 2692 2684 2692 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.22133</td>
###xml 2692 2700 2692 2700 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW076768</td>
###xml 2700 2703 2700 2703 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.7</td>
###xml 2703 2720 2703 2720 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">c1rs-A and clrs-B</td>
###xml 2684 2720 2684 2720 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.22133</td><td align="left">AW076768</td><td char="." align="char">3.7</td><td align="left">c1rs-A and clrs-B</td></tr>
###xml 2720 2727 2720 2727 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.5528</td>
###xml 2727 2735 2727 2735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI497212</td>
###xml 2735 2738 2735 2738 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.2</td>
###xml 2738 2761 2738 2761 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement component C9</td>
###xml 2720 2761 2720 2761 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.5528</td><td align="left">AI497212</td><td char="." align="char">4.2</td><td align="left">Complement component C9</td></tr>
###xml 2761 2768 2761 2768 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.2452</td>
###xml 2768 2776 2768 2776 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ284848</td>
###xml 2776 2779 2776 2779 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.3</td>
###xml 2779 2803 2779 2803 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement component C9 </td>
###xml 2761 2803 2761 2803 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9 </td></tr>
###xml 2803 2810 2803 2810 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1730</td>
###xml 2810 2818 2810 2818 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI721528</td>
###xml 2818 2821 2818 2821 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.8</td>
###xml 2821 2865 2821 2865 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">cfI-B complement control protein factor I-B </td>
###xml 2803 2865 2803 2865 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1730</td><td align="left">AI721528</td><td char="." align="char">4.8</td><td align="left">cfI-B complement control protein factor I-B </td></tr>
###xml 2865 2872 2865 2872 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.2452</td>
###xml 2872 2880 2872 2880 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM778002</td>
###xml 2880 2883 2880 2883 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.8</td>
###xml 2883 2906 2883 2906 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement component C9</td>
###xml 2865 2906 2865 2906 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.2452</td><td align="left">BM778002</td><td char="." align="char">5.8</td><td align="left">Complement component C9</td></tr>
###xml 2906 2914 2906 2914 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.20291</td>
###xml 2914 2922 2914 2922 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM036389</td>
###xml 2922 2925 2922 2925 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.5</td>
###xml 2925 2940 2925 2940 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement C3-S</td>
###xml 2906 2940 2906 2940 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.20291</td><td align="left">BM036389</td><td char="." align="char">6.5</td><td align="left">Complement C3-S</td></tr>
###xml 2940 2946 2940 2946 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.190</td>
###xml 2946 2955 2946 2955 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131338</td>
###xml 2955 2958 2955 2958 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.9</td>
###xml 2958 2988 2958 2988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement component factor B </td>
###xml 2940 2988 2940 2988 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.190</td><td align="left">NM_131338</td><td char="." align="char">7.9</td><td align="left">Complement component factor B </td></tr>
###xml 2988 2995 2988 2995 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1192</td>
###xml 2995 3003 2995 3003 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AB071601</td>
###xml 3003 3005 3003 3005 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.</td>
###xml 3005 3057 3005 3057 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Lipocalin-type prostaglandin D synthase-like protein</td>
###xml 2988 3057 2988 3057 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1192</td><td align="left">AB071601</td><td char="." align="char">2.</td><td align="left">Lipocalin-type prostaglandin D synthase-like protein</td></tr>
###xml 3057 3067 3057 3067 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Metabolism</td>
###xml 3057 3067 3057 3067 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Metabolism</td></tr>
###xml 3067 3074 3067 3074 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.9492</td>
###xml 3074 3082 3074 3082 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI882244</td>
###xml 3082 3085 3082 3085 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.0</td>
###xml 3085 3111 3085 3111 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sulfide dehydrogenase like</td>
###xml 3067 3111 3067 3111 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.9492</td><td align="left">BI882244</td><td char="." align="char">2.0</td><td align="left">Sulfide dehydrogenase like</td></tr>
###xml 3111 3119 3111 3119 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.15574</td>
###xml 3119 3127 3119 3127 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM571467</td>
###xml 3127 3130 3127 3130 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.1</td>
###xml 3130 3172 3130 3172 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hypoxanthine _hosphor-ribosyltransferase 1</td>
###xml 3111 3172 3111 3172 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.15574</td><td align="left">BM571467</td><td char="." align="char">2.1</td><td align="left">Hypoxanthine _hosphor-ribosyltransferase 1</td></tr>
###xml 3172 3179 3172 3179 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3332</td>
###xml 3179 3187 3179 3187 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI943053</td>
###xml 3187 3190 3187 3190 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.2</td>
###xml 3190 3205 3190 3205 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Angiopoietin 5 </td>
###xml 3172 3205 3172 3205 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3332</td><td align="left">AI943053</td><td char="." align="char">2.2</td><td align="left">Angiopoietin 5 </td></tr>
###xml 3205 3213 3205 3213 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.16130</td>
###xml 3213 3221 3213 3221 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD014898</td>
###xml 3221 3224 3221 3224 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 3224 3249 3224 3249 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alcohol dehydrogenase 8&#160;b</td>
###xml 3205 3249 3205 3249 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.16130</td><td align="left">CD014898</td><td char="." align="char">2.3</td><td align="left">Alcohol dehydrogenase 8&#160;b</td></tr>
###xml 3249 3256 3249 3256 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3959</td>
###xml 3256 3263 3256 3263 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI43001</td>
###xml 3263 3266 3263 3266 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.5</td>
###xml 3266 3281 3266 3281 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5&#8242;-nucleotidase</td>
###xml 3249 3281 3249 3281 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3959</td><td align="left">BI43001</td><td char="." align="char">2.5</td><td align="left">5&#8242;-nucleotidase</td></tr>
###xml 3281 3289 3281 3289 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.22205</td>
###xml 3289 3297 3289 3297 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW019477</td>
###xml 3297 3300 3297 3300 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.6</td>
###xml 3300 3314 3300 3314 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Oxidoreductase</td>
###xml 3281 3314 3281 3314 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.22205</td><td align="left">AW019477</td><td char="." align="char">2.6</td><td align="left">Oxidoreductase</td></tr>
###xml 3314 3321 3314 3321 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1699</td>
###xml 3321 3329 3321 3329 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI667249</td>
###xml 3329 3332 3329 3332 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.7</td>
###xml 3332 3347 3332 3347 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pyruvate kinase</td>
###xml 3314 3347 3314 3347 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1699</td><td align="left">AI667249</td><td char="." align="char">2.7</td><td align="left">Pyruvate kinase</td></tr>
###xml 3347 3354 3347 3354 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.5504</td>
###xml 3354 3362 3354 3362 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI879550</td>
###xml 3362 3365 3362 3365 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.2</td>
###xml 3365 3392 3365 3392 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cystathionine-beta-synthase</td>
###xml 3347 3392 3347 3392 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.5504</td><td align="left">BI879550</td><td char="." align="char">3.2</td><td align="left">Cystathionine-beta-synthase</td></tr>
###xml 3392 3399 3392 3399 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1202</td>
###xml 3399 3407 3399 3407 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AJ245491</td>
###xml 3407 3410 3407 3410 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.9</td>
###xml 3410 3428 3410 3428 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Apolipoprotein A-I</td>
###xml 3392 3428 3392 3428 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1202</td><td align="left">AJ245491</td><td char="." align="char">3.9</td><td align="left">Apolipoprotein A-I</td></tr>
###xml 3428 3435 3428 3435 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4111</td>
###xml 3435 3443 3435 3443 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC053267</td>
###xml 3443 3446 3443 3446 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.2</td>
###xml 3446 3475 3446 3475 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fructose-1,6-bisphosphatase 1</td>
###xml 3428 3475 3428 3475 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4111</td><td align="left">BC053267</td><td char="." align="char">4.2</td><td align="left">Fructose-1,6-bisphosphatase 1</td></tr>
###xml 3475 3483 3475 3483 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.18834</td>
###xml 3483 3491 3483 3491 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW019321</td>
###xml 3491 3494 3491 3494 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.2</td>
###xml 3494 3507 3494 3507 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Urate oxidase</td>
###xml 3475 3507 3475 3507 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.18834</td><td align="left">AW019321</td><td char="." align="char">4.2</td><td align="left">Urate oxidase</td></tr>
###xml 3507 3515 3507 3515 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.19224</td>
###xml 3515 3523 3515 3523 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC050167</td>
###xml 3523 3526 3523 3526 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.3</td>
###xml 3526 3536 3526 3536 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Aldolase b</td>
###xml 3507 3536 3507 3536 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.19224</td><td align="left">BC050167</td><td char="." align="char">4.3</td><td align="left">Aldolase b</td></tr>
###xml 3536 3543 3536 3543 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4938</td>
###xml 3543 3552 3543 3552 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131645</td>
###xml 3552 3555 3552 3555 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.4</td>
###xml 3555 3578 3555 3578 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fatty acid desaturase 2</td>
###xml 3536 3578 3536 3578 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4938</td><td align="left">NM_131645</td><td char="." align="char">4.4</td><td align="left">Fatty acid desaturase 2</td></tr>
###xml 3578 3586 3578 3586 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12654</td>
###xml 3586 3594 3586 3594 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC046901</td>
###xml 3594 3598 3594 3598 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14.8</td>
###xml 3598 3620 3598 3620 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ELOVL family member 6,</td>
###xml 3578 3620 3578 3620 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12654</td><td align="left">BC046901</td><td char="." align="char">14.8</td><td align="left">ELOVL family member 6,</td></tr>
###xml 3620 3627 3620 3627 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.5488</td>
###xml 3627 3635 3627 3635 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI545593</td>
###xml 3635 3639 3635 3639 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17.3</td>
###xml 3639 3659 3639 3659 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Apolipoprotein A-IV </td>
###xml 3620 3659 3620 3659 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.5488</td><td align="left">AI545593</td><td char="." align="char">17.3</td><td align="left">Apolipoprotein A-IV </td></tr>
###xml 3659 3673 3659 3673 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Muscle related</td>
###xml 3659 3673 3659 3673 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Muscle related</td></tr>
###xml 3673 3680 3673 3680 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3585</td>
###xml 3680 3688 3680 3688 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AY049731</td>
###xml 3688 3691 3688 3691 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.6</td>
###xml 3691 3706 3691 3706 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Angiotensinogen</td>
###xml 3673 3706 3673 3706 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3585</td><td align="left">AY049731</td><td char="." align="char">6.6</td><td align="left">Angiotensinogen</td></tr>
###xml 3706 3713 3706 3713 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.2452</td>
###xml 3713 3721 3713 3721 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ284848</td>
###xml 3721 3724 3721 3724 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.3</td>
###xml 3724 3747 3724 3747 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Complement component C9</td>
###xml 3706 3747 3706 3747 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9</td></tr>
###xml 3747 3758 3747 3758 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Proteolysis</td>
###xml 3747 3758 3747 3758 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Proteolysis</td></tr>
###xml 3758 3766 3758 3766 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.20934</td>
###xml 3766 3774 3766 3774 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AF541952</td>
###xml 3774 3777 3774 3777 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.6</td>
###xml 3777 3794 3777 3794 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Trypsin precursor</td>
###xml 3758 3794 3758 3794 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.20934</td><td align="left">AF541952</td><td char="." align="char">2.6</td><td align="left">Trypsin precursor</td></tr>
###xml 3794 3801 3794 3801 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3025</td>
###xml 3801 3809 3801 3809 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BG738204</td>
###xml 3809 3812 3809 3812 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.7</td>
###xml 3812 3834 3812 3834 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alpha-2-macroglobulin </td>
###xml 3794 3834 3794 3834 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3025</td><td align="left">BG738204</td><td char="." align="char">2.7</td><td align="left">Alpha-2-macroglobulin </td></tr>
###xml 3834 3842 3834 3842 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.22139</td>
###xml 3842 3850 3842 3850 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW018965</td>
###xml 3850 3853 3850 3853 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.0</td>
###xml 3853 3872 3853 3872 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alpha-1-antitrypsin</td>
###xml 3834 3872 3834 3872 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.22139</td><td align="left">AW018965</td><td char="." align="char">3.0</td><td align="left">Alpha-1-antitrypsin</td></tr>
###xml 3872 3880 3872 3880 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.25331</td>
###xml 3880 3888 3880 3888 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI658072</td>
###xml 3888 3891 3888 3891 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.1</td>
###xml 3891 3914 3891 3914 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alpha-2-macroglobulin-2</td>
###xml 3872 3914 3872 3914 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.25331</td><td align="left">AI658072</td><td char="." align="char">4.1</td><td align="left">Alpha-2-macroglobulin-2</td></tr>
###xml 3914 3922 3914 3922 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12602</td>
###xml 3922 3931 3922 3931 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_139180</td>
###xml 3931 3934 3931 3934 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.3</td>
###xml 3934 3942 3934 3942 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Lysozyme</td>
###xml 3914 3942 3914 3942 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12602</td><td align="left">NM_139180</td><td char="." align="char">4.3</td><td align="left">Lysozyme</td></tr>
###xml 3942 3949 3942 3949 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1605</td>
###xml 3949 3957 3949 3957 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM185388</td>
###xml 3957 3960 3957 3960 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.4</td>
###xml 3960 3980 3960 3980 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Protease inhibitor 1</td>
###xml 3942 3980 3942 3980 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1605</td><td align="left">BM185388</td><td char="." align="char">4.4</td><td align="left">Protease inhibitor 1</td></tr>
###xml 3980 3988 3980 3988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.17459</td>
###xml 3988 3996 3988 3996 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD586837</td>
###xml 3996 3999 3996 3999 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.8</td>
###xml 3999 4044 3999 4044 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Inter-alpha-trypsin inhibitor heavy chain H3 </td>
###xml 3980 4044 3980 4044 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.17459</td><td align="left">CD586837</td><td char="." align="char">4.8</td><td align="left">Inter-alpha-trypsin inhibitor heavy chain H3 </td></tr>
###xml 4044 4051 4044 4051 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3073</td>
###xml 4051 4059 4051 4059 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI585030</td>
###xml 4059 4062 4059 4062 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.0</td>
###xml 4062 4095 4062 4095 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Serine protease inhibitor alpha 1</td>
###xml 4044 4095 4044 4095 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3073</td><td align="left">AI585030</td><td char="." align="char">5.0</td><td align="left">Serine protease inhibitor alpha 1</td></tr>
###xml 4095 4103 4095 4103 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.26371</td>
###xml 4103 4111 4103 4111 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI667676</td>
###xml 4111 4114 4111 4114 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.4</td>
###xml 4114 4123 4114 4123 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Prostasin</td>
###xml 4095 4123 4095 4123 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.26371</td><td align="left">AI667676</td><td char="." align="char">5.4</td><td align="left">Prostasin</td></tr>
###xml 4123 4130 4123 4130 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3025</td>
###xml 4130 4138 4130 4138 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM530427</td>
###xml 4138 4141 4138 4141 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.6</td>
###xml 4141 4164 4141 4164 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alpha-2-macroglobulin-1</td>
###xml 4123 4164 4123 4164 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3025</td><td align="left">BM530427</td><td char="." align="char">5.6</td><td align="left">Alpha-2-macroglobulin-1</td></tr>
###xml 4164 4171 4164 4171 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3025</td>
###xml 4171 4179 4171 4179 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM316867</td>
###xml 4179 4182 4179 4182 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.5</td>
###xml 4182 4205 4182 4205 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alpha-2-macroglobulin-2</td>
###xml 4164 4205 4164 4205 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3025</td><td align="left">BM316867</td><td char="." align="char">6.5</td><td align="left">Alpha-2-macroglobulin-2</td></tr>
###xml 4205 4212 4205 4212 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.2960</td>
###xml 4212 4218 4212 4218 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X67055</td>
###xml 4218 4221 4218 4221 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.5</td>
###xml 4221 4273 4221 4273 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ITIH3 pre-alpha (globulin) inhibitor, H3 polypeptide</td>
###xml 4205 4273 4205 4273 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.2960</td><td align="left">X67055</td><td char="." align="char">3.5</td><td align="left">ITIH3 pre-alpha (globulin) inhibitor, H3 polypeptide</td></tr>
###xml 4273 4281 4273 4281 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.25379</td>
###xml 4281 4289 4281 4289 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI326783</td>
###xml 4289 4292 4289 4292 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.7</td>
###xml 4292 4313 4292 4313 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alpha-2-macroglobulin</td>
###xml 4273 4313 4273 4313 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.25379</td><td align="left">BI326783</td><td char="." align="char">6.7</td><td align="left">Alpha-2-macroglobulin</td></tr>
###xml 4313 4320 4313 4320 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4797</td>
###xml 4320 4328 4320 4328 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI959534</td>
###xml 4328 4331 4328 4331 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.8</td>
###xml 4331 4358 4331 4358 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26&#8211;29&#160;kD-Proteinase protein</td>
###xml 4313 4358 4313 4358 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4797</td><td align="left">AI959534</td><td char="." align="char">7.8</td><td align="left">26&#8211;29&#160;kD-Proteinase protein</td></tr>
###xml 4358 4372 4358 4372 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">ROS protection</td>
###xml 4358 4372 4358 4372 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">ROS protection</td></tr>
###xml 4372 4380 4372 4380 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.20068</td>
###xml 4380 4389 4380 4389 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131075</td>
###xml 4389 4392 4389 4392 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.1</td>
###xml 4392 4412 4392 4412 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Metallothionein (mt)</td>
###xml 4372 4412 4372 4412 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.20068</td><td align="left">NM_131075</td><td char="." align="char">2.1</td><td align="left">Metallothionein (mt)</td></tr>
###xml 4412 4419 4412 4419 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.5399</td>
###xml 4419 4427 4419 4427 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI957765</td>
###xml 4427 4430 4427 4430 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 4430 4457 4430 4457 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Biliverdin I Beta Reductase</td>
###xml 4412 4457 4412 4457 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.5399</td><td align="left">AI957765</td><td char="." align="char">2.3</td><td align="left">Biliverdin I Beta Reductase</td></tr>
###xml 4457 4465 4457 4465 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.14058</td>
###xml 4465 4473 4465 4473 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD015351</td>
###xml 4473 4476 4473 4476 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.5</td>
###xml 4488 4489 4488 4489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 4476 4509 4476 4509 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Glutathione <italic>S</italic>-transferase theta 1</td>
###xml 4457 4509 4457 4509 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.14058</td><td align="left">CD015351</td><td char="." align="char">3.5</td><td align="left">Glutathione <italic>S</italic>-transferase theta 1</td></tr>
###xml 4509 4517 4509 4517 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.25160</td>
###xml 4517 4525 4517 4525 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC049475</td>
###xml 4525 4528 4525 4528 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.9</td>
###xml 4528 4545 4528 4545 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Metallothionein 2</td>
###xml 4509 4545 4509 4545 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.25160</td><td align="left">BC049475</td><td char="." align="char">5.9</td><td align="left">Metallothionein 2</td></tr>
###xml 4545 4552 4545 4552 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3613</td>
###xml 4552 4560 4552 4560 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC048037</td>
###xml 4560 4563 4560 4563 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.0</td>
###xml 4563 4575 4563 4575 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cerulopasmin</td>
###xml 4545 4575 4545 4575 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3613</td><td align="left">BC048037</td><td char="." align="char">6.0</td><td align="left">Cerulopasmin</td></tr>
###xml 4575 4584 4575 4584 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4905.1</td>
###xml 4584 4592 4584 4592 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC045464</td>
###xml 4592 4595 4592 4595 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.5</td>
###xml 4595 4615 4595 4615 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Uncoupling protein 4</td>
###xml 4575 4615 4575 4615 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4905.1</td><td align="left">BC045464</td><td char="." align="char">6.5</td><td align="left">Uncoupling protein 4</td></tr>
###xml 4615 4634 4615 4634 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Signal transduction</td>
###xml 4615 4634 4615 4634 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Signal transduction</td></tr>
###xml 4634 4641 4634 4641 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.9852</td>
###xml 4641 4649 4641 4649 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW826425</td>
###xml 4649 4652 4649 4652 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.1</td>
###xml 4652 4664 4652 4664 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CAM kinase 1</td>
###xml 4634 4664 4634 4664 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.9852</td><td align="left">AW826425</td><td char="." align="char">2.1</td><td align="left">CAM kinase 1</td></tr>
###xml 4664 4671 4664 4671 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.8591</td>
###xml 4671 4679 4671 4679 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM186508</td>
###xml 4679 4682 4679 4682 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.9</td>
###xml 4682 4723 4682 4723 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Rho guanine nucleotide exchange factor 10</td>
###xml 4664 4723 4664 4723 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.8591</td><td align="left">BM186508</td><td char="." align="char">2.9</td><td align="left">Rho guanine nucleotide exchange factor 10</td></tr>
###xml 4723 4730 4723 4730 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.6236</td>
###xml 4730 4738 4730 4738 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW115973</td>
###xml 4738 4741 4738 4741 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.1</td>
###xml 4741 4781 4741 4781 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Rho guanine nucleotide exchange factor 5</td>
###xml 4723 4781 4723 4781 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.6236</td><td align="left">AW115973</td><td char="." align="char">3.1</td><td align="left">Rho guanine nucleotide exchange factor 5</td></tr>
###xml 4781 4788 4781 4788 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1267</td>
###xml 4788 4796 4788 4796 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC051157</td>
###xml 4796 4799 4796 4799 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.4</td>
###xml 4799 4820 4799 4820 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Phospholipase C delta</td>
###xml 4781 4820 4781 4820 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1267</td><td align="left">BC051157</td><td char="." align="char">3.4</td><td align="left">Phospholipase C delta</td></tr>
###xml 4820 4828 4820 4828 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.22129</td>
###xml 4828 4836 4828 4836 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC016668</td>
###xml 4836 4839 4836 4839 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.9</td>
###xml 4839 4878 4839 4878 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RRAGC Rag C (Ras-related GTP binding C)</td>
###xml 4820 4878 4820 4878 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.22129</td><td align="left">BC016668</td><td char="." align="char">3.9</td><td align="left">RRAGC Rag C (Ras-related GTP binding C)</td></tr>
###xml 4878 4885 4878 4885 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.7255</td>
###xml 4885 4893 4885 4893 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW116479</td>
###xml 4893 4896 4893 4896 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.4</td>
###xml 4896 4918 4896 4918 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Protein phosphatase 1,</td>
###xml 4878 4918 4878 4918 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.7255</td><td align="left">AW116479</td><td char="." align="char">4.4</td><td align="left">Protein phosphatase 1,</td></tr>
###xml 4918 4925 4918 4925 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4453</td>
###xml 4925 4933 4925 4933 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC044421</td>
###xml 4933 4936 4933 4936 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.8</td>
###xml 4936 4962 4936 4962 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Phosphoprotein phosphatase</td>
###xml 4918 4962 4918 4962 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4453</td><td align="left">BC044421</td><td char="." align="char">5.8</td><td align="left">Phosphoprotein phosphatase</td></tr>
###xml 4962 4973 4962 4973 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Translation</td>
###xml 4962 4973 4962 4973 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Translation</td></tr>
###xml 4973 4981 4973 4981 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.13234</td>
###xml 4981 4989 4981 4989 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM036471</td>
###xml 4989 4992 4989 4992 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.0</td>
###xml 4992 5007 4992 5007 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ribonuclease P </td>
###xml 4973 5007 4973 5007 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.13234</td><td align="left">BM036471</td><td char="." align="char">2.0</td><td align="left">Ribonuclease P </td></tr>
###xml 5007 5013 5007 5013 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.382</td>
###xml 5013 5021 5013 5021 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CB363830</td>
###xml 5021 5024 5021 5024 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.1</td>
###xml 5024 5033 5024 5033 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Nucleolin</td>
###xml 5007 5033 5007 5033 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.382</td><td align="left">CB363830</td><td char="." align="char">2.1</td><td align="left">Nucleolin</td></tr>
###xml 5033 5040 5033 5040 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.6949</td>
###xml 5040 5048 5040 5048 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW078116</td>
###xml 5048 5051 5048 5051 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.1</td>
###xml 5051 5107 5051 5107 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RNA 3&#8242;-terminal phosphate cyclase-like protein (HSPC338)</td>
###xml 5033 5107 5033 5107 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.6949</td><td align="left">AW078116</td><td char="." align="char">2.1</td><td align="left">RNA 3&#8242;-terminal phosphate cyclase-like protein (HSPC338)</td></tr>
###xml 5107 5115 5107 5115 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.13563</td>
###xml 5115 5123 5115 5123 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI890729</td>
###xml 5123 5126 5123 5126 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 5126 5152 5126 5152 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Methionyl aminopeptidase 2</td>
###xml 5107 5152 5107 5152 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.13563</td><td align="left">BI890729</td><td char="." align="char">2.3</td><td align="left">Methionyl aminopeptidase 2</td></tr>
###xml 5152 5160 5152 5160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.26328</td>
###xml 5160 5168 5160 5168 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AL723696</td>
###xml 5168 5171 5168 5171 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 5171 5215 5171 5215 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Eukaryotic translation initiation factor 4A,</td>
###xml 5152 5215 5152 5215 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.26328</td><td align="left">AL723696</td><td char="." align="char">2.3</td><td align="left">Eukaryotic translation initiation factor 4A,</td></tr>
###xml 5215 5223 5215 5223 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.17693</td>
###xml 5223 5231 5223 5231 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ078285</td>
###xml 5231 5234 5231 5234 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.7</td>
###xml 5234 5259 5234 5259 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">40&#160;S ribosomal protein S6</td>
###xml 5215 5259 5215 5259 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.17693</td><td align="left">BQ078285</td><td char="." align="char">3.7</td><td align="left">40&#160;S ribosomal protein S6</td></tr>
###xml 5259 5267 5259 5267 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.20270</td>
###xml 5267 5275 5267 5275 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI674050</td>
###xml 5275 5278 5275 5278 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.9</td>
###xml 5278 5300 5278 5300 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ribosomal protein L12 </td>
###xml 5259 5300 5259 5300 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.20270</td><td align="left">BI674050</td><td char="." align="char">5.9</td><td align="left">Ribosomal protein L12 </td></tr>
###xml 5300 5308 5300 5308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.25224</td>
###xml 5308 5316 5308 5316 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD015330</td>
###xml 5316 5320 5316 5320 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20.4</td>
###xml 5320 5342 5320 5342 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ribosomal protein L12 </td>
###xml 5300 5342 5300 5342 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.25224</td><td align="left">CD015330</td><td char="." align="char">20.4</td><td align="left">Ribosomal protein L12 </td></tr>
###xml 5342 5350 5342 5350 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12439</td>
###xml 5350 5358 5350 5358 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM533848</td>
###xml 5358 5362 5358 5362 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17.5</td>
###xml 5362 5404 5362 5404 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Heterogeneous nuclear ribonucleoprotein K </td>
###xml 5342 5404 5342 5404 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12439</td><td align="left">BM533848</td><td char="." align="char">17.5</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr>
###xml 5404 5412 5404 5412 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12439</td>
###xml 5412 5420 5412 5420 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM533848</td>
###xml 5420 5424 5420 5424 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24.2</td>
###xml 5424 5465 5424 5465 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Heterogeneous nuclear ribonucleoprotein K</td>
###xml 5404 5465 5404 5465 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12439</td><td align="left">BM533848</td><td char="." align="char">24.2</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr>
###xml 5465 5473 5465 5473 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.14821</td>
###xml 5473 5481 5473 5481 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM071714</td>
###xml 5481 5485 5481 5485 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33.8</td>
###xml 5485 5527 5485 5527 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Heterogeneous nuclear ribonucleoprotein K </td>
###xml 5465 5527 5465 5527 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.14821</td><td align="left">BM071714</td><td char="." align="char">33.8</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr>
###xml 5527 5535 5527 5535 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12502</td>
###xml 5535 5543 5535 5543 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ284686</td>
###xml 5543 5547 5543 5547 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">40.7</td>
###xml 5547 5589 5547 5589 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Heterogeneous nuclear ribonucleoprotein K </td>
###xml 5527 5589 5527 5589 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12502</td><td align="left">BQ284686</td><td char="." align="char">40.7</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr>
###xml 5589 5599 5589 5599 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12439. </td>
###xml 5599 5607 5599 5607 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM534432</td>
###xml 5607 5611 5607 5611 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">40.9</td>
###xml 5611 5652 5611 5652 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Heterogeneous nuclear ribonucleoprotein K</td>
###xml 5589 5652 5589 5652 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12439. </td><td align="left">BM534432</td><td char="." align="char">40.9</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr>
###xml 5652 5660 5652 5660 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12439</td>
###xml 5660 5668 5660 5668 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ616930</td>
###xml 5668 5672 5668 5672 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">45.4</td>
###xml 5672 5713 5672 5713 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Heterogeneous nuclear ribonucleoprotein K</td>
###xml 5652 5713 5652 5713 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12439</td><td align="left">BQ616930</td><td char="." align="char">45.4</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr>
###xml 5713 5722 5713 5722 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Transport</td>
###xml 5713 5722 5713 5722 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Transport</td></tr>
###xml 5722 5729 5722 5729 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1084</td>
###xml 5729 5737 5729 5737 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ109772</td>
###xml 5737 5740 5737 5740 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.0</td>
###xml 5740 5775 5740 5775 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Clathrin coat assembly protein AP19</td>
###xml 5722 5775 5722 5775 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1084</td><td align="left">BQ109772</td><td char="." align="char">3.0</td><td align="left">Clathrin coat assembly protein AP19</td></tr>
###xml 5775 5782 5775 5782 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.5562</td>
###xml 5782 5788 5782 5788 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X04506</td>
###xml 5788 5791 5788 5791 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.0</td>
###xml 5791 5838 5791 5838 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">APOB apolipoprotein B (including Ag(x) antigen)</td>
###xml 5775 5838 5775 5838 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.5562</td><td align="left">X04506</td><td char="." align="char">3.0</td><td align="left">APOB apolipoprotein B (including Ag(x) antigen)</td></tr>
###xml 5838 5846 5838 5846 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.13231</td>
###xml 5846 5854 5846 5854 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM778646</td>
###xml 5854 5857 5854 5857 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.2</td>
###xml 5857 5881 5857 5881 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solute carrier family 22</td>
###xml 5838 5881 5838 5881 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.13231</td><td align="left">BM778646</td><td char="." align="char">4.2</td><td align="left">Solute carrier family 22</td></tr>
###xml 5881 5889 5881 5889 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.30444</td>
###xml 5889 5897 5889 5897 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AY329629</td>
###xml 5897 5900 5897 5900 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.3</td>
###xml 5900 5924 5900 5924 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Embryonic globin beta e2</td>
###xml 5881 5924 5881 5924 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.30444</td><td align="left">AY329629</td><td char="." align="char">4.3</td><td align="left">Embryonic globin beta e2</td></tr>
###xml 5924 5932 5924 5932 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.24250</td>
###xml 5932 5940 5932 5940 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AF489105</td>
###xml 5940 5943 5940 5943 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.0</td>
###xml 5943 5972 5943 5972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Uroporphyrinogen III synthase</td>
###xml 5924 5972 5924 5972 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.24250</td><td align="left">AF489105</td><td char="." align="char">2.0</td><td align="left">Uroporphyrinogen III synthase</td></tr>
###xml 5972 5980 5972 5980 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.10343</td>
###xml 5980 5989 5980 5989 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131687</td>
###xml 5989 5992 5989 5992 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.7</td>
###xml 5992 6034 5992 6034 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Na+K+ transporting, alpha 1a.2 polypeptide</td>
###xml 5972 6034 5972 6034 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.10343</td><td align="left">NM_131687</td><td char="." align="char">4.7</td><td align="left">Na+K+ transporting, alpha 1a.2 polypeptide</td></tr>
###xml 6034 6041 6034 6041 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.7634</td>
###xml 6041 6049 6041 6049 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW115757</td>
###xml 6049 6053 6049 6053 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11.3</td>
###xml 6053 6062 6053 6062 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hemopexin</td>
###xml 6034 6062 6034 6062 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.7634</td><td align="left">AW115757</td><td char="." align="char">11.3</td><td align="left">Hemopexin</td></tr>
###xml 6062 6081 6062 6081 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Downregulated genes</td>
###xml 6062 6081 6062 6081 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Downregulated genes</td></tr>
###xml 6081 6093 6081 6093 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Angiogenesis</td>
###xml 6081 6093 6081 6093 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Angiogenesis</td></tr>
###xml 6093 6101 6093 6101 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.26411</td>
###xml 6101 6109 6101 6109 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ783571</td>
###xml 6109 6113 6109 6113 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;8.9</td>
###xml 6113 6135 6113 6135 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fast muscle troponin I</td>
###xml 6093 6135 6093 6135 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.26411</td><td align="left">BQ783571</td><td char="." align="char">&#8722;8.9</td><td align="left">Fast muscle troponin I</td></tr>
###xml 6135 6143 6135 6143 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.15501</td>
###xml 6143 6151 6143 6151 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM316040</td>
###xml 6151 6155 6151 6155 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.1</td>
###xml 6155 6247 6155 6247 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Similar to CYR6 HUMAN CYR61 protein precursor, Insulin-like growth factor-binding protein 10</td>
###xml 6135 6247 6135 6247 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.15501</td><td align="left">BM316040</td><td char="." align="char">&#8722;2.1</td><td align="left">Similar to CYR6 HUMAN CYR61 protein precursor, Insulin-like growth factor-binding protein 10</td></tr>
###xml 6247 6260 6247 6260 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Cell adhesion</td>
###xml 6247 6260 6247 6260 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Cell adhesion</td></tr>
###xml 6260 6266 6260 6266 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.251</td>
###xml 6266 6274 6266 6274 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ285646</td>
###xml 6274 6278 6274 6278 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.3</td>
###xml 6278 6289 6278 6289 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cadherin 11</td>
###xml 6260 6289 6260 6289 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.251</td><td align="left">BQ285646</td><td char="." align="char">&#8722;2.3</td><td align="left">Cadherin 11</td></tr>
###xml 6289 6304 6289 6304 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Disease related</td>
###xml 6289 6304 6289 6304 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Disease related</td></tr>
###xml 6304 6312 6304 6312 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.22774</td>
###xml 6312 6320 6312 6320 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW280206</td>
###xml 6320 6324 6320 6324 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;5.7</td>
###xml 6324 6359 6324 6359 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ras-like GTP-binding protein RAB27A</td>
###xml 6304 6359 6304 6359 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.22774</td><td align="left">AW280206</td><td char="." align="char">&#8722;5.7</td><td align="left">ras-like GTP-binding protein RAB27A</td></tr>
###xml 6359 6366 6359 6366 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1816</td>
###xml 6366 6374 6366 6374 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AL720262</td>
###xml 6374 6378 6374 6378 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;4.4</td>
###xml 6378 6402 6378 6402 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ataxin 2-binding protein</td>
###xml 6359 6402 6359 6402 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1816</td><td align="left">AL720262</td><td char="." align="char">&#8722;4.4</td><td align="left">Ataxin 2-binding protein</td></tr>
###xml 6402 6409 6402 6409 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.9893</td>
###xml 6409 6417 6409 6417 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM036473</td>
###xml 6417 6421 6417 6421 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.3</td>
###xml 6421 6432 6421 6432 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibrillarin</td>
###xml 6402 6432 6402 6432 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.9893</td><td align="left">BM036473</td><td char="." align="char">&#8722;2.3</td><td align="left">Fibrillarin</td></tr>
###xml 6432 6440 6432 6440 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.16726</td>
###xml 6440 6448 6440 6448 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI429372</td>
###xml 6448 6452 6448 6452 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.0</td>
###xml 6452 6461 6452 6461 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">netrin G1</td>
###xml 6432 6461 6432 6461 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.16726</td><td align="left">BI429372</td><td char="." align="char">&#8722;2.0</td><td align="left">netrin G1</td></tr>
###xml 6461 6478 6461 6478 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Growth regulation</td>
###xml 6461 6478 6461 6478 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Growth regulation</td></tr>
###xml 6478 6486 6478 6486 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12986</td>
###xml 6486 6494 6486 6494 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CA787334</td>
###xml 6494 6498 6494 6498 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;5.3</td>
###xml 6498 6503 6498 6503 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">v-fos</td>
###xml 6478 6503 6478 6503 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12986</td><td align="left">CA787334</td><td char="." align="char">&#8722;5.3</td><td align="left">v-fos</td></tr>
###xml 6503 6511 6503 6511 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12986</td>
###xml 6511 6519 6511 6519 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI881979</td>
###xml 6519 6523 6519 6523 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;5.0</td>
###xml 6523 6528 6523 6528 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">v-fos</td>
###xml 6503 6528 6503 6528 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12986</td><td align="left">BI881979</td><td char="." align="char">&#8722;5.0</td><td align="left">v-fos</td></tr>
###xml 6528 6536 6528 6536 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12986</td>
###xml 6536 6544 6536 6544 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM957279</td>
###xml 6544 6548 6544 6548 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;4.5</td>
###xml 6548 6553 6548 6553 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">v-fos</td>
###xml 6528 6553 6528 6553 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12986</td><td align="left">BM957279</td><td char="." align="char">&#8722;4.5</td><td align="left">v-fos</td></tr>
###xml 6553 6560 6553 6560 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1221</td>
###xml 6560 6568 6560 6568 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW510198</td>
###xml 6568 6572 6568 6572 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;4.3</td>
###xml 6572 6587 6572 6587 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pmx-1b (PHOX-1)</td>
###xml 6553 6587 6553 6587 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1221</td><td align="left">AW510198</td><td char="." align="char">&#8722;4.3</td><td align="left">Pmx-1b (PHOX-1)</td></tr>
###xml 6587 6595 6587 6595 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12986</td>
###xml 6595 6603 6595 6603 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI881979</td>
###xml 6603 6607 6603 6607 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;4.2</td>
###xml 6607 6612 6607 6612 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">v-fos</td>
###xml 6587 6612 6587 6612 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12986</td><td align="left">BI881979</td><td char="." align="char">&#8722;4.2</td><td align="left">v-fos</td></tr>
###xml 6612 6620 6612 6620 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12410</td>
###xml 6620 6629 6620 6629 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131826</td>
###xml 6629 6633 6629 6633 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.4</td>
###xml 6633 6651 6633 6651 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sprouty homolog 4 </td>
###xml 6612 6651 6612 6651 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12410</td><td align="left">NM_131826</td><td char="." align="char">&#8722;2.4</td><td align="left">Sprouty homolog 4 </td></tr>
###xml 6651 6658 6651 6658 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.6431</td>
###xml 6658 6666 6658 6666 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC049326</td>
###xml 6666 6670 6666 6670 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.3</td>
###xml 6670 6705 6670 6705 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Suppressors of cytokine signaling 3</td>
###xml 6651 6705 6651 6705 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.6431</td><td align="left">BC049326</td><td char="." align="char">&#8722;2.3</td><td align="left">Suppressors of cytokine signaling 3</td></tr>
###xml 6705 6712 6705 6712 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.6511</td>
###xml 6712 6721 6712 6721 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_130922</td>
###xml 6721 6725 6721 6725 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.2</td>
###xml 6725 6752 6725 6752 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">B-cell translocation gene 2</td>
###xml 6705 6752 6705 6752 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.6511</td><td align="left">NM_130922</td><td char="." align="char">&#8722;2.2</td><td align="left">B-cell translocation gene 2</td></tr>
###xml 6752 6759 6752 6759 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.5365</td>
###xml 6759 6767 6759 6767 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI601685</td>
###xml 6767 6771 6767 6771 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.2</td>
###xml 6771 6801 6771 6801 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dual specificity phosphatase 5</td>
###xml 6752 6801 6752 6801 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.5365</td><td align="left">AI601685</td><td char="." align="char">&#8722;2.2</td><td align="left">Dual specificity phosphatase 5</td></tr>
###xml 6801 6809 6801 6809 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.12062</td>
###xml 6809 6817 6809 6817 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC047814</td>
###xml 6817 6821 6817 6821 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.1</td>
###xml 6821 6875 6821 6875 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Epidermal growth factor receptor kinase substrate EPS8</td>
###xml 6801 6875 6801 6875 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.12062</td><td align="left">BC047814</td><td char="." align="char">&#8722;2.1</td><td align="left">Epidermal growth factor receptor kinase substrate EPS8</td></tr>
###xml 6875 6883 6875 6883 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.17286</td>
###xml 6883 6891 6883 6891 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM777144</td>
###xml 6891 6895 6891 6895 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.0</td>
###xml 6895 6952 6895 6952 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hormone-regulated proliferation-associated 20&#160;kDa protein</td>
###xml 6875 6952 6875 6952 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.17286</td><td align="left">BM777144</td><td char="." align="char">&#8722;2.0</td><td align="left">Hormone-regulated proliferation-associated 20&#160;kDa protein</td></tr>
###xml 6952 6959 6952 6959 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.9448</td>
###xml 6959 6967 6959 6967 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM156058</td>
###xml 6967 6971 6967 6971 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.0</td>
###xml 6971 7021 6971 7021 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TGF-beta-inducible early growth response protein 2</td>
###xml 6952 7021 6952 7021 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.9448</td><td align="left">BM156058</td><td char="." align="char">&#8722;2.0</td><td align="left">TGF-beta-inducible early growth response protein 2</td></tr>
###xml 7021 7034 7021 7034 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Heart related</td>
###xml 7021 7034 7021 7034 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Heart related</td></tr>
###xml 7034 7042 7034 7042 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.20010</td>
###xml 7042 7050 7042 7050 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ826502</td>
###xml 7050 7054 7050 7054 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;7.0</td>
###xml 7054 7104 7054 7104 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ATPase, Ca++ transporting, cardiac muscle (ATP2A1)</td>
###xml 7034 7104 7034 7104 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.20010</td><td align="left">BQ826502</td><td char="." align="char">&#8722;7.0</td><td align="left">ATPase, Ca++ transporting, cardiac muscle (ATP2A1)</td></tr>
###xml 7104 7111 7104 7111 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1448</td>
###xml 7111 7119 7111 7119 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AL717344</td>
###xml 7119 7123 7119 7123 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;3.5</td>
###xml 7123 7158 7123 7158 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fast skeletal myosin light chain 1a</td>
###xml 7104 7158 7104 7158 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1448</td><td align="left">AL717344</td><td char="." align="char">&#8722;3.5</td><td align="left">Fast skeletal myosin light chain 1a</td></tr>
###xml 7158 7166 7158 7166 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.20990</td>
###xml 7166 7183 7166 7183 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AY033829 AY081167</td>
###xml 7183 7191 7183 7191 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.4&#8211;2.1</td>
###xml 7191 7196 7191 7196 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Titin</td>
###xml 7158 7196 7158 7196 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.20990</td><td align="left">AY033829 AY081167</td><td char="." align="char">&#8722;2.4&#8211;2.1</td><td align="left">Titin</td></tr>
###xml 7196 7206 7196 7206 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Metabolism</td>
###xml 7196 7206 7196 7206 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Metabolism</td></tr>
###xml 7206 7214 7206 7214 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.24950</td>
###xml 7214 7222 7214 7222 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC053305</td>
###xml 7222 7226 7222 7226 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;4.1</td>
###xml 7226 7246 7226 7246 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Creatine kinase CKM3</td>
###xml 7206 7246 7206 7246 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.24950</td><td align="left">BC053305</td><td char="." align="char">&#8722;4.1</td><td align="left">Creatine kinase CKM3</td></tr>
###xml 7246 7253 7246 7253 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.9528</td>
###xml 7253 7261 7253 7261 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC045993</td>
###xml 7261 7265 7261 7265 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;3.5</td>
###xml 7265 7294 7265 7294 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pyruvate dehydrogenase kinase</td>
###xml 7246 7294 7246 7294 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.9528</td><td align="left">BC045993</td><td char="." align="char">&#8722;3.5</td><td align="left">Pyruvate dehydrogenase kinase</td></tr>
###xml 7294 7300 7294 7300 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.146</td>
###xml 7300 7308 7300 7308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI477401</td>
###xml 7308 7312 7308 7312 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.9</td>
###xml 7322 7323 7322 7323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 7312 7347 7312 7347 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Carnitine <italic>O</italic>-palmitoyltransferase II</td>
###xml 7294 7347 7294 7347 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.146</td><td align="left">AI477401</td><td char="." align="char">&#8722;2.9</td><td align="left">Carnitine <italic>O</italic>-palmitoyltransferase II</td></tr>
###xml 7347 7355 7347 7355 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.21501</td>
###xml 7355 7363 7355 7363 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI667180</td>
###xml 7363 7367 7363 7367 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.4</td>
###xml 7367 7402 7367 7402 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Short-chain acyl-CoA dehydrogenase </td>
###xml 7347 7402 7347 7402 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.21501</td><td align="left">AI667180</td><td char="." align="char">&#8722;2.4</td><td align="left">Short-chain acyl-CoA dehydrogenase </td></tr>
###xml 7402 7410 7402 7410 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.19643</td>
###xml 7410 7418 7410 7418 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AL918850</td>
###xml 7418 7422 7418 7422 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.4</td>
###xml 7422 7451 7422 7451 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FabG beta-ketoacyl -reductase</td>
###xml 7402 7451 7402 7451 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.19643</td><td align="left">AL918850</td><td char="." align="char">&#8722;2.4</td><td align="left">FabG beta-ketoacyl -reductase</td></tr>
###xml 7451 7459 7451 7459 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.15059</td>
###xml 7459 7467 7459 7467 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM530407</td>
###xml 7467 7471 7467 7471 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.2</td>
###xml 7471 7520 7471 7520 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Elongation of very long chain fatty acids (Cig30)</td>
###xml 7451 7520 7451 7520 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.15059</td><td align="left">BM530407</td><td char="." align="char">&#8722;2.2</td><td align="left">Elongation of very long chain fatty acids (Cig30)</td></tr>
###xml 7520 7528 7520 7528 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.21040</td>
###xml 7528 7536 7528 7536 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC045479</td>
###xml 7536 7540 7536 7540 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.1</td>
###xml 7540 7582 7540 7582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Glucose-6-phosphatase, transport protein 1</td>
###xml 7520 7582 7520 7582 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.21040</td><td align="left">BC045479</td><td char="." align="char">&#8722;2.1</td><td align="left">Glucose-6-phosphatase, transport protein 1</td></tr>
###xml 7582 7588 7582 7588 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.988</td>
###xml 7588 7596 7588 7596 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW154697</td>
###xml 7596 7600 7596 7600 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.1</td>
###xml 7600 7638 7600 7638 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dodecenoyl-coenzyme A delta isomerase </td>
###xml 7582 7638 7582 7638 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.988</td><td align="left">AW154697</td><td char="." align="char">&#8722;2.1</td><td align="left">Dodecenoyl-coenzyme A delta isomerase </td></tr>
###xml 7638 7646 7638 7646 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.11971</td>
###xml 7646 7654 7646 7654 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BG727588</td>
###xml 7654 7658 7654 7658 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.0</td>
###xml 7668 7669 7668 7669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 7658 7688 7658 7688 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Carnitine <italic>O</italic>-acetyl-transferase</td>
###xml 7638 7688 7638 7688 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.11971</td><td align="left">BG727588</td><td char="." align="char">&#8722;2.0</td><td align="left">Carnitine <italic>O</italic>-acetyl-transferase</td></tr>
###xml 7688 7695 7688 7695 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.4777</td>
###xml 7695 7703 7695 7703 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW420997</td>
###xml 7703 7707 7703 7707 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.0</td>
###xml 7707 7727 7707 7727 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Succinate-CoA ligase</td>
###xml 7688 7727 7688 7727 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.4777</td><td align="left">AW420997</td><td char="." align="char">&#8722;2.0</td><td align="left">Succinate-CoA ligase</td></tr>
###xml 7727 7735 7727 7735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.11252</td>
###xml 7735 7743 7735 7743 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC047826</td>
###xml 7743 7747 7743 7747 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.0</td>
###xml 7747 7780 7747 7780 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Creatine kinase, mitochondrial 1 </td>
###xml 7727 7780 7727 7780 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.11252</td><td align="left">BC047826</td><td char="." align="char">&#8722;2.0</td><td align="left">Creatine kinase, mitochondrial 1 </td></tr>
###xml 7780 7794 7780 7794 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Muscle related</td>
###xml 7780 7794 7780 7794 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Muscle related</td></tr>
###xml 7794 7802 7794 7802 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.21800</td>
###xml 7802 7810 7802 7810 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI883923</td>
###xml 7810 7814 7810 7814 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;5.0</td>
###xml 7814 7838 7814 7838 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Myosin binding protein C</td>
###xml 7794 7838 7794 7838 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.21800</td><td align="left">AI883923</td><td char="." align="char">&#8722;5.0</td><td align="left">Myosin binding protein C</td></tr>
###xml 7838 7845 7838 7845 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.5066</td>
###xml 7845 7853 7845 7853 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AF524840</td>
###xml 7853 7857 7853 7857 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;3.4</td>
###xml 7857 7872 7857 7872 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Alpha-actinin 3</td>
###xml 7838 7872 7838 7872 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.5066</td><td align="left">AF524840</td><td char="." align="char">&#8722;3.4</td><td align="left">Alpha-actinin 3</td></tr>
###xml 7872 7880 7872 7880 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.24260</td>
###xml 7880 7889 7880 7889 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NM_131619</td>
###xml 7889 7893 7889 7893 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;3.0</td>
###xml 7893 7920 7893 7920 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Myosin, light polypeptide 3</td>
###xml 7872 7920 7872 7920 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.24260</td><td align="left">NM_131619</td><td char="." align="char">&#8722;3.0</td><td align="left">Myosin, light polypeptide 3</td></tr>
###xml 7920 7927 7920 7927 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.2914</td>
###xml 7927 7935 7927 7935 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC045520</td>
###xml 7935 7939 7935 7939 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.5</td>
###xml 7939 7972 7939 7972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Myosin light polypeptide 2; mylz2</td>
###xml 7920 7972 7920 7972 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.2914</td><td align="left">BC045520</td><td char="." align="char">&#8722;2.5</td><td align="left">Myosin light polypeptide 2; mylz2</td></tr>
###xml 7972 7980 7972 7980 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.20990</td>
###xml 7980 7997 7980 7997 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AY033829 AY081167</td>
###xml 7997 8005 7997 8005 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.4&#8211;2.1</td>
###xml 8005 8010 8005 8010 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Titin</td>
###xml 7972 8010 7972 8010 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.20990</td><td align="left">AY033829 AY081167</td><td char="." align="char">&#8722;2.4&#8211;2.1</td><td align="left">Titin</td></tr>
###xml 8010 8017 8010 8017 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1435</td>
###xml 8017 8025 8017 8025 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI353817</td>
###xml 8025 8029 8025 8029 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.0</td>
###xml 8029 8039 8029 8039 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Caveolin 3</td>
###xml 8010 8039 8010 8039 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1435</td><td align="left">AI353817</td><td char="." align="char">&#8722;2.0</td><td align="left">Caveolin 3</td></tr>
###xml 8039 8047 8039 8047 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.18657</td>
###xml 8047 8055 8047 8055 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ479700</td>
###xml 8055 8059 8055 8059 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.1</td>
###xml 8059 8080 8059 8080 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Carbonic anhydrase II</td>
###xml 8039 8080 8039 8080 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.18657</td><td align="left">BQ479700</td><td char="." align="char">&#8722;2.1</td><td align="left">Carbonic anhydrase II</td></tr>
###xml 8080 8088 8080 8088 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.26411</td>
###xml 8088 8096 8088 8096 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BQ783571</td>
###xml 8096 8100 8096 8100 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;8.9</td>
###xml 8100 8110 8100 8110 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Troponin I</td>
###xml 8080 8110 8080 8110 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.26411</td><td align="left">BQ783571</td><td char="." align="char">&#8722;8.9</td><td align="left">Troponin I</td></tr>
###xml 8110 8121 8110 8121 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Proteolysis</td>
###xml 8110 8121 8110 8121 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Proteolysis</td></tr>
###xml 8121 8128 8121 8128 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3581</td>
###xml 8128 8136 8128 8136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM101561</td>
###xml 8136 8140 8136 8140 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;8.3</td>
###xml 8140 8160 8140 8160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Chymotrypsinogen B1 </td>
###xml 8121 8160 8121 8160 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3581</td><td align="left">BM101561</td><td char="." align="char">&#8722;8.3</td><td align="left">Chymotrypsinogen B1 </td></tr>
###xml 8160 8167 8160 8167 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.3581</td>
###xml 8167 8175 8167 8175 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM101561</td>
###xml 8175 8179 8175 8179 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;7.5</td>
###xml 8179 8198 8179 8198 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Chymotrypsinogen B1</td>
###xml 8160 8198 8160 8198 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.3581</td><td align="left">BM101561</td><td char="." align="char">&#8722;7.5</td><td align="left">Chymotrypsinogen B1</td></tr>
###xml 8198 8217 8198 8217 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Signal transduction</td>
###xml 8198 8217 8198 8217 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Signal transduction</td></tr>
###xml 8217 8225 8217 8225 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.22841</td>
###xml 8225 8233 8225 8233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI641080</td>
###xml 8233 8237 8233 8237 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.4</td>
###xml 8237 8278 8237 8278 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Serum deprivation response protein (SDPR)</td>
###xml 8217 8278 8217 8278 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.22841</td><td align="left">AI641080</td><td char="." align="char">&#8722;2.4</td><td align="left">Serum deprivation response protein (SDPR)</td></tr>
###xml 8278 8289 8278 8289 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Translation</td>
###xml 8278 8289 8278 8289 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Translation</td></tr>
###xml 8289 8296 8289 8296 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.7939</td>
###xml 8296 8304 8296 8304 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW281840</td>
###xml 8304 8308 8304 8308 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.7</td>
###xml 8308 8342 8308 8342 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mitochondrial elongation factor G1</td>
###xml 8289 8342 8289 8342 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.7939</td><td align="left">AW281840</td><td char="." align="char">&#8722;2.7</td><td align="left">Mitochondrial elongation factor G1</td></tr>
###xml 8342 8349 8342 8349 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.1286</td>
###xml 8349 8357 8349 8357 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BM036808</td>
###xml 8357 8361 8357 8361 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.2</td>
###xml 8361 8396 8361 8396 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mitochondrial ribosomal protein L48</td>
###xml 8342 8396 8342 8396 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.1286</td><td align="left">BM036808</td><td char="." align="char">&#8722;2.2</td><td align="left">Mitochondrial ribosomal protein L48</td></tr>
###xml 8396 8404 8396 8404 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.18218</td>
###xml 8404 8412 8404 8412 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AL909921</td>
###xml 8412 8416 8412 8416 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.1</td>
###xml 8416 8457 8416 8457 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mitochondrial 28&#160;S ribosomal protein S12 </td>
###xml 8396 8457 8396 8457 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.18218</td><td align="left">AL909921</td><td char="." align="char">&#8722;2.1</td><td align="left">Mitochondrial 28&#160;S ribosomal protein S12 </td></tr>
###xml 8457 8466 8457 8466 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Transport</td>
###xml 8457 8466 8457 8466 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Transport</td></tr>
###xml 8466 8472 8466 8472 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.676</td>
###xml 8472 8480 8472 8480 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC050956</td>
###xml 8480 8484 8480 8484 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;4.4</td>
###xml 8484 8513 8484 8513 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ADT2, ADP,ATP carrier protein</td>
###xml 8466 8513 8466 8513 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.676</td><td align="left">BC050956</td><td char="." align="char">&#8722;4.4</td><td align="left">ADT2, ADP,ATP carrier protein</td></tr>
###xml 8513 8521 8513 8521 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.25199</td>
###xml 8521 8529 8521 8529 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD014403</td>
###xml 8529 8533 8529 8533 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.1</td>
###xml 8533 8596 8533 8596 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Calcium-binding mitochondrial carrier protein Aralar2 (Citrin) </td>
###xml 8513 8596 8513 8596 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.25199</td><td align="left">CD014403</td><td char="." align="char">&#8722;2.1</td><td align="left">Calcium-binding mitochondrial carrier protein Aralar2 (Citrin) </td></tr>
###xml 8596 8603 8596 8603 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.2784</td>
###xml 8603 8611 8603 8611 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AI942949</td>
###xml 8611 8615 8611 8615 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.0</td>
###xml 8615 8640 8615 8640 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solute carrier family 25 </td>
###xml 8596 8640 8596 8640 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.2784</td><td align="left">AI942949</td><td char="." align="char">&#8722;2.0</td><td align="left">Solute carrier family 25 </td></tr>
###xml 8640 8648 8640 8648 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.11127</td>
###xml 8648 8656 8648 8656 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BG306498</td>
###xml 8656 8660 8656 8660 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;3.7</td>
###xml 8660 8675 8660 8675 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Synaptotagmin I</td>
###xml 8640 8675 8640 8675 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.11127</td><td align="left">BG306498</td><td char="." align="char">&#8722;3.7</td><td align="left">Synaptotagmin I</td></tr>
###xml 8675 8683 8675 8683 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.11127</td>
###xml 8683 8691 8683 8691 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW826278</td>
###xml 8691 8695 8691 8695 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;3.2</td>
###xml 8695 8711 8695 8711 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Synaptotagmin I </td>
###xml 8675 8711 8675 8711 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.11127</td><td align="left">AW826278</td><td char="." align="char">&#8722;3.2</td><td align="left">Synaptotagmin I </td></tr>
###xml 8711 8719 8711 8719 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.13273</td>
###xml 8719 8727 8719 8727 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BI885460</td>
###xml 8727 8731 8727 8731 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.3</td>
###xml 8731 8757 8731 8757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GTP-binding protein rab15 </td>
###xml 8711 8757 8711 8757 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.13273</td><td align="left">BI885460</td><td char="." align="char">&#8722;2.3</td><td align="left">GTP-binding protein rab15 </td></tr>
###xml 8757 8765 8757 8765 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.22748</td>
###xml 8765 8773 8765 8773 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AW280026</td>
###xml 8773 8777 8773 8777 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.7</td>
###xml 8777 8782 8777 8782 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">trpn1</td>
###xml 8757 8782 8757 8782 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.22748</td><td align="left">AW280026</td><td char="." align="char">&#8722;2.7</td><td align="left">trpn1</td></tr>
###xml 8782 8790 8782 8790 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dr.11302</td>
###xml 8790 8798 8790 8798 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BG306530</td>
###xml 8798 8802 8798 8802 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.1</td>
###xml 8802 8846 8802 8846 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ATPase (Ca++ transporting plasma membrane 2)</td>
###xml 8782 8846 8782 8846 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dr.11302</td><td align="left">BG306530</td><td char="." align="char">&#8722;2.1</td><td align="left">ATPase (Ca++ transporting plasma membrane 2)</td></tr>
###xml 521 8846 521 8846 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="4">Upregulated genes</td></tr><tr><td align="left" colspan="4">Angiogenesis</td></tr><tr><td align="left">Dr.11575</td><td align="left">NM_173244</td><td char="." align="char">2.3</td><td align="left">T-cell acute lymphocytic leukemia 1; TAL1</td></tr><tr><td align="left">Dr.845</td><td align="left">BG729013</td><td char="." align="char">2.8</td><td align="left">Fibrinogen alpha/alpha-E chain </td></tr><tr><td align="left">Dr.4907</td><td align="left">BC045868</td><td char="." align="char">4.2</td><td align="left">Fibrinogen, gamma polypeptide</td></tr><tr><td align="left" colspan="4">Apoptosis</td></tr><tr><td align="left">Dr.15862</td><td align="left">AF493987</td><td char="." align="char">2.1</td><td align="left">BCL2adenovirus E1b 19 interacting protein3</td></tr><tr><td align="left">DrAffx.1.39</td><td align="left">AF302789</td><td char="." align="char">2.3</td><td align="left">Death receptor</td></tr><tr><td align="left">Dr.20106</td><td align="left">AI722277</td><td char="." align="char">2.8</td><td align="left">Apoptosis inhibitor 5</td></tr><tr><td align="left">Dr.4039</td><td align="left">BQ480688</td><td char="." align="char">21.8</td><td align="left">BAX inhibitor 1</td></tr><tr><td align="left" colspan="4">Cell adhesion</td></tr><tr><td align="left">Dr.6007</td><td align="left">NM_131820</td><td char="." align="char">2.9</td><td align="left">Cadherin 1</td></tr><tr><td align="left">Dr.25140</td><td align="left">BQ262802</td><td char="." align="char">3.3</td><td align="left">Tumor-associated calcium signal transducer </td></tr><tr><td align="left">Dr.4409</td><td align="left">BC049036</td><td char="." align="char">4.4</td><td align="left">CD9 antigen</td></tr><tr><td align="left">Dr.25140</td><td align="left">BQ262802</td><td char="." align="char">7.7</td><td align="left">Tumor-associated calcium signal transducer glycoprotein</td></tr><tr><td align="left" colspan="4">Development</td></tr><tr><td align="left">Dr.11575</td><td align="left">NM_1732</td><td char="." align="char">2.3</td><td align="left">T-cell acute lymphocyte leukemia 1 (tal 1)</td></tr><tr><td align="left">Dr.23348</td><td align="left">BE201653</td><td char="." align="char">2.6</td><td align="left">Bone morphogenetic protein 3b; (bmp 3)</td></tr><tr><td align="left">Dr25405</td><td align="left">BC013923</td><td char="." align="char">2.8</td><td align="left">SOX2 SRY-box 2</td></tr><tr><td align="left">Dr.6382</td><td align="left">AW165053</td><td char="." align="char">2.9</td><td align="left">Hedgehog-interacting protein</td></tr><tr><td align="left">Dr.10879</td><td align="left">U97669</td><td char="." align="char">3.0</td><td align="left">NOTCH3 Notch homolog 3 (<italic>Drosophila</italic>)</td></tr><tr><td align="left">Dr.15055</td><td align="left">BC050172</td><td char="." align="char">3.6</td><td align="left">Chemokine receptor 4a</td></tr><tr><td align="left">Dr.6787</td><td align="left">BI533426</td><td char="." align="char">5.5</td><td align="left">Noelin</td></tr><tr><td align="left">Dr.16720</td><td align="left">BI980847</td><td char="." align="char">6.3</td><td align="left">notch 2</td></tr><tr><td align="left" colspan="4">Disease related</td></tr><tr><td align="left">Dr.6349</td><td align="left">AW116668</td><td char="." align="char">2.4</td><td align="left">Eparin cofactor II</td></tr><tr><td align="left">Dr.21064</td><td align="left">BC046075</td><td char="." align="char">4.5</td><td align="left">4hydroxyphenylpyruvate dioxygenase HPD</td></tr><tr><td align="left">Dr.12584</td><td align="left">NM_131211</td><td char="." align="char">5.4</td><td align="left">Gata binding protein 3 (GATA3)</td></tr><tr><td align="left">Dr.3530</td><td align="left">AI497545</td><td char="." align="char">79.3</td><td align="left">Prion protein (prp) gene</td></tr><tr><td align="left" colspan="4">Growth regulation</td></tr><tr><td align="left">Dr.8145</td><td align="left">NM_13143</td><td char="." align="char">2.2</td><td align="left">Insulin like growth factor 2 (IGF-2)</td></tr><tr><td align="left">Dr.7609</td><td align="left">BI475857</td><td char="." align="char">2.4</td><td align="left">Prolactin receptor</td></tr><tr><td align="left">Dr.8285</td><td align="left">NM_13136</td><td char="." align="char">2.4</td><td align="left">Mad homolog 2 </td></tr><tr><td align="left">Dr.8947</td><td align="left">CD594735</td><td char="." align="char">2.5</td><td align="left">Spint 2</td></tr><tr><td align="left">Dr.822</td><td align="left">BM184127</td><td char="." align="char">2.5</td><td align="left">Spint 2</td></tr><tr><td align="left">Dr.3563</td><td align="left">CD014488</td><td char="." align="char">2.8</td><td align="left">Tetraspan membrane protein IL-TMP</td></tr><tr><td align="left">Dr.8587</td><td align="left">NM_17328</td><td char="." align="char">2.9</td><td align="left">Insulin-like growth factor binding protein 1 </td></tr><tr><td align="left">Dr.2596</td><td align="left">BM342901</td><td char="." align="char">3.2</td><td align="left">Cyclin I</td></tr><tr><td align="left">Dr.8587</td><td align="left">AL910822</td><td char="." align="char">3.4</td><td align="left">Insulin-like growth factor binding protein 1</td></tr><tr><td align="left">Dr.26458</td><td align="left">BC053206</td><td char="." align="char">5.6</td><td align="left">m-ras</td></tr><tr><td align="left" colspan="4">Heart related</td></tr><tr><td align="left">Dr.15088</td><td align="left">BM181749</td><td char="." align="char">4.3</td><td align="left">Lectin galactoside-binding soluble 1; (galectin10-like 3)</td></tr><tr><td align="left">Dr.4867</td><td align="left">AI496840</td><td char="." align="char">5.5</td><td align="left">Haptoglobin</td></tr><tr><td align="left">Dr.3585</td><td align="left">AY049731</td><td char="." align="char">6.6</td><td align="left">Angiotensinogen </td></tr><tr><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9 </td></tr><tr><td align="left">Dr.18453</td><td align="left">BC044525</td><td char="." align="char">4.8</td><td align="left">Uridine phosphorylase</td></tr><tr><td align="left">Dr.3025</td><td align="left">BG738204</td><td char="." align="char">2.7</td><td align="left">Alpha-2 macro-globulin; A2MG</td></tr><tr><td align="left" colspan="4">Inflammation</td></tr><tr><td align="left">Dr.12491</td><td align="left">BI672168</td><td char="." align="char">2.1</td><td align="left">Complement C4&#8211;2</td></tr><tr><td align="left">Dr.4047</td><td align="left">NM_131627</td><td char="." align="char">2.3</td><td align="left">Small inducible cytokine A (scyba)</td></tr><tr><td align="left">Dr.5053</td><td align="left">NM_131723</td><td char="." align="char">2.3</td><td align="left">Kruppel-like factor 4 </td></tr><tr><td align="left">Dr25207</td><td align="left">X06465</td><td char="." align="char">2.5</td><td align="left">Complement component 8, gamma polypeptide</td></tr><tr><td align="left">Dr.6845</td><td align="left">K02765</td><td char="." align="char">2.9</td><td align="left">C3 complement component 3</td></tr><tr><td align="left">Dr.5741</td><td align="left">BU710482</td><td char="." align="char">3.2</td><td align="left">Complement component b fb</td></tr><tr><td align="left">Dr.7722</td><td align="left">BI878414</td><td char="." align="char">3.5</td><td align="left">Complement C3-H1</td></tr><tr><td align="left">Dr.22244</td><td align="left">AW019781</td><td char="." align="char">3.6</td><td align="left">Complement C1s</td></tr><tr><td align="left">Dr.22133</td><td align="left">AW076768</td><td char="." align="char">3.7</td><td align="left">c1rs-A and clrs-B</td></tr><tr><td align="left">Dr.5528</td><td align="left">AI497212</td><td char="." align="char">4.2</td><td align="left">Complement component C9</td></tr><tr><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9 </td></tr><tr><td align="left">Dr.1730</td><td align="left">AI721528</td><td char="." align="char">4.8</td><td align="left">cfI-B complement control protein factor I-B </td></tr><tr><td align="left">Dr.2452</td><td align="left">BM778002</td><td char="." align="char">5.8</td><td align="left">Complement component C9</td></tr><tr><td align="left">Dr.20291</td><td align="left">BM036389</td><td char="." align="char">6.5</td><td align="left">Complement C3-S</td></tr><tr><td align="left">Dr.190</td><td align="left">NM_131338</td><td char="." align="char">7.9</td><td align="left">Complement component factor B </td></tr><tr><td align="left">Dr.1192</td><td align="left">AB071601</td><td char="." align="char">2.</td><td align="left">Lipocalin-type prostaglandin D synthase-like protein</td></tr><tr><td align="left" colspan="4">Metabolism</td></tr><tr><td align="left">Dr.9492</td><td align="left">BI882244</td><td char="." align="char">2.0</td><td align="left">Sulfide dehydrogenase like</td></tr><tr><td align="left">Dr.15574</td><td align="left">BM571467</td><td char="." align="char">2.1</td><td align="left">Hypoxanthine _hosphor-ribosyltransferase 1</td></tr><tr><td align="left">Dr.3332</td><td align="left">AI943053</td><td char="." align="char">2.2</td><td align="left">Angiopoietin 5 </td></tr><tr><td align="left">Dr.16130</td><td align="left">CD014898</td><td char="." align="char">2.3</td><td align="left">Alcohol dehydrogenase 8&#160;b</td></tr><tr><td align="left">Dr.3959</td><td align="left">BI43001</td><td char="." align="char">2.5</td><td align="left">5&#8242;-nucleotidase</td></tr><tr><td align="left">Dr.22205</td><td align="left">AW019477</td><td char="." align="char">2.6</td><td align="left">Oxidoreductase</td></tr><tr><td align="left">Dr.1699</td><td align="left">AI667249</td><td char="." align="char">2.7</td><td align="left">Pyruvate kinase</td></tr><tr><td align="left">Dr.5504</td><td align="left">BI879550</td><td char="." align="char">3.2</td><td align="left">Cystathionine-beta-synthase</td></tr><tr><td align="left">Dr.1202</td><td align="left">AJ245491</td><td char="." align="char">3.9</td><td align="left">Apolipoprotein A-I</td></tr><tr><td align="left">Dr.4111</td><td align="left">BC053267</td><td char="." align="char">4.2</td><td align="left">Fructose-1,6-bisphosphatase 1</td></tr><tr><td align="left">Dr.18834</td><td align="left">AW019321</td><td char="." align="char">4.2</td><td align="left">Urate oxidase</td></tr><tr><td align="left">Dr.19224</td><td align="left">BC050167</td><td char="." align="char">4.3</td><td align="left">Aldolase b</td></tr><tr><td align="left">Dr.4938</td><td align="left">NM_131645</td><td char="." align="char">4.4</td><td align="left">Fatty acid desaturase 2</td></tr><tr><td align="left">Dr.12654</td><td align="left">BC046901</td><td char="." align="char">14.8</td><td align="left">ELOVL family member 6,</td></tr><tr><td align="left">Dr.5488</td><td align="left">AI545593</td><td char="." align="char">17.3</td><td align="left">Apolipoprotein A-IV </td></tr><tr><td align="left" colspan="4">Muscle related</td></tr><tr><td align="left">Dr.3585</td><td align="left">AY049731</td><td char="." align="char">6.6</td><td align="left">Angiotensinogen</td></tr><tr><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9</td></tr><tr><td align="left" colspan="4">Proteolysis</td></tr><tr><td align="left">Dr.20934</td><td align="left">AF541952</td><td char="." align="char">2.6</td><td align="left">Trypsin precursor</td></tr><tr><td align="left">Dr.3025</td><td align="left">BG738204</td><td char="." align="char">2.7</td><td align="left">Alpha-2-macroglobulin </td></tr><tr><td align="left">Dr.22139</td><td align="left">AW018965</td><td char="." align="char">3.0</td><td align="left">Alpha-1-antitrypsin</td></tr><tr><td align="left">Dr.25331</td><td align="left">AI658072</td><td char="." align="char">4.1</td><td align="left">Alpha-2-macroglobulin-2</td></tr><tr><td align="left">Dr.12602</td><td align="left">NM_139180</td><td char="." align="char">4.3</td><td align="left">Lysozyme</td></tr><tr><td align="left">Dr.1605</td><td align="left">BM185388</td><td char="." align="char">4.4</td><td align="left">Protease inhibitor 1</td></tr><tr><td align="left">Dr.17459</td><td align="left">CD586837</td><td char="." align="char">4.8</td><td align="left">Inter-alpha-trypsin inhibitor heavy chain H3 </td></tr><tr><td align="left">Dr.3073</td><td align="left">AI585030</td><td char="." align="char">5.0</td><td align="left">Serine protease inhibitor alpha 1</td></tr><tr><td align="left">Dr.26371</td><td align="left">AI667676</td><td char="." align="char">5.4</td><td align="left">Prostasin</td></tr><tr><td align="left">Dr.3025</td><td align="left">BM530427</td><td char="." align="char">5.6</td><td align="left">Alpha-2-macroglobulin-1</td></tr><tr><td align="left">Dr.3025</td><td align="left">BM316867</td><td char="." align="char">6.5</td><td align="left">Alpha-2-macroglobulin-2</td></tr><tr><td align="left">Dr.2960</td><td align="left">X67055</td><td char="." align="char">3.5</td><td align="left">ITIH3 pre-alpha (globulin) inhibitor, H3 polypeptide</td></tr><tr><td align="left">Dr.25379</td><td align="left">BI326783</td><td char="." align="char">6.7</td><td align="left">Alpha-2-macroglobulin</td></tr><tr><td align="left">Dr.4797</td><td align="left">AI959534</td><td char="." align="char">7.8</td><td align="left">26&#8211;29&#160;kD-Proteinase protein</td></tr><tr><td align="left" colspan="4">ROS protection</td></tr><tr><td align="left">Dr.20068</td><td align="left">NM_131075</td><td char="." align="char">2.1</td><td align="left">Metallothionein (mt)</td></tr><tr><td align="left">Dr.5399</td><td align="left">AI957765</td><td char="." align="char">2.3</td><td align="left">Biliverdin I Beta Reductase</td></tr><tr><td align="left">Dr.14058</td><td align="left">CD015351</td><td char="." align="char">3.5</td><td align="left">Glutathione <italic>S</italic>-transferase theta 1</td></tr><tr><td align="left">Dr.25160</td><td align="left">BC049475</td><td char="." align="char">5.9</td><td align="left">Metallothionein 2</td></tr><tr><td align="left">Dr.3613</td><td align="left">BC048037</td><td char="." align="char">6.0</td><td align="left">Cerulopasmin</td></tr><tr><td align="left">Dr.4905.1</td><td align="left">BC045464</td><td char="." align="char">6.5</td><td align="left">Uncoupling protein 4</td></tr><tr><td align="left" colspan="4">Signal transduction</td></tr><tr><td align="left">Dr.9852</td><td align="left">AW826425</td><td char="." align="char">2.1</td><td align="left">CAM kinase 1</td></tr><tr><td align="left">Dr.8591</td><td align="left">BM186508</td><td char="." align="char">2.9</td><td align="left">Rho guanine nucleotide exchange factor 10</td></tr><tr><td align="left">Dr.6236</td><td align="left">AW115973</td><td char="." align="char">3.1</td><td align="left">Rho guanine nucleotide exchange factor 5</td></tr><tr><td align="left">Dr.1267</td><td align="left">BC051157</td><td char="." align="char">3.4</td><td align="left">Phospholipase C delta</td></tr><tr><td align="left">Dr.22129</td><td align="left">BC016668</td><td char="." align="char">3.9</td><td align="left">RRAGC Rag C (Ras-related GTP binding C)</td></tr><tr><td align="left">Dr.7255</td><td align="left">AW116479</td><td char="." align="char">4.4</td><td align="left">Protein phosphatase 1,</td></tr><tr><td align="left">Dr.4453</td><td align="left">BC044421</td><td char="." align="char">5.8</td><td align="left">Phosphoprotein phosphatase</td></tr><tr><td align="left" colspan="4">Translation</td></tr><tr><td align="left">Dr.13234</td><td align="left">BM036471</td><td char="." align="char">2.0</td><td align="left">Ribonuclease P </td></tr><tr><td align="left">Dr.382</td><td align="left">CB363830</td><td char="." align="char">2.1</td><td align="left">Nucleolin</td></tr><tr><td align="left">Dr.6949</td><td align="left">AW078116</td><td char="." align="char">2.1</td><td align="left">RNA 3&#8242;-terminal phosphate cyclase-like protein (HSPC338)</td></tr><tr><td align="left">Dr.13563</td><td align="left">BI890729</td><td char="." align="char">2.3</td><td align="left">Methionyl aminopeptidase 2</td></tr><tr><td align="left">Dr.26328</td><td align="left">AL723696</td><td char="." align="char">2.3</td><td align="left">Eukaryotic translation initiation factor 4A,</td></tr><tr><td align="left">Dr.17693</td><td align="left">BQ078285</td><td char="." align="char">3.7</td><td align="left">40&#160;S ribosomal protein S6</td></tr><tr><td align="left">Dr.20270</td><td align="left">BI674050</td><td char="." align="char">5.9</td><td align="left">Ribosomal protein L12 </td></tr><tr><td align="left">Dr.25224</td><td align="left">CD015330</td><td char="." align="char">20.4</td><td align="left">Ribosomal protein L12 </td></tr><tr><td align="left">Dr.12439</td><td align="left">BM533848</td><td char="." align="char">17.5</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr><tr><td align="left">Dr.12439</td><td align="left">BM533848</td><td char="." align="char">24.2</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr><tr><td align="left">Dr.14821</td><td align="left">BM071714</td><td char="." align="char">33.8</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr><tr><td align="left">Dr.12502</td><td align="left">BQ284686</td><td char="." align="char">40.7</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr><tr><td align="left">Dr.12439. </td><td align="left">BM534432</td><td char="." align="char">40.9</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr><tr><td align="left">Dr.12439</td><td align="left">BQ616930</td><td char="." align="char">45.4</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr><tr><td align="left" colspan="4">Transport</td></tr><tr><td align="left">Dr.1084</td><td align="left">BQ109772</td><td char="." align="char">3.0</td><td align="left">Clathrin coat assembly protein AP19</td></tr><tr><td align="left">Dr.5562</td><td align="left">X04506</td><td char="." align="char">3.0</td><td align="left">APOB apolipoprotein B (including Ag(x) antigen)</td></tr><tr><td align="left">Dr.13231</td><td align="left">BM778646</td><td char="." align="char">4.2</td><td align="left">Solute carrier family 22</td></tr><tr><td align="left">Dr.30444</td><td align="left">AY329629</td><td char="." align="char">4.3</td><td align="left">Embryonic globin beta e2</td></tr><tr><td align="left">Dr.24250</td><td align="left">AF489105</td><td char="." align="char">2.0</td><td align="left">Uroporphyrinogen III synthase</td></tr><tr><td align="left">Dr.10343</td><td align="left">NM_131687</td><td char="." align="char">4.7</td><td align="left">Na+K+ transporting, alpha 1a.2 polypeptide</td></tr><tr><td align="left">Dr.7634</td><td align="left">AW115757</td><td char="." align="char">11.3</td><td align="left">Hemopexin</td></tr><tr><td align="left" colspan="4">Downregulated genes</td></tr><tr><td align="left" colspan="4">Angiogenesis</td></tr><tr><td align="left">Dr.26411</td><td align="left">BQ783571</td><td char="." align="char">&#8722;8.9</td><td align="left">Fast muscle troponin I</td></tr><tr><td align="left">Dr.15501</td><td align="left">BM316040</td><td char="." align="char">&#8722;2.1</td><td align="left">Similar to CYR6 HUMAN CYR61 protein precursor, Insulin-like growth factor-binding protein 10</td></tr><tr><td align="left" colspan="4">Cell adhesion</td></tr><tr><td align="left">Dr.251</td><td align="left">BQ285646</td><td char="." align="char">&#8722;2.3</td><td align="left">Cadherin 11</td></tr><tr><td align="left" colspan="4">Disease related</td></tr><tr><td align="left">Dr.22774</td><td align="left">AW280206</td><td char="." align="char">&#8722;5.7</td><td align="left">ras-like GTP-binding protein RAB27A</td></tr><tr><td align="left">Dr.1816</td><td align="left">AL720262</td><td char="." align="char">&#8722;4.4</td><td align="left">Ataxin 2-binding protein</td></tr><tr><td align="left">Dr.9893</td><td align="left">BM036473</td><td char="." align="char">&#8722;2.3</td><td align="left">Fibrillarin</td></tr><tr><td align="left">Dr.16726</td><td align="left">BI429372</td><td char="." align="char">&#8722;2.0</td><td align="left">netrin G1</td></tr><tr><td align="left" colspan="4">Growth regulation</td></tr><tr><td align="left">Dr.12986</td><td align="left">CA787334</td><td char="." align="char">&#8722;5.3</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.12986</td><td align="left">BI881979</td><td char="." align="char">&#8722;5.0</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.12986</td><td align="left">BM957279</td><td char="." align="char">&#8722;4.5</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.1221</td><td align="left">AW510198</td><td char="." align="char">&#8722;4.3</td><td align="left">Pmx-1b (PHOX-1)</td></tr><tr><td align="left">Dr.12986</td><td align="left">BI881979</td><td char="." align="char">&#8722;4.2</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.12410</td><td align="left">NM_131826</td><td char="." align="char">&#8722;2.4</td><td align="left">Sprouty homolog 4 </td></tr><tr><td align="left">Dr.6431</td><td align="left">BC049326</td><td char="." align="char">&#8722;2.3</td><td align="left">Suppressors of cytokine signaling 3</td></tr><tr><td align="left">Dr.6511</td><td align="left">NM_130922</td><td char="." align="char">&#8722;2.2</td><td align="left">B-cell translocation gene 2</td></tr><tr><td align="left">Dr.5365</td><td align="left">AI601685</td><td char="." align="char">&#8722;2.2</td><td align="left">Dual specificity phosphatase 5</td></tr><tr><td align="left">Dr.12062</td><td align="left">BC047814</td><td char="." align="char">&#8722;2.1</td><td align="left">Epidermal growth factor receptor kinase substrate EPS8</td></tr><tr><td align="left">Dr.17286</td><td align="left">BM777144</td><td char="." align="char">&#8722;2.0</td><td align="left">Hormone-regulated proliferation-associated 20&#160;kDa protein</td></tr><tr><td align="left">Dr.9448</td><td align="left">BM156058</td><td char="." align="char">&#8722;2.0</td><td align="left">TGF-beta-inducible early growth response protein 2</td></tr><tr><td align="left" colspan="4">Heart related</td></tr><tr><td align="left">Dr.20010</td><td align="left">BQ826502</td><td char="." align="char">&#8722;7.0</td><td align="left">ATPase, Ca++ transporting, cardiac muscle (ATP2A1)</td></tr><tr><td align="left">Dr.1448</td><td align="left">AL717344</td><td char="." align="char">&#8722;3.5</td><td align="left">Fast skeletal myosin light chain 1a</td></tr><tr><td align="left">Dr.20990</td><td align="left">AY033829 AY081167</td><td char="." align="char">&#8722;2.4&#8211;2.1</td><td align="left">Titin</td></tr><tr><td align="left" colspan="4">Metabolism</td></tr><tr><td align="left">Dr.24950</td><td align="left">BC053305</td><td char="." align="char">&#8722;4.1</td><td align="left">Creatine kinase CKM3</td></tr><tr><td align="left">Dr.9528</td><td align="left">BC045993</td><td char="." align="char">&#8722;3.5</td><td align="left">Pyruvate dehydrogenase kinase</td></tr><tr><td align="left">Dr.146</td><td align="left">AI477401</td><td char="." align="char">&#8722;2.9</td><td align="left">Carnitine <italic>O</italic>-palmitoyltransferase II</td></tr><tr><td align="left">Dr.21501</td><td align="left">AI667180</td><td char="." align="char">&#8722;2.4</td><td align="left">Short-chain acyl-CoA dehydrogenase </td></tr><tr><td align="left">Dr.19643</td><td align="left">AL918850</td><td char="." align="char">&#8722;2.4</td><td align="left">FabG beta-ketoacyl -reductase</td></tr><tr><td align="left">Dr.15059</td><td align="left">BM530407</td><td char="." align="char">&#8722;2.2</td><td align="left">Elongation of very long chain fatty acids (Cig30)</td></tr><tr><td align="left">Dr.21040</td><td align="left">BC045479</td><td char="." align="char">&#8722;2.1</td><td align="left">Glucose-6-phosphatase, transport protein 1</td></tr><tr><td align="left">Dr.988</td><td align="left">AW154697</td><td char="." align="char">&#8722;2.1</td><td align="left">Dodecenoyl-coenzyme A delta isomerase </td></tr><tr><td align="left">Dr.11971</td><td align="left">BG727588</td><td char="." align="char">&#8722;2.0</td><td align="left">Carnitine <italic>O</italic>-acetyl-transferase</td></tr><tr><td align="left">Dr.4777</td><td align="left">AW420997</td><td char="." align="char">&#8722;2.0</td><td align="left">Succinate-CoA ligase</td></tr><tr><td align="left">Dr.11252</td><td align="left">BC047826</td><td char="." align="char">&#8722;2.0</td><td align="left">Creatine kinase, mitochondrial 1 </td></tr><tr><td align="left" colspan="4">Muscle related</td></tr><tr><td align="left">Dr.21800</td><td align="left">AI883923</td><td char="." align="char">&#8722;5.0</td><td align="left">Myosin binding protein C</td></tr><tr><td align="left">Dr.5066</td><td align="left">AF524840</td><td char="." align="char">&#8722;3.4</td><td align="left">Alpha-actinin 3</td></tr><tr><td align="left">Dr.24260</td><td align="left">NM_131619</td><td char="." align="char">&#8722;3.0</td><td align="left">Myosin, light polypeptide 3</td></tr><tr><td align="left">Dr.2914</td><td align="left">BC045520</td><td char="." align="char">&#8722;2.5</td><td align="left">Myosin light polypeptide 2; mylz2</td></tr><tr><td align="left">Dr.20990</td><td align="left">AY033829 AY081167</td><td char="." align="char">&#8722;2.4&#8211;2.1</td><td align="left">Titin</td></tr><tr><td align="left">Dr.1435</td><td align="left">AI353817</td><td char="." align="char">&#8722;2.0</td><td align="left">Caveolin 3</td></tr><tr><td align="left">Dr.18657</td><td align="left">BQ479700</td><td char="." align="char">&#8722;2.1</td><td align="left">Carbonic anhydrase II</td></tr><tr><td align="left">Dr.26411</td><td align="left">BQ783571</td><td char="." align="char">&#8722;8.9</td><td align="left">Troponin I</td></tr><tr><td align="left" colspan="4">Proteolysis</td></tr><tr><td align="left">Dr.3581</td><td align="left">BM101561</td><td char="." align="char">&#8722;8.3</td><td align="left">Chymotrypsinogen B1 </td></tr><tr><td align="left">Dr.3581</td><td align="left">BM101561</td><td char="." align="char">&#8722;7.5</td><td align="left">Chymotrypsinogen B1</td></tr><tr><td align="left" colspan="4">Signal transduction</td></tr><tr><td align="left">Dr.22841</td><td align="left">AI641080</td><td char="." align="char">&#8722;2.4</td><td align="left">Serum deprivation response protein (SDPR)</td></tr><tr><td align="left" colspan="4">Translation</td></tr><tr><td align="left">Dr.7939</td><td align="left">AW281840</td><td char="." align="char">&#8722;2.7</td><td align="left">Mitochondrial elongation factor G1</td></tr><tr><td align="left">Dr.1286</td><td align="left">BM036808</td><td char="." align="char">&#8722;2.2</td><td align="left">Mitochondrial ribosomal protein L48</td></tr><tr><td align="left">Dr.18218</td><td align="left">AL909921</td><td char="." align="char">&#8722;2.1</td><td align="left">Mitochondrial 28&#160;S ribosomal protein S12 </td></tr><tr><td align="left" colspan="4">Transport</td></tr><tr><td align="left">Dr.676</td><td align="left">BC050956</td><td char="." align="char">&#8722;4.4</td><td align="left">ADT2, ADP,ATP carrier protein</td></tr><tr><td align="left">Dr.25199</td><td align="left">CD014403</td><td char="." align="char">&#8722;2.1</td><td align="left">Calcium-binding mitochondrial carrier protein Aralar2 (Citrin) </td></tr><tr><td align="left">Dr.2784</td><td align="left">AI942949</td><td char="." align="char">&#8722;2.0</td><td align="left">Solute carrier family 25 </td></tr><tr><td align="left">Dr.11127</td><td align="left">BG306498</td><td char="." align="char">&#8722;3.7</td><td align="left">Synaptotagmin I</td></tr><tr><td align="left">Dr.11127</td><td align="left">AW826278</td><td char="." align="char">&#8722;3.2</td><td align="left">Synaptotagmin I </td></tr><tr><td align="left">Dr.13273</td><td align="left">BI885460</td><td char="." align="char">&#8722;2.3</td><td align="left">GTP-binding protein rab15 </td></tr><tr><td align="left">Dr.22748</td><td align="left">AW280026</td><td char="." align="char">&#8722;2.7</td><td align="left">trpn1</td></tr><tr><td align="left">Dr.11302</td><td align="left">BG306530</td><td char="." align="char">&#8722;2.1</td><td align="left">ATPase (Ca++ transporting plasma membrane 2)</td></tr></tbody>
###xml 493 8846 493 8846 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">UniGene</th><th align="left">GeneBank</th><th align="left">Fold</th><th align="left">Gene name</th></tr></thead><tbody><tr><td align="left" colspan="4">Upregulated genes</td></tr><tr><td align="left" colspan="4">Angiogenesis</td></tr><tr><td align="left">Dr.11575</td><td align="left">NM_173244</td><td char="." align="char">2.3</td><td align="left">T-cell acute lymphocytic leukemia 1; TAL1</td></tr><tr><td align="left">Dr.845</td><td align="left">BG729013</td><td char="." align="char">2.8</td><td align="left">Fibrinogen alpha/alpha-E chain </td></tr><tr><td align="left">Dr.4907</td><td align="left">BC045868</td><td char="." align="char">4.2</td><td align="left">Fibrinogen, gamma polypeptide</td></tr><tr><td align="left" colspan="4">Apoptosis</td></tr><tr><td align="left">Dr.15862</td><td align="left">AF493987</td><td char="." align="char">2.1</td><td align="left">BCL2adenovirus E1b 19 interacting protein3</td></tr><tr><td align="left">DrAffx.1.39</td><td align="left">AF302789</td><td char="." align="char">2.3</td><td align="left">Death receptor</td></tr><tr><td align="left">Dr.20106</td><td align="left">AI722277</td><td char="." align="char">2.8</td><td align="left">Apoptosis inhibitor 5</td></tr><tr><td align="left">Dr.4039</td><td align="left">BQ480688</td><td char="." align="char">21.8</td><td align="left">BAX inhibitor 1</td></tr><tr><td align="left" colspan="4">Cell adhesion</td></tr><tr><td align="left">Dr.6007</td><td align="left">NM_131820</td><td char="." align="char">2.9</td><td align="left">Cadherin 1</td></tr><tr><td align="left">Dr.25140</td><td align="left">BQ262802</td><td char="." align="char">3.3</td><td align="left">Tumor-associated calcium signal transducer </td></tr><tr><td align="left">Dr.4409</td><td align="left">BC049036</td><td char="." align="char">4.4</td><td align="left">CD9 antigen</td></tr><tr><td align="left">Dr.25140</td><td align="left">BQ262802</td><td char="." align="char">7.7</td><td align="left">Tumor-associated calcium signal transducer glycoprotein</td></tr><tr><td align="left" colspan="4">Development</td></tr><tr><td align="left">Dr.11575</td><td align="left">NM_1732</td><td char="." align="char">2.3</td><td align="left">T-cell acute lymphocyte leukemia 1 (tal 1)</td></tr><tr><td align="left">Dr.23348</td><td align="left">BE201653</td><td char="." align="char">2.6</td><td align="left">Bone morphogenetic protein 3b; (bmp 3)</td></tr><tr><td align="left">Dr25405</td><td align="left">BC013923</td><td char="." align="char">2.8</td><td align="left">SOX2 SRY-box 2</td></tr><tr><td align="left">Dr.6382</td><td align="left">AW165053</td><td char="." align="char">2.9</td><td align="left">Hedgehog-interacting protein</td></tr><tr><td align="left">Dr.10879</td><td align="left">U97669</td><td char="." align="char">3.0</td><td align="left">NOTCH3 Notch homolog 3 (<italic>Drosophila</italic>)</td></tr><tr><td align="left">Dr.15055</td><td align="left">BC050172</td><td char="." align="char">3.6</td><td align="left">Chemokine receptor 4a</td></tr><tr><td align="left">Dr.6787</td><td align="left">BI533426</td><td char="." align="char">5.5</td><td align="left">Noelin</td></tr><tr><td align="left">Dr.16720</td><td align="left">BI980847</td><td char="." align="char">6.3</td><td align="left">notch 2</td></tr><tr><td align="left" colspan="4">Disease related</td></tr><tr><td align="left">Dr.6349</td><td align="left">AW116668</td><td char="." align="char">2.4</td><td align="left">Eparin cofactor II</td></tr><tr><td align="left">Dr.21064</td><td align="left">BC046075</td><td char="." align="char">4.5</td><td align="left">4hydroxyphenylpyruvate dioxygenase HPD</td></tr><tr><td align="left">Dr.12584</td><td align="left">NM_131211</td><td char="." align="char">5.4</td><td align="left">Gata binding protein 3 (GATA3)</td></tr><tr><td align="left">Dr.3530</td><td align="left">AI497545</td><td char="." align="char">79.3</td><td align="left">Prion protein (prp) gene</td></tr><tr><td align="left" colspan="4">Growth regulation</td></tr><tr><td align="left">Dr.8145</td><td align="left">NM_13143</td><td char="." align="char">2.2</td><td align="left">Insulin like growth factor 2 (IGF-2)</td></tr><tr><td align="left">Dr.7609</td><td align="left">BI475857</td><td char="." align="char">2.4</td><td align="left">Prolactin receptor</td></tr><tr><td align="left">Dr.8285</td><td align="left">NM_13136</td><td char="." align="char">2.4</td><td align="left">Mad homolog 2 </td></tr><tr><td align="left">Dr.8947</td><td align="left">CD594735</td><td char="." align="char">2.5</td><td align="left">Spint 2</td></tr><tr><td align="left">Dr.822</td><td align="left">BM184127</td><td char="." align="char">2.5</td><td align="left">Spint 2</td></tr><tr><td align="left">Dr.3563</td><td align="left">CD014488</td><td char="." align="char">2.8</td><td align="left">Tetraspan membrane protein IL-TMP</td></tr><tr><td align="left">Dr.8587</td><td align="left">NM_17328</td><td char="." align="char">2.9</td><td align="left">Insulin-like growth factor binding protein 1 </td></tr><tr><td align="left">Dr.2596</td><td align="left">BM342901</td><td char="." align="char">3.2</td><td align="left">Cyclin I</td></tr><tr><td align="left">Dr.8587</td><td align="left">AL910822</td><td char="." align="char">3.4</td><td align="left">Insulin-like growth factor binding protein 1</td></tr><tr><td align="left">Dr.26458</td><td align="left">BC053206</td><td char="." align="char">5.6</td><td align="left">m-ras</td></tr><tr><td align="left" colspan="4">Heart related</td></tr><tr><td align="left">Dr.15088</td><td align="left">BM181749</td><td char="." align="char">4.3</td><td align="left">Lectin galactoside-binding soluble 1; (galectin10-like 3)</td></tr><tr><td align="left">Dr.4867</td><td align="left">AI496840</td><td char="." align="char">5.5</td><td align="left">Haptoglobin</td></tr><tr><td align="left">Dr.3585</td><td align="left">AY049731</td><td char="." align="char">6.6</td><td align="left">Angiotensinogen </td></tr><tr><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9 </td></tr><tr><td align="left">Dr.18453</td><td align="left">BC044525</td><td char="." align="char">4.8</td><td align="left">Uridine phosphorylase</td></tr><tr><td align="left">Dr.3025</td><td align="left">BG738204</td><td char="." align="char">2.7</td><td align="left">Alpha-2 macro-globulin; A2MG</td></tr><tr><td align="left" colspan="4">Inflammation</td></tr><tr><td align="left">Dr.12491</td><td align="left">BI672168</td><td char="." align="char">2.1</td><td align="left">Complement C4&#8211;2</td></tr><tr><td align="left">Dr.4047</td><td align="left">NM_131627</td><td char="." align="char">2.3</td><td align="left">Small inducible cytokine A (scyba)</td></tr><tr><td align="left">Dr.5053</td><td align="left">NM_131723</td><td char="." align="char">2.3</td><td align="left">Kruppel-like factor 4 </td></tr><tr><td align="left">Dr25207</td><td align="left">X06465</td><td char="." align="char">2.5</td><td align="left">Complement component 8, gamma polypeptide</td></tr><tr><td align="left">Dr.6845</td><td align="left">K02765</td><td char="." align="char">2.9</td><td align="left">C3 complement component 3</td></tr><tr><td align="left">Dr.5741</td><td align="left">BU710482</td><td char="." align="char">3.2</td><td align="left">Complement component b fb</td></tr><tr><td align="left">Dr.7722</td><td align="left">BI878414</td><td char="." align="char">3.5</td><td align="left">Complement C3-H1</td></tr><tr><td align="left">Dr.22244</td><td align="left">AW019781</td><td char="." align="char">3.6</td><td align="left">Complement C1s</td></tr><tr><td align="left">Dr.22133</td><td align="left">AW076768</td><td char="." align="char">3.7</td><td align="left">c1rs-A and clrs-B</td></tr><tr><td align="left">Dr.5528</td><td align="left">AI497212</td><td char="." align="char">4.2</td><td align="left">Complement component C9</td></tr><tr><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9 </td></tr><tr><td align="left">Dr.1730</td><td align="left">AI721528</td><td char="." align="char">4.8</td><td align="left">cfI-B complement control protein factor I-B </td></tr><tr><td align="left">Dr.2452</td><td align="left">BM778002</td><td char="." align="char">5.8</td><td align="left">Complement component C9</td></tr><tr><td align="left">Dr.20291</td><td align="left">BM036389</td><td char="." align="char">6.5</td><td align="left">Complement C3-S</td></tr><tr><td align="left">Dr.190</td><td align="left">NM_131338</td><td char="." align="char">7.9</td><td align="left">Complement component factor B </td></tr><tr><td align="left">Dr.1192</td><td align="left">AB071601</td><td char="." align="char">2.</td><td align="left">Lipocalin-type prostaglandin D synthase-like protein</td></tr><tr><td align="left" colspan="4">Metabolism</td></tr><tr><td align="left">Dr.9492</td><td align="left">BI882244</td><td char="." align="char">2.0</td><td align="left">Sulfide dehydrogenase like</td></tr><tr><td align="left">Dr.15574</td><td align="left">BM571467</td><td char="." align="char">2.1</td><td align="left">Hypoxanthine _hosphor-ribosyltransferase 1</td></tr><tr><td align="left">Dr.3332</td><td align="left">AI943053</td><td char="." align="char">2.2</td><td align="left">Angiopoietin 5 </td></tr><tr><td align="left">Dr.16130</td><td align="left">CD014898</td><td char="." align="char">2.3</td><td align="left">Alcohol dehydrogenase 8&#160;b</td></tr><tr><td align="left">Dr.3959</td><td align="left">BI43001</td><td char="." align="char">2.5</td><td align="left">5&#8242;-nucleotidase</td></tr><tr><td align="left">Dr.22205</td><td align="left">AW019477</td><td char="." align="char">2.6</td><td align="left">Oxidoreductase</td></tr><tr><td align="left">Dr.1699</td><td align="left">AI667249</td><td char="." align="char">2.7</td><td align="left">Pyruvate kinase</td></tr><tr><td align="left">Dr.5504</td><td align="left">BI879550</td><td char="." align="char">3.2</td><td align="left">Cystathionine-beta-synthase</td></tr><tr><td align="left">Dr.1202</td><td align="left">AJ245491</td><td char="." align="char">3.9</td><td align="left">Apolipoprotein A-I</td></tr><tr><td align="left">Dr.4111</td><td align="left">BC053267</td><td char="." align="char">4.2</td><td align="left">Fructose-1,6-bisphosphatase 1</td></tr><tr><td align="left">Dr.18834</td><td align="left">AW019321</td><td char="." align="char">4.2</td><td align="left">Urate oxidase</td></tr><tr><td align="left">Dr.19224</td><td align="left">BC050167</td><td char="." align="char">4.3</td><td align="left">Aldolase b</td></tr><tr><td align="left">Dr.4938</td><td align="left">NM_131645</td><td char="." align="char">4.4</td><td align="left">Fatty acid desaturase 2</td></tr><tr><td align="left">Dr.12654</td><td align="left">BC046901</td><td char="." align="char">14.8</td><td align="left">ELOVL family member 6,</td></tr><tr><td align="left">Dr.5488</td><td align="left">AI545593</td><td char="." align="char">17.3</td><td align="left">Apolipoprotein A-IV </td></tr><tr><td align="left" colspan="4">Muscle related</td></tr><tr><td align="left">Dr.3585</td><td align="left">AY049731</td><td char="." align="char">6.6</td><td align="left">Angiotensinogen</td></tr><tr><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9</td></tr><tr><td align="left" colspan="4">Proteolysis</td></tr><tr><td align="left">Dr.20934</td><td align="left">AF541952</td><td char="." align="char">2.6</td><td align="left">Trypsin precursor</td></tr><tr><td align="left">Dr.3025</td><td align="left">BG738204</td><td char="." align="char">2.7</td><td align="left">Alpha-2-macroglobulin </td></tr><tr><td align="left">Dr.22139</td><td align="left">AW018965</td><td char="." align="char">3.0</td><td align="left">Alpha-1-antitrypsin</td></tr><tr><td align="left">Dr.25331</td><td align="left">AI658072</td><td char="." align="char">4.1</td><td align="left">Alpha-2-macroglobulin-2</td></tr><tr><td align="left">Dr.12602</td><td align="left">NM_139180</td><td char="." align="char">4.3</td><td align="left">Lysozyme</td></tr><tr><td align="left">Dr.1605</td><td align="left">BM185388</td><td char="." align="char">4.4</td><td align="left">Protease inhibitor 1</td></tr><tr><td align="left">Dr.17459</td><td align="left">CD586837</td><td char="." align="char">4.8</td><td align="left">Inter-alpha-trypsin inhibitor heavy chain H3 </td></tr><tr><td align="left">Dr.3073</td><td align="left">AI585030</td><td char="." align="char">5.0</td><td align="left">Serine protease inhibitor alpha 1</td></tr><tr><td align="left">Dr.26371</td><td align="left">AI667676</td><td char="." align="char">5.4</td><td align="left">Prostasin</td></tr><tr><td align="left">Dr.3025</td><td align="left">BM530427</td><td char="." align="char">5.6</td><td align="left">Alpha-2-macroglobulin-1</td></tr><tr><td align="left">Dr.3025</td><td align="left">BM316867</td><td char="." align="char">6.5</td><td align="left">Alpha-2-macroglobulin-2</td></tr><tr><td align="left">Dr.2960</td><td align="left">X67055</td><td char="." align="char">3.5</td><td align="left">ITIH3 pre-alpha (globulin) inhibitor, H3 polypeptide</td></tr><tr><td align="left">Dr.25379</td><td align="left">BI326783</td><td char="." align="char">6.7</td><td align="left">Alpha-2-macroglobulin</td></tr><tr><td align="left">Dr.4797</td><td align="left">AI959534</td><td char="." align="char">7.8</td><td align="left">26&#8211;29&#160;kD-Proteinase protein</td></tr><tr><td align="left" colspan="4">ROS protection</td></tr><tr><td align="left">Dr.20068</td><td align="left">NM_131075</td><td char="." align="char">2.1</td><td align="left">Metallothionein (mt)</td></tr><tr><td align="left">Dr.5399</td><td align="left">AI957765</td><td char="." align="char">2.3</td><td align="left">Biliverdin I Beta Reductase</td></tr><tr><td align="left">Dr.14058</td><td align="left">CD015351</td><td char="." align="char">3.5</td><td align="left">Glutathione <italic>S</italic>-transferase theta 1</td></tr><tr><td align="left">Dr.25160</td><td align="left">BC049475</td><td char="." align="char">5.9</td><td align="left">Metallothionein 2</td></tr><tr><td align="left">Dr.3613</td><td align="left">BC048037</td><td char="." align="char">6.0</td><td align="left">Cerulopasmin</td></tr><tr><td align="left">Dr.4905.1</td><td align="left">BC045464</td><td char="." align="char">6.5</td><td align="left">Uncoupling protein 4</td></tr><tr><td align="left" colspan="4">Signal transduction</td></tr><tr><td align="left">Dr.9852</td><td align="left">AW826425</td><td char="." align="char">2.1</td><td align="left">CAM kinase 1</td></tr><tr><td align="left">Dr.8591</td><td align="left">BM186508</td><td char="." align="char">2.9</td><td align="left">Rho guanine nucleotide exchange factor 10</td></tr><tr><td align="left">Dr.6236</td><td align="left">AW115973</td><td char="." align="char">3.1</td><td align="left">Rho guanine nucleotide exchange factor 5</td></tr><tr><td align="left">Dr.1267</td><td align="left">BC051157</td><td char="." align="char">3.4</td><td align="left">Phospholipase C delta</td></tr><tr><td align="left">Dr.22129</td><td align="left">BC016668</td><td char="." align="char">3.9</td><td align="left">RRAGC Rag C (Ras-related GTP binding C)</td></tr><tr><td align="left">Dr.7255</td><td align="left">AW116479</td><td char="." align="char">4.4</td><td align="left">Protein phosphatase 1,</td></tr><tr><td align="left">Dr.4453</td><td align="left">BC044421</td><td char="." align="char">5.8</td><td align="left">Phosphoprotein phosphatase</td></tr><tr><td align="left" colspan="4">Translation</td></tr><tr><td align="left">Dr.13234</td><td align="left">BM036471</td><td char="." align="char">2.0</td><td align="left">Ribonuclease P </td></tr><tr><td align="left">Dr.382</td><td align="left">CB363830</td><td char="." align="char">2.1</td><td align="left">Nucleolin</td></tr><tr><td align="left">Dr.6949</td><td align="left">AW078116</td><td char="." align="char">2.1</td><td align="left">RNA 3&#8242;-terminal phosphate cyclase-like protein (HSPC338)</td></tr><tr><td align="left">Dr.13563</td><td align="left">BI890729</td><td char="." align="char">2.3</td><td align="left">Methionyl aminopeptidase 2</td></tr><tr><td align="left">Dr.26328</td><td align="left">AL723696</td><td char="." align="char">2.3</td><td align="left">Eukaryotic translation initiation factor 4A,</td></tr><tr><td align="left">Dr.17693</td><td align="left">BQ078285</td><td char="." align="char">3.7</td><td align="left">40&#160;S ribosomal protein S6</td></tr><tr><td align="left">Dr.20270</td><td align="left">BI674050</td><td char="." align="char">5.9</td><td align="left">Ribosomal protein L12 </td></tr><tr><td align="left">Dr.25224</td><td align="left">CD015330</td><td char="." align="char">20.4</td><td align="left">Ribosomal protein L12 </td></tr><tr><td align="left">Dr.12439</td><td align="left">BM533848</td><td char="." align="char">17.5</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr><tr><td align="left">Dr.12439</td><td align="left">BM533848</td><td char="." align="char">24.2</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr><tr><td align="left">Dr.14821</td><td align="left">BM071714</td><td char="." align="char">33.8</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr><tr><td align="left">Dr.12502</td><td align="left">BQ284686</td><td char="." align="char">40.7</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr><tr><td align="left">Dr.12439. </td><td align="left">BM534432</td><td char="." align="char">40.9</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr><tr><td align="left">Dr.12439</td><td align="left">BQ616930</td><td char="." align="char">45.4</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr><tr><td align="left" colspan="4">Transport</td></tr><tr><td align="left">Dr.1084</td><td align="left">BQ109772</td><td char="." align="char">3.0</td><td align="left">Clathrin coat assembly protein AP19</td></tr><tr><td align="left">Dr.5562</td><td align="left">X04506</td><td char="." align="char">3.0</td><td align="left">APOB apolipoprotein B (including Ag(x) antigen)</td></tr><tr><td align="left">Dr.13231</td><td align="left">BM778646</td><td char="." align="char">4.2</td><td align="left">Solute carrier family 22</td></tr><tr><td align="left">Dr.30444</td><td align="left">AY329629</td><td char="." align="char">4.3</td><td align="left">Embryonic globin beta e2</td></tr><tr><td align="left">Dr.24250</td><td align="left">AF489105</td><td char="." align="char">2.0</td><td align="left">Uroporphyrinogen III synthase</td></tr><tr><td align="left">Dr.10343</td><td align="left">NM_131687</td><td char="." align="char">4.7</td><td align="left">Na+K+ transporting, alpha 1a.2 polypeptide</td></tr><tr><td align="left">Dr.7634</td><td align="left">AW115757</td><td char="." align="char">11.3</td><td align="left">Hemopexin</td></tr><tr><td align="left" colspan="4">Downregulated genes</td></tr><tr><td align="left" colspan="4">Angiogenesis</td></tr><tr><td align="left">Dr.26411</td><td align="left">BQ783571</td><td char="." align="char">&#8722;8.9</td><td align="left">Fast muscle troponin I</td></tr><tr><td align="left">Dr.15501</td><td align="left">BM316040</td><td char="." align="char">&#8722;2.1</td><td align="left">Similar to CYR6 HUMAN CYR61 protein precursor, Insulin-like growth factor-binding protein 10</td></tr><tr><td align="left" colspan="4">Cell adhesion</td></tr><tr><td align="left">Dr.251</td><td align="left">BQ285646</td><td char="." align="char">&#8722;2.3</td><td align="left">Cadherin 11</td></tr><tr><td align="left" colspan="4">Disease related</td></tr><tr><td align="left">Dr.22774</td><td align="left">AW280206</td><td char="." align="char">&#8722;5.7</td><td align="left">ras-like GTP-binding protein RAB27A</td></tr><tr><td align="left">Dr.1816</td><td align="left">AL720262</td><td char="." align="char">&#8722;4.4</td><td align="left">Ataxin 2-binding protein</td></tr><tr><td align="left">Dr.9893</td><td align="left">BM036473</td><td char="." align="char">&#8722;2.3</td><td align="left">Fibrillarin</td></tr><tr><td align="left">Dr.16726</td><td align="left">BI429372</td><td char="." align="char">&#8722;2.0</td><td align="left">netrin G1</td></tr><tr><td align="left" colspan="4">Growth regulation</td></tr><tr><td align="left">Dr.12986</td><td align="left">CA787334</td><td char="." align="char">&#8722;5.3</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.12986</td><td align="left">BI881979</td><td char="." align="char">&#8722;5.0</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.12986</td><td align="left">BM957279</td><td char="." align="char">&#8722;4.5</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.1221</td><td align="left">AW510198</td><td char="." align="char">&#8722;4.3</td><td align="left">Pmx-1b (PHOX-1)</td></tr><tr><td align="left">Dr.12986</td><td align="left">BI881979</td><td char="." align="char">&#8722;4.2</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.12410</td><td align="left">NM_131826</td><td char="." align="char">&#8722;2.4</td><td align="left">Sprouty homolog 4 </td></tr><tr><td align="left">Dr.6431</td><td align="left">BC049326</td><td char="." align="char">&#8722;2.3</td><td align="left">Suppressors of cytokine signaling 3</td></tr><tr><td align="left">Dr.6511</td><td align="left">NM_130922</td><td char="." align="char">&#8722;2.2</td><td align="left">B-cell translocation gene 2</td></tr><tr><td align="left">Dr.5365</td><td align="left">AI601685</td><td char="." align="char">&#8722;2.2</td><td align="left">Dual specificity phosphatase 5</td></tr><tr><td align="left">Dr.12062</td><td align="left">BC047814</td><td char="." align="char">&#8722;2.1</td><td align="left">Epidermal growth factor receptor kinase substrate EPS8</td></tr><tr><td align="left">Dr.17286</td><td align="left">BM777144</td><td char="." align="char">&#8722;2.0</td><td align="left">Hormone-regulated proliferation-associated 20&#160;kDa protein</td></tr><tr><td align="left">Dr.9448</td><td align="left">BM156058</td><td char="." align="char">&#8722;2.0</td><td align="left">TGF-beta-inducible early growth response protein 2</td></tr><tr><td align="left" colspan="4">Heart related</td></tr><tr><td align="left">Dr.20010</td><td align="left">BQ826502</td><td char="." align="char">&#8722;7.0</td><td align="left">ATPase, Ca++ transporting, cardiac muscle (ATP2A1)</td></tr><tr><td align="left">Dr.1448</td><td align="left">AL717344</td><td char="." align="char">&#8722;3.5</td><td align="left">Fast skeletal myosin light chain 1a</td></tr><tr><td align="left">Dr.20990</td><td align="left">AY033829 AY081167</td><td char="." align="char">&#8722;2.4&#8211;2.1</td><td align="left">Titin</td></tr><tr><td align="left" colspan="4">Metabolism</td></tr><tr><td align="left">Dr.24950</td><td align="left">BC053305</td><td char="." align="char">&#8722;4.1</td><td align="left">Creatine kinase CKM3</td></tr><tr><td align="left">Dr.9528</td><td align="left">BC045993</td><td char="." align="char">&#8722;3.5</td><td align="left">Pyruvate dehydrogenase kinase</td></tr><tr><td align="left">Dr.146</td><td align="left">AI477401</td><td char="." align="char">&#8722;2.9</td><td align="left">Carnitine <italic>O</italic>-palmitoyltransferase II</td></tr><tr><td align="left">Dr.21501</td><td align="left">AI667180</td><td char="." align="char">&#8722;2.4</td><td align="left">Short-chain acyl-CoA dehydrogenase </td></tr><tr><td align="left">Dr.19643</td><td align="left">AL918850</td><td char="." align="char">&#8722;2.4</td><td align="left">FabG beta-ketoacyl -reductase</td></tr><tr><td align="left">Dr.15059</td><td align="left">BM530407</td><td char="." align="char">&#8722;2.2</td><td align="left">Elongation of very long chain fatty acids (Cig30)</td></tr><tr><td align="left">Dr.21040</td><td align="left">BC045479</td><td char="." align="char">&#8722;2.1</td><td align="left">Glucose-6-phosphatase, transport protein 1</td></tr><tr><td align="left">Dr.988</td><td align="left">AW154697</td><td char="." align="char">&#8722;2.1</td><td align="left">Dodecenoyl-coenzyme A delta isomerase </td></tr><tr><td align="left">Dr.11971</td><td align="left">BG727588</td><td char="." align="char">&#8722;2.0</td><td align="left">Carnitine <italic>O</italic>-acetyl-transferase</td></tr><tr><td align="left">Dr.4777</td><td align="left">AW420997</td><td char="." align="char">&#8722;2.0</td><td align="left">Succinate-CoA ligase</td></tr><tr><td align="left">Dr.11252</td><td align="left">BC047826</td><td char="." align="char">&#8722;2.0</td><td align="left">Creatine kinase, mitochondrial 1 </td></tr><tr><td align="left" colspan="4">Muscle related</td></tr><tr><td align="left">Dr.21800</td><td align="left">AI883923</td><td char="." align="char">&#8722;5.0</td><td align="left">Myosin binding protein C</td></tr><tr><td align="left">Dr.5066</td><td align="left">AF524840</td><td char="." align="char">&#8722;3.4</td><td align="left">Alpha-actinin 3</td></tr><tr><td align="left">Dr.24260</td><td align="left">NM_131619</td><td char="." align="char">&#8722;3.0</td><td align="left">Myosin, light polypeptide 3</td></tr><tr><td align="left">Dr.2914</td><td align="left">BC045520</td><td char="." align="char">&#8722;2.5</td><td align="left">Myosin light polypeptide 2; mylz2</td></tr><tr><td align="left">Dr.20990</td><td align="left">AY033829 AY081167</td><td char="." align="char">&#8722;2.4&#8211;2.1</td><td align="left">Titin</td></tr><tr><td align="left">Dr.1435</td><td align="left">AI353817</td><td char="." align="char">&#8722;2.0</td><td align="left">Caveolin 3</td></tr><tr><td align="left">Dr.18657</td><td align="left">BQ479700</td><td char="." align="char">&#8722;2.1</td><td align="left">Carbonic anhydrase II</td></tr><tr><td align="left">Dr.26411</td><td align="left">BQ783571</td><td char="." align="char">&#8722;8.9</td><td align="left">Troponin I</td></tr><tr><td align="left" colspan="4">Proteolysis</td></tr><tr><td align="left">Dr.3581</td><td align="left">BM101561</td><td char="." align="char">&#8722;8.3</td><td align="left">Chymotrypsinogen B1 </td></tr><tr><td align="left">Dr.3581</td><td align="left">BM101561</td><td char="." align="char">&#8722;7.5</td><td align="left">Chymotrypsinogen B1</td></tr><tr><td align="left" colspan="4">Signal transduction</td></tr><tr><td align="left">Dr.22841</td><td align="left">AI641080</td><td char="." align="char">&#8722;2.4</td><td align="left">Serum deprivation response protein (SDPR)</td></tr><tr><td align="left" colspan="4">Translation</td></tr><tr><td align="left">Dr.7939</td><td align="left">AW281840</td><td char="." align="char">&#8722;2.7</td><td align="left">Mitochondrial elongation factor G1</td></tr><tr><td align="left">Dr.1286</td><td align="left">BM036808</td><td char="." align="char">&#8722;2.2</td><td align="left">Mitochondrial ribosomal protein L48</td></tr><tr><td align="left">Dr.18218</td><td align="left">AL909921</td><td char="." align="char">&#8722;2.1</td><td align="left">Mitochondrial 28&#160;S ribosomal protein S12 </td></tr><tr><td align="left" colspan="4">Transport</td></tr><tr><td align="left">Dr.676</td><td align="left">BC050956</td><td char="." align="char">&#8722;4.4</td><td align="left">ADT2, ADP,ATP carrier protein</td></tr><tr><td align="left">Dr.25199</td><td align="left">CD014403</td><td char="." align="char">&#8722;2.1</td><td align="left">Calcium-binding mitochondrial carrier protein Aralar2 (Citrin) </td></tr><tr><td align="left">Dr.2784</td><td align="left">AI942949</td><td char="." align="char">&#8722;2.0</td><td align="left">Solute carrier family 25 </td></tr><tr><td align="left">Dr.11127</td><td align="left">BG306498</td><td char="." align="char">&#8722;3.7</td><td align="left">Synaptotagmin I</td></tr><tr><td align="left">Dr.11127</td><td align="left">AW826278</td><td char="." align="char">&#8722;3.2</td><td align="left">Synaptotagmin I </td></tr><tr><td align="left">Dr.13273</td><td align="left">BI885460</td><td char="." align="char">&#8722;2.3</td><td align="left">GTP-binding protein rab15 </td></tr><tr><td align="left">Dr.22748</td><td align="left">AW280026</td><td char="." align="char">&#8722;2.7</td><td align="left">trpn1</td></tr><tr><td align="left">Dr.11302</td><td align="left">BG306530</td><td char="." align="char">&#8722;2.1</td><td align="left">ATPase (Ca++ transporting plasma membrane 2)</td></tr></tbody></table>
###xml 435 8846 435 8846 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="48">Functional groups of differentially expressed genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">UniGene</th><th align="left">GeneBank</th><th align="left">Fold</th><th align="left">Gene name</th></tr></thead><tbody><tr><td align="left" colspan="4">Upregulated genes</td></tr><tr><td align="left" colspan="4">Angiogenesis</td></tr><tr><td align="left">Dr.11575</td><td align="left">NM_173244</td><td char="." align="char">2.3</td><td align="left">T-cell acute lymphocytic leukemia 1; TAL1</td></tr><tr><td align="left">Dr.845</td><td align="left">BG729013</td><td char="." align="char">2.8</td><td align="left">Fibrinogen alpha/alpha-E chain </td></tr><tr><td align="left">Dr.4907</td><td align="left">BC045868</td><td char="." align="char">4.2</td><td align="left">Fibrinogen, gamma polypeptide</td></tr><tr><td align="left" colspan="4">Apoptosis</td></tr><tr><td align="left">Dr.15862</td><td align="left">AF493987</td><td char="." align="char">2.1</td><td align="left">BCL2adenovirus E1b 19 interacting protein3</td></tr><tr><td align="left">DrAffx.1.39</td><td align="left">AF302789</td><td char="." align="char">2.3</td><td align="left">Death receptor</td></tr><tr><td align="left">Dr.20106</td><td align="left">AI722277</td><td char="." align="char">2.8</td><td align="left">Apoptosis inhibitor 5</td></tr><tr><td align="left">Dr.4039</td><td align="left">BQ480688</td><td char="." align="char">21.8</td><td align="left">BAX inhibitor 1</td></tr><tr><td align="left" colspan="4">Cell adhesion</td></tr><tr><td align="left">Dr.6007</td><td align="left">NM_131820</td><td char="." align="char">2.9</td><td align="left">Cadherin 1</td></tr><tr><td align="left">Dr.25140</td><td align="left">BQ262802</td><td char="." align="char">3.3</td><td align="left">Tumor-associated calcium signal transducer </td></tr><tr><td align="left">Dr.4409</td><td align="left">BC049036</td><td char="." align="char">4.4</td><td align="left">CD9 antigen</td></tr><tr><td align="left">Dr.25140</td><td align="left">BQ262802</td><td char="." align="char">7.7</td><td align="left">Tumor-associated calcium signal transducer glycoprotein</td></tr><tr><td align="left" colspan="4">Development</td></tr><tr><td align="left">Dr.11575</td><td align="left">NM_1732</td><td char="." align="char">2.3</td><td align="left">T-cell acute lymphocyte leukemia 1 (tal 1)</td></tr><tr><td align="left">Dr.23348</td><td align="left">BE201653</td><td char="." align="char">2.6</td><td align="left">Bone morphogenetic protein 3b; (bmp 3)</td></tr><tr><td align="left">Dr25405</td><td align="left">BC013923</td><td char="." align="char">2.8</td><td align="left">SOX2 SRY-box 2</td></tr><tr><td align="left">Dr.6382</td><td align="left">AW165053</td><td char="." align="char">2.9</td><td align="left">Hedgehog-interacting protein</td></tr><tr><td align="left">Dr.10879</td><td align="left">U97669</td><td char="." align="char">3.0</td><td align="left">NOTCH3 Notch homolog 3 (<italic>Drosophila</italic>)</td></tr><tr><td align="left">Dr.15055</td><td align="left">BC050172</td><td char="." align="char">3.6</td><td align="left">Chemokine receptor 4a</td></tr><tr><td align="left">Dr.6787</td><td align="left">BI533426</td><td char="." align="char">5.5</td><td align="left">Noelin</td></tr><tr><td align="left">Dr.16720</td><td align="left">BI980847</td><td char="." align="char">6.3</td><td align="left">notch 2</td></tr><tr><td align="left" colspan="4">Disease related</td></tr><tr><td align="left">Dr.6349</td><td align="left">AW116668</td><td char="." align="char">2.4</td><td align="left">Eparin cofactor II</td></tr><tr><td align="left">Dr.21064</td><td align="left">BC046075</td><td char="." align="char">4.5</td><td align="left">4hydroxyphenylpyruvate dioxygenase HPD</td></tr><tr><td align="left">Dr.12584</td><td align="left">NM_131211</td><td char="." align="char">5.4</td><td align="left">Gata binding protein 3 (GATA3)</td></tr><tr><td align="left">Dr.3530</td><td align="left">AI497545</td><td char="." align="char">79.3</td><td align="left">Prion protein (prp) gene</td></tr><tr><td align="left" colspan="4">Growth regulation</td></tr><tr><td align="left">Dr.8145</td><td align="left">NM_13143</td><td char="." align="char">2.2</td><td align="left">Insulin like growth factor 2 (IGF-2)</td></tr><tr><td align="left">Dr.7609</td><td align="left">BI475857</td><td char="." align="char">2.4</td><td align="left">Prolactin receptor</td></tr><tr><td align="left">Dr.8285</td><td align="left">NM_13136</td><td char="." align="char">2.4</td><td align="left">Mad homolog 2 </td></tr><tr><td align="left">Dr.8947</td><td align="left">CD594735</td><td char="." align="char">2.5</td><td align="left">Spint 2</td></tr><tr><td align="left">Dr.822</td><td align="left">BM184127</td><td char="." align="char">2.5</td><td align="left">Spint 2</td></tr><tr><td align="left">Dr.3563</td><td align="left">CD014488</td><td char="." align="char">2.8</td><td align="left">Tetraspan membrane protein IL-TMP</td></tr><tr><td align="left">Dr.8587</td><td align="left">NM_17328</td><td char="." align="char">2.9</td><td align="left">Insulin-like growth factor binding protein 1 </td></tr><tr><td align="left">Dr.2596</td><td align="left">BM342901</td><td char="." align="char">3.2</td><td align="left">Cyclin I</td></tr><tr><td align="left">Dr.8587</td><td align="left">AL910822</td><td char="." align="char">3.4</td><td align="left">Insulin-like growth factor binding protein 1</td></tr><tr><td align="left">Dr.26458</td><td align="left">BC053206</td><td char="." align="char">5.6</td><td align="left">m-ras</td></tr><tr><td align="left" colspan="4">Heart related</td></tr><tr><td align="left">Dr.15088</td><td align="left">BM181749</td><td char="." align="char">4.3</td><td align="left">Lectin galactoside-binding soluble 1; (galectin10-like 3)</td></tr><tr><td align="left">Dr.4867</td><td align="left">AI496840</td><td char="." align="char">5.5</td><td align="left">Haptoglobin</td></tr><tr><td align="left">Dr.3585</td><td align="left">AY049731</td><td char="." align="char">6.6</td><td align="left">Angiotensinogen </td></tr><tr><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9 </td></tr><tr><td align="left">Dr.18453</td><td align="left">BC044525</td><td char="." align="char">4.8</td><td align="left">Uridine phosphorylase</td></tr><tr><td align="left">Dr.3025</td><td align="left">BG738204</td><td char="." align="char">2.7</td><td align="left">Alpha-2 macro-globulin; A2MG</td></tr><tr><td align="left" colspan="4">Inflammation</td></tr><tr><td align="left">Dr.12491</td><td align="left">BI672168</td><td char="." align="char">2.1</td><td align="left">Complement C4&#8211;2</td></tr><tr><td align="left">Dr.4047</td><td align="left">NM_131627</td><td char="." align="char">2.3</td><td align="left">Small inducible cytokine A (scyba)</td></tr><tr><td align="left">Dr.5053</td><td align="left">NM_131723</td><td char="." align="char">2.3</td><td align="left">Kruppel-like factor 4 </td></tr><tr><td align="left">Dr25207</td><td align="left">X06465</td><td char="." align="char">2.5</td><td align="left">Complement component 8, gamma polypeptide</td></tr><tr><td align="left">Dr.6845</td><td align="left">K02765</td><td char="." align="char">2.9</td><td align="left">C3 complement component 3</td></tr><tr><td align="left">Dr.5741</td><td align="left">BU710482</td><td char="." align="char">3.2</td><td align="left">Complement component b fb</td></tr><tr><td align="left">Dr.7722</td><td align="left">BI878414</td><td char="." align="char">3.5</td><td align="left">Complement C3-H1</td></tr><tr><td align="left">Dr.22244</td><td align="left">AW019781</td><td char="." align="char">3.6</td><td align="left">Complement C1s</td></tr><tr><td align="left">Dr.22133</td><td align="left">AW076768</td><td char="." align="char">3.7</td><td align="left">c1rs-A and clrs-B</td></tr><tr><td align="left">Dr.5528</td><td align="left">AI497212</td><td char="." align="char">4.2</td><td align="left">Complement component C9</td></tr><tr><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9 </td></tr><tr><td align="left">Dr.1730</td><td align="left">AI721528</td><td char="." align="char">4.8</td><td align="left">cfI-B complement control protein factor I-B </td></tr><tr><td align="left">Dr.2452</td><td align="left">BM778002</td><td char="." align="char">5.8</td><td align="left">Complement component C9</td></tr><tr><td align="left">Dr.20291</td><td align="left">BM036389</td><td char="." align="char">6.5</td><td align="left">Complement C3-S</td></tr><tr><td align="left">Dr.190</td><td align="left">NM_131338</td><td char="." align="char">7.9</td><td align="left">Complement component factor B </td></tr><tr><td align="left">Dr.1192</td><td align="left">AB071601</td><td char="." align="char">2.</td><td align="left">Lipocalin-type prostaglandin D synthase-like protein</td></tr><tr><td align="left" colspan="4">Metabolism</td></tr><tr><td align="left">Dr.9492</td><td align="left">BI882244</td><td char="." align="char">2.0</td><td align="left">Sulfide dehydrogenase like</td></tr><tr><td align="left">Dr.15574</td><td align="left">BM571467</td><td char="." align="char">2.1</td><td align="left">Hypoxanthine _hosphor-ribosyltransferase 1</td></tr><tr><td align="left">Dr.3332</td><td align="left">AI943053</td><td char="." align="char">2.2</td><td align="left">Angiopoietin 5 </td></tr><tr><td align="left">Dr.16130</td><td align="left">CD014898</td><td char="." align="char">2.3</td><td align="left">Alcohol dehydrogenase 8&#160;b</td></tr><tr><td align="left">Dr.3959</td><td align="left">BI43001</td><td char="." align="char">2.5</td><td align="left">5&#8242;-nucleotidase</td></tr><tr><td align="left">Dr.22205</td><td align="left">AW019477</td><td char="." align="char">2.6</td><td align="left">Oxidoreductase</td></tr><tr><td align="left">Dr.1699</td><td align="left">AI667249</td><td char="." align="char">2.7</td><td align="left">Pyruvate kinase</td></tr><tr><td align="left">Dr.5504</td><td align="left">BI879550</td><td char="." align="char">3.2</td><td align="left">Cystathionine-beta-synthase</td></tr><tr><td align="left">Dr.1202</td><td align="left">AJ245491</td><td char="." align="char">3.9</td><td align="left">Apolipoprotein A-I</td></tr><tr><td align="left">Dr.4111</td><td align="left">BC053267</td><td char="." align="char">4.2</td><td align="left">Fructose-1,6-bisphosphatase 1</td></tr><tr><td align="left">Dr.18834</td><td align="left">AW019321</td><td char="." align="char">4.2</td><td align="left">Urate oxidase</td></tr><tr><td align="left">Dr.19224</td><td align="left">BC050167</td><td char="." align="char">4.3</td><td align="left">Aldolase b</td></tr><tr><td align="left">Dr.4938</td><td align="left">NM_131645</td><td char="." align="char">4.4</td><td align="left">Fatty acid desaturase 2</td></tr><tr><td align="left">Dr.12654</td><td align="left">BC046901</td><td char="." align="char">14.8</td><td align="left">ELOVL family member 6,</td></tr><tr><td align="left">Dr.5488</td><td align="left">AI545593</td><td char="." align="char">17.3</td><td align="left">Apolipoprotein A-IV </td></tr><tr><td align="left" colspan="4">Muscle related</td></tr><tr><td align="left">Dr.3585</td><td align="left">AY049731</td><td char="." align="char">6.6</td><td align="left">Angiotensinogen</td></tr><tr><td align="left">Dr.2452</td><td align="left">BQ284848</td><td char="." align="char">4.3</td><td align="left">Complement component C9</td></tr><tr><td align="left" colspan="4">Proteolysis</td></tr><tr><td align="left">Dr.20934</td><td align="left">AF541952</td><td char="." align="char">2.6</td><td align="left">Trypsin precursor</td></tr><tr><td align="left">Dr.3025</td><td align="left">BG738204</td><td char="." align="char">2.7</td><td align="left">Alpha-2-macroglobulin </td></tr><tr><td align="left">Dr.22139</td><td align="left">AW018965</td><td char="." align="char">3.0</td><td align="left">Alpha-1-antitrypsin</td></tr><tr><td align="left">Dr.25331</td><td align="left">AI658072</td><td char="." align="char">4.1</td><td align="left">Alpha-2-macroglobulin-2</td></tr><tr><td align="left">Dr.12602</td><td align="left">NM_139180</td><td char="." align="char">4.3</td><td align="left">Lysozyme</td></tr><tr><td align="left">Dr.1605</td><td align="left">BM185388</td><td char="." align="char">4.4</td><td align="left">Protease inhibitor 1</td></tr><tr><td align="left">Dr.17459</td><td align="left">CD586837</td><td char="." align="char">4.8</td><td align="left">Inter-alpha-trypsin inhibitor heavy chain H3 </td></tr><tr><td align="left">Dr.3073</td><td align="left">AI585030</td><td char="." align="char">5.0</td><td align="left">Serine protease inhibitor alpha 1</td></tr><tr><td align="left">Dr.26371</td><td align="left">AI667676</td><td char="." align="char">5.4</td><td align="left">Prostasin</td></tr><tr><td align="left">Dr.3025</td><td align="left">BM530427</td><td char="." align="char">5.6</td><td align="left">Alpha-2-macroglobulin-1</td></tr><tr><td align="left">Dr.3025</td><td align="left">BM316867</td><td char="." align="char">6.5</td><td align="left">Alpha-2-macroglobulin-2</td></tr><tr><td align="left">Dr.2960</td><td align="left">X67055</td><td char="." align="char">3.5</td><td align="left">ITIH3 pre-alpha (globulin) inhibitor, H3 polypeptide</td></tr><tr><td align="left">Dr.25379</td><td align="left">BI326783</td><td char="." align="char">6.7</td><td align="left">Alpha-2-macroglobulin</td></tr><tr><td align="left">Dr.4797</td><td align="left">AI959534</td><td char="." align="char">7.8</td><td align="left">26&#8211;29&#160;kD-Proteinase protein</td></tr><tr><td align="left" colspan="4">ROS protection</td></tr><tr><td align="left">Dr.20068</td><td align="left">NM_131075</td><td char="." align="char">2.1</td><td align="left">Metallothionein (mt)</td></tr><tr><td align="left">Dr.5399</td><td align="left">AI957765</td><td char="." align="char">2.3</td><td align="left">Biliverdin I Beta Reductase</td></tr><tr><td align="left">Dr.14058</td><td align="left">CD015351</td><td char="." align="char">3.5</td><td align="left">Glutathione <italic>S</italic>-transferase theta 1</td></tr><tr><td align="left">Dr.25160</td><td align="left">BC049475</td><td char="." align="char">5.9</td><td align="left">Metallothionein 2</td></tr><tr><td align="left">Dr.3613</td><td align="left">BC048037</td><td char="." align="char">6.0</td><td align="left">Cerulopasmin</td></tr><tr><td align="left">Dr.4905.1</td><td align="left">BC045464</td><td char="." align="char">6.5</td><td align="left">Uncoupling protein 4</td></tr><tr><td align="left" colspan="4">Signal transduction</td></tr><tr><td align="left">Dr.9852</td><td align="left">AW826425</td><td char="." align="char">2.1</td><td align="left">CAM kinase 1</td></tr><tr><td align="left">Dr.8591</td><td align="left">BM186508</td><td char="." align="char">2.9</td><td align="left">Rho guanine nucleotide exchange factor 10</td></tr><tr><td align="left">Dr.6236</td><td align="left">AW115973</td><td char="." align="char">3.1</td><td align="left">Rho guanine nucleotide exchange factor 5</td></tr><tr><td align="left">Dr.1267</td><td align="left">BC051157</td><td char="." align="char">3.4</td><td align="left">Phospholipase C delta</td></tr><tr><td align="left">Dr.22129</td><td align="left">BC016668</td><td char="." align="char">3.9</td><td align="left">RRAGC Rag C (Ras-related GTP binding C)</td></tr><tr><td align="left">Dr.7255</td><td align="left">AW116479</td><td char="." align="char">4.4</td><td align="left">Protein phosphatase 1,</td></tr><tr><td align="left">Dr.4453</td><td align="left">BC044421</td><td char="." align="char">5.8</td><td align="left">Phosphoprotein phosphatase</td></tr><tr><td align="left" colspan="4">Translation</td></tr><tr><td align="left">Dr.13234</td><td align="left">BM036471</td><td char="." align="char">2.0</td><td align="left">Ribonuclease P </td></tr><tr><td align="left">Dr.382</td><td align="left">CB363830</td><td char="." align="char">2.1</td><td align="left">Nucleolin</td></tr><tr><td align="left">Dr.6949</td><td align="left">AW078116</td><td char="." align="char">2.1</td><td align="left">RNA 3&#8242;-terminal phosphate cyclase-like protein (HSPC338)</td></tr><tr><td align="left">Dr.13563</td><td align="left">BI890729</td><td char="." align="char">2.3</td><td align="left">Methionyl aminopeptidase 2</td></tr><tr><td align="left">Dr.26328</td><td align="left">AL723696</td><td char="." align="char">2.3</td><td align="left">Eukaryotic translation initiation factor 4A,</td></tr><tr><td align="left">Dr.17693</td><td align="left">BQ078285</td><td char="." align="char">3.7</td><td align="left">40&#160;S ribosomal protein S6</td></tr><tr><td align="left">Dr.20270</td><td align="left">BI674050</td><td char="." align="char">5.9</td><td align="left">Ribosomal protein L12 </td></tr><tr><td align="left">Dr.25224</td><td align="left">CD015330</td><td char="." align="char">20.4</td><td align="left">Ribosomal protein L12 </td></tr><tr><td align="left">Dr.12439</td><td align="left">BM533848</td><td char="." align="char">17.5</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr><tr><td align="left">Dr.12439</td><td align="left">BM533848</td><td char="." align="char">24.2</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr><tr><td align="left">Dr.14821</td><td align="left">BM071714</td><td char="." align="char">33.8</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr><tr><td align="left">Dr.12502</td><td align="left">BQ284686</td><td char="." align="char">40.7</td><td align="left">Heterogeneous nuclear ribonucleoprotein K </td></tr><tr><td align="left">Dr.12439. </td><td align="left">BM534432</td><td char="." align="char">40.9</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr><tr><td align="left">Dr.12439</td><td align="left">BQ616930</td><td char="." align="char">45.4</td><td align="left">Heterogeneous nuclear ribonucleoprotein K</td></tr><tr><td align="left" colspan="4">Transport</td></tr><tr><td align="left">Dr.1084</td><td align="left">BQ109772</td><td char="." align="char">3.0</td><td align="left">Clathrin coat assembly protein AP19</td></tr><tr><td align="left">Dr.5562</td><td align="left">X04506</td><td char="." align="char">3.0</td><td align="left">APOB apolipoprotein B (including Ag(x) antigen)</td></tr><tr><td align="left">Dr.13231</td><td align="left">BM778646</td><td char="." align="char">4.2</td><td align="left">Solute carrier family 22</td></tr><tr><td align="left">Dr.30444</td><td align="left">AY329629</td><td char="." align="char">4.3</td><td align="left">Embryonic globin beta e2</td></tr><tr><td align="left">Dr.24250</td><td align="left">AF489105</td><td char="." align="char">2.0</td><td align="left">Uroporphyrinogen III synthase</td></tr><tr><td align="left">Dr.10343</td><td align="left">NM_131687</td><td char="." align="char">4.7</td><td align="left">Na+K+ transporting, alpha 1a.2 polypeptide</td></tr><tr><td align="left">Dr.7634</td><td align="left">AW115757</td><td char="." align="char">11.3</td><td align="left">Hemopexin</td></tr><tr><td align="left" colspan="4">Downregulated genes</td></tr><tr><td align="left" colspan="4">Angiogenesis</td></tr><tr><td align="left">Dr.26411</td><td align="left">BQ783571</td><td char="." align="char">&#8722;8.9</td><td align="left">Fast muscle troponin I</td></tr><tr><td align="left">Dr.15501</td><td align="left">BM316040</td><td char="." align="char">&#8722;2.1</td><td align="left">Similar to CYR6 HUMAN CYR61 protein precursor, Insulin-like growth factor-binding protein 10</td></tr><tr><td align="left" colspan="4">Cell adhesion</td></tr><tr><td align="left">Dr.251</td><td align="left">BQ285646</td><td char="." align="char">&#8722;2.3</td><td align="left">Cadherin 11</td></tr><tr><td align="left" colspan="4">Disease related</td></tr><tr><td align="left">Dr.22774</td><td align="left">AW280206</td><td char="." align="char">&#8722;5.7</td><td align="left">ras-like GTP-binding protein RAB27A</td></tr><tr><td align="left">Dr.1816</td><td align="left">AL720262</td><td char="." align="char">&#8722;4.4</td><td align="left">Ataxin 2-binding protein</td></tr><tr><td align="left">Dr.9893</td><td align="left">BM036473</td><td char="." align="char">&#8722;2.3</td><td align="left">Fibrillarin</td></tr><tr><td align="left">Dr.16726</td><td align="left">BI429372</td><td char="." align="char">&#8722;2.0</td><td align="left">netrin G1</td></tr><tr><td align="left" colspan="4">Growth regulation</td></tr><tr><td align="left">Dr.12986</td><td align="left">CA787334</td><td char="." align="char">&#8722;5.3</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.12986</td><td align="left">BI881979</td><td char="." align="char">&#8722;5.0</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.12986</td><td align="left">BM957279</td><td char="." align="char">&#8722;4.5</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.1221</td><td align="left">AW510198</td><td char="." align="char">&#8722;4.3</td><td align="left">Pmx-1b (PHOX-1)</td></tr><tr><td align="left">Dr.12986</td><td align="left">BI881979</td><td char="." align="char">&#8722;4.2</td><td align="left">v-fos</td></tr><tr><td align="left">Dr.12410</td><td align="left">NM_131826</td><td char="." align="char">&#8722;2.4</td><td align="left">Sprouty homolog 4 </td></tr><tr><td align="left">Dr.6431</td><td align="left">BC049326</td><td char="." align="char">&#8722;2.3</td><td align="left">Suppressors of cytokine signaling 3</td></tr><tr><td align="left">Dr.6511</td><td align="left">NM_130922</td><td char="." align="char">&#8722;2.2</td><td align="left">B-cell translocation gene 2</td></tr><tr><td align="left">Dr.5365</td><td align="left">AI601685</td><td char="." align="char">&#8722;2.2</td><td align="left">Dual specificity phosphatase 5</td></tr><tr><td align="left">Dr.12062</td><td align="left">BC047814</td><td char="." align="char">&#8722;2.1</td><td align="left">Epidermal growth factor receptor kinase substrate EPS8</td></tr><tr><td align="left">Dr.17286</td><td align="left">BM777144</td><td char="." align="char">&#8722;2.0</td><td align="left">Hormone-regulated proliferation-associated 20&#160;kDa protein</td></tr><tr><td align="left">Dr.9448</td><td align="left">BM156058</td><td char="." align="char">&#8722;2.0</td><td align="left">TGF-beta-inducible early growth response protein 2</td></tr><tr><td align="left" colspan="4">Heart related</td></tr><tr><td align="left">Dr.20010</td><td align="left">BQ826502</td><td char="." align="char">&#8722;7.0</td><td align="left">ATPase, Ca++ transporting, cardiac muscle (ATP2A1)</td></tr><tr><td align="left">Dr.1448</td><td align="left">AL717344</td><td char="." align="char">&#8722;3.5</td><td align="left">Fast skeletal myosin light chain 1a</td></tr><tr><td align="left">Dr.20990</td><td align="left">AY033829 AY081167</td><td char="." align="char">&#8722;2.4&#8211;2.1</td><td align="left">Titin</td></tr><tr><td align="left" colspan="4">Metabolism</td></tr><tr><td align="left">Dr.24950</td><td align="left">BC053305</td><td char="." align="char">&#8722;4.1</td><td align="left">Creatine kinase CKM3</td></tr><tr><td align="left">Dr.9528</td><td align="left">BC045993</td><td char="." align="char">&#8722;3.5</td><td align="left">Pyruvate dehydrogenase kinase</td></tr><tr><td align="left">Dr.146</td><td align="left">AI477401</td><td char="." align="char">&#8722;2.9</td><td align="left">Carnitine <italic>O</italic>-palmitoyltransferase II</td></tr><tr><td align="left">Dr.21501</td><td align="left">AI667180</td><td char="." align="char">&#8722;2.4</td><td align="left">Short-chain acyl-CoA dehydrogenase </td></tr><tr><td align="left">Dr.19643</td><td align="left">AL918850</td><td char="." align="char">&#8722;2.4</td><td align="left">FabG beta-ketoacyl -reductase</td></tr><tr><td align="left">Dr.15059</td><td align="left">BM530407</td><td char="." align="char">&#8722;2.2</td><td align="left">Elongation of very long chain fatty acids (Cig30)</td></tr><tr><td align="left">Dr.21040</td><td align="left">BC045479</td><td char="." align="char">&#8722;2.1</td><td align="left">Glucose-6-phosphatase, transport protein 1</td></tr><tr><td align="left">Dr.988</td><td align="left">AW154697</td><td char="." align="char">&#8722;2.1</td><td align="left">Dodecenoyl-coenzyme A delta isomerase </td></tr><tr><td align="left">Dr.11971</td><td align="left">BG727588</td><td char="." align="char">&#8722;2.0</td><td align="left">Carnitine <italic>O</italic>-acetyl-transferase</td></tr><tr><td align="left">Dr.4777</td><td align="left">AW420997</td><td char="." align="char">&#8722;2.0</td><td align="left">Succinate-CoA ligase</td></tr><tr><td align="left">Dr.11252</td><td align="left">BC047826</td><td char="." align="char">&#8722;2.0</td><td align="left">Creatine kinase, mitochondrial 1 </td></tr><tr><td align="left" colspan="4">Muscle related</td></tr><tr><td align="left">Dr.21800</td><td align="left">AI883923</td><td char="." align="char">&#8722;5.0</td><td align="left">Myosin binding protein C</td></tr><tr><td align="left">Dr.5066</td><td align="left">AF524840</td><td char="." align="char">&#8722;3.4</td><td align="left">Alpha-actinin 3</td></tr><tr><td align="left">Dr.24260</td><td align="left">NM_131619</td><td char="." align="char">&#8722;3.0</td><td align="left">Myosin, light polypeptide 3</td></tr><tr><td align="left">Dr.2914</td><td align="left">BC045520</td><td char="." align="char">&#8722;2.5</td><td align="left">Myosin light polypeptide 2; mylz2</td></tr><tr><td align="left">Dr.20990</td><td align="left">AY033829 AY081167</td><td char="." align="char">&#8722;2.4&#8211;2.1</td><td align="left">Titin</td></tr><tr><td align="left">Dr.1435</td><td align="left">AI353817</td><td char="." align="char">&#8722;2.0</td><td align="left">Caveolin 3</td></tr><tr><td align="left">Dr.18657</td><td align="left">BQ479700</td><td char="." align="char">&#8722;2.1</td><td align="left">Carbonic anhydrase II</td></tr><tr><td align="left">Dr.26411</td><td align="left">BQ783571</td><td char="." align="char">&#8722;8.9</td><td align="left">Troponin I</td></tr><tr><td align="left" colspan="4">Proteolysis</td></tr><tr><td align="left">Dr.3581</td><td align="left">BM101561</td><td char="." align="char">&#8722;8.3</td><td align="left">Chymotrypsinogen B1 </td></tr><tr><td align="left">Dr.3581</td><td align="left">BM101561</td><td char="." align="char">&#8722;7.5</td><td align="left">Chymotrypsinogen B1</td></tr><tr><td align="left" colspan="4">Signal transduction</td></tr><tr><td align="left">Dr.22841</td><td align="left">AI641080</td><td char="." align="char">&#8722;2.4</td><td align="left">Serum deprivation response protein (SDPR)</td></tr><tr><td align="left" colspan="4">Translation</td></tr><tr><td align="left">Dr.7939</td><td align="left">AW281840</td><td char="." align="char">&#8722;2.7</td><td align="left">Mitochondrial elongation factor G1</td></tr><tr><td align="left">Dr.1286</td><td align="left">BM036808</td><td char="." align="char">&#8722;2.2</td><td align="left">Mitochondrial ribosomal protein L48</td></tr><tr><td align="left">Dr.18218</td><td align="left">AL909921</td><td char="." align="char">&#8722;2.1</td><td align="left">Mitochondrial 28&#160;S ribosomal protein S12 </td></tr><tr><td align="left" colspan="4">Transport</td></tr><tr><td align="left">Dr.676</td><td align="left">BC050956</td><td char="." align="char">&#8722;4.4</td><td align="left">ADT2, ADP,ATP carrier protein</td></tr><tr><td align="left">Dr.25199</td><td align="left">CD014403</td><td char="." align="char">&#8722;2.1</td><td align="left">Calcium-binding mitochondrial carrier protein Aralar2 (Citrin) </td></tr><tr><td align="left">Dr.2784</td><td align="left">AI942949</td><td char="." align="char">&#8722;2.0</td><td align="left">Solute carrier family 25 </td></tr><tr><td align="left">Dr.11127</td><td align="left">BG306498</td><td char="." align="char">&#8722;3.7</td><td align="left">Synaptotagmin I</td></tr><tr><td align="left">Dr.11127</td><td align="left">AW826278</td><td char="." align="char">&#8722;3.2</td><td align="left">Synaptotagmin I </td></tr><tr><td align="left">Dr.13273</td><td align="left">BI885460</td><td char="." align="char">&#8722;2.3</td><td align="left">GTP-binding protein rab15 </td></tr><tr><td align="left">Dr.22748</td><td align="left">AW280026</td><td char="." align="char">&#8722;2.7</td><td align="left">trpn1</td></tr><tr><td align="left">Dr.11302</td><td align="left">BG306530</td><td char="." align="char">&#8722;2.1</td><td align="left">ATPase (Ca++ transporting plasma membrane 2)</td></tr></tbody></table></table-wrap>
###xml 1340 1350 <span type="species:ncbi:7227">Drosophila</span>
We have clustered the differential expressed genes according to known functions (Table 2). Genes can have more than one particular function assigned, so some genes can appear in more than one group. In addition, a gene ontology analysis was performed using eGOn to determine gene enrichment and overrepresentation in the three categories of molecular function, biological processes and cellular components (Supplemental Data 1 and 2). Table 2Functional groups of differentially expressed genesUniGeneGeneBankFoldGene nameUpregulated genesAngiogenesisDr.11575NM_1732442.3T-cell acute lymphocytic leukemia 1; TAL1Dr.845BG7290132.8Fibrinogen alpha/alpha-E chain Dr.4907BC0458684.2Fibrinogen, gamma polypeptideApoptosisDr.15862AF4939872.1BCL2adenovirus E1b 19 interacting protein3DrAffx.1.39AF3027892.3Death receptorDr.20106AI7222772.8Apoptosis inhibitor 5Dr.4039BQ48068821.8BAX inhibitor 1Cell adhesionDr.6007NM_1318202.9Cadherin 1Dr.25140BQ2628023.3Tumor-associated calcium signal transducer Dr.4409BC0490364.4CD9 antigenDr.25140BQ2628027.7Tumor-associated calcium signal transducer glycoproteinDevelopmentDr.11575NM_17322.3T-cell acute lymphocyte leukemia 1 (tal 1)Dr.23348BE2016532.6Bone morphogenetic protein 3b; (bmp 3)Dr25405BC0139232.8SOX2 SRY-box 2Dr.6382AW1650532.9Hedgehog-interacting proteinDr.10879U976693.0NOTCH3 Notch homolog 3 (Drosophila)Dr.15055BC0501723.6Chemokine receptor 4aDr.6787BI5334265.5NoelinDr.16720BI9808476.3notch 2Disease relatedDr.6349AW1166682.4Eparin cofactor IIDr.21064BC0460754.54hydroxyphenylpyruvate dioxygenase HPDDr.12584NM_1312115.4Gata binding protein 3 (GATA3)Dr.3530AI49754579.3Prion protein (prp) geneGrowth regulationDr.8145NM_131432.2Insulin like growth factor 2 (IGF-2)Dr.7609BI4758572.4Prolactin receptorDr.8285NM_131362.4Mad homolog 2 Dr.8947CD5947352.5Spint 2Dr.822BM1841272.5Spint 2Dr.3563CD0144882.8Tetraspan membrane protein IL-TMPDr.8587NM_173282.9Insulin-like growth factor binding protein 1 Dr.2596BM3429013.2Cyclin IDr.8587AL9108223.4Insulin-like growth factor binding protein 1Dr.26458BC0532065.6m-rasHeart relatedDr.15088BM1817494.3Lectin galactoside-binding soluble 1; (galectin10-like 3)Dr.4867AI4968405.5HaptoglobinDr.3585AY0497316.6Angiotensinogen Dr.2452BQ2848484.3Complement component C9 Dr.18453BC0445254.8Uridine phosphorylaseDr.3025BG7382042.7Alpha-2 macro-globulin; A2MGInflammationDr.12491BI6721682.1Complement C4-2Dr.4047NM_1316272.3Small inducible cytokine A (scyba)Dr.5053NM_1317232.3Kruppel-like factor 4 Dr25207X064652.5Complement component 8, gamma polypeptideDr.6845K027652.9C3 complement component 3Dr.5741BU7104823.2Complement component b fbDr.7722BI8784143.5Complement C3-H1Dr.22244AW0197813.6Complement C1sDr.22133AW0767683.7c1rs-A and clrs-BDr.5528AI4972124.2Complement component C9Dr.2452BQ2848484.3Complement component C9 Dr.1730AI7215284.8cfI-B complement control protein factor I-B Dr.2452BM7780025.8Complement component C9Dr.20291BM0363896.5Complement C3-SDr.190NM_1313387.9Complement component factor B Dr.1192AB0716012.Lipocalin-type prostaglandin D synthase-like proteinMetabolismDr.9492BI8822442.0Sulfide dehydrogenase likeDr.15574BM5714672.1Hypoxanthine _hosphor-ribosyltransferase 1Dr.3332AI9430532.2Angiopoietin 5 Dr.16130CD0148982.3Alcohol dehydrogenase 8 bDr.3959BI430012.55'-nucleotidaseDr.22205AW0194772.6OxidoreductaseDr.1699AI6672492.7Pyruvate kinaseDr.5504BI8795503.2Cystathionine-beta-synthaseDr.1202AJ2454913.9Apolipoprotein A-IDr.4111BC0532674.2Fructose-1,6-bisphosphatase 1Dr.18834AW0193214.2Urate oxidaseDr.19224BC0501674.3Aldolase bDr.4938NM_1316454.4Fatty acid desaturase 2Dr.12654BC04690114.8ELOVL family member 6,Dr.5488AI54559317.3Apolipoprotein A-IV Muscle relatedDr.3585AY0497316.6AngiotensinogenDr.2452BQ2848484.3Complement component C9ProteolysisDr.20934AF5419522.6Trypsin precursorDr.3025BG7382042.7Alpha-2-macroglobulin Dr.22139AW0189653.0Alpha-1-antitrypsinDr.25331AI6580724.1Alpha-2-macroglobulin-2Dr.12602NM_1391804.3LysozymeDr.1605BM1853884.4Protease inhibitor 1Dr.17459CD5868374.8Inter-alpha-trypsin inhibitor heavy chain H3 Dr.3073AI5850305.0Serine protease inhibitor alpha 1Dr.26371AI6676765.4ProstasinDr.3025BM5304275.6Alpha-2-macroglobulin-1Dr.3025BM3168676.5Alpha-2-macroglobulin-2Dr.2960X670553.5ITIH3 pre-alpha (globulin) inhibitor, H3 polypeptideDr.25379BI3267836.7Alpha-2-macroglobulinDr.4797AI9595347.826-29 kD-Proteinase proteinROS protectionDr.20068NM_1310752.1Metallothionein (mt)Dr.5399AI9577652.3Biliverdin I Beta ReductaseDr.14058CD0153513.5Glutathione S-transferase theta 1Dr.25160BC0494755.9Metallothionein 2Dr.3613BC0480376.0CerulopasminDr.4905.1BC0454646.5Uncoupling protein 4Signal transductionDr.9852AW8264252.1CAM kinase 1Dr.8591BM1865082.9Rho guanine nucleotide exchange factor 10Dr.6236AW1159733.1Rho guanine nucleotide exchange factor 5Dr.1267BC0511573.4Phospholipase C deltaDr.22129BC0166683.9RRAGC Rag C (Ras-related GTP binding C)Dr.7255AW1164794.4Protein phosphatase 1,Dr.4453BC0444215.8Phosphoprotein phosphataseTranslationDr.13234BM0364712.0Ribonuclease P Dr.382CB3638302.1NucleolinDr.6949AW0781162.1RNA 3'-terminal phosphate cyclase-like protein (HSPC338)Dr.13563BI8907292.3Methionyl aminopeptidase 2Dr.26328AL7236962.3Eukaryotic translation initiation factor 4A,Dr.17693BQ0782853.740 S ribosomal protein S6Dr.20270BI6740505.9Ribosomal protein L12 Dr.25224CD01533020.4Ribosomal protein L12 Dr.12439BM53384817.5Heterogeneous nuclear ribonucleoprotein K Dr.12439BM53384824.2Heterogeneous nuclear ribonucleoprotein KDr.14821BM07171433.8Heterogeneous nuclear ribonucleoprotein K Dr.12502BQ28468640.7Heterogeneous nuclear ribonucleoprotein K Dr.12439. BM53443240.9Heterogeneous nuclear ribonucleoprotein KDr.12439BQ61693045.4Heterogeneous nuclear ribonucleoprotein KTransportDr.1084BQ1097723.0Clathrin coat assembly protein AP19Dr.5562X045063.0APOB apolipoprotein B (including Ag(x) antigen)Dr.13231BM7786464.2Solute carrier family 22Dr.30444AY3296294.3Embryonic globin beta e2Dr.24250AF4891052.0Uroporphyrinogen III synthaseDr.10343NM_1316874.7Na+K+ transporting, alpha 1a.2 polypeptideDr.7634AW11575711.3HemopexinDownregulated genesAngiogenesisDr.26411BQ783571-8.9Fast muscle troponin IDr.15501BM316040-2.1Similar to CYR6 HUMAN CYR61 protein precursor, Insulin-like growth factor-binding protein 10Cell adhesionDr.251BQ285646-2.3Cadherin 11Disease relatedDr.22774AW280206-5.7ras-like GTP-binding protein RAB27ADr.1816AL720262-4.4Ataxin 2-binding proteinDr.9893BM036473-2.3FibrillarinDr.16726BI429372-2.0netrin G1Growth regulationDr.12986CA787334-5.3v-fosDr.12986BI881979-5.0v-fosDr.12986BM957279-4.5v-fosDr.1221AW510198-4.3Pmx-1b (PHOX-1)Dr.12986BI881979-4.2v-fosDr.12410NM_131826-2.4Sprouty homolog 4 Dr.6431BC049326-2.3Suppressors of cytokine signaling 3Dr.6511NM_130922-2.2B-cell translocation gene 2Dr.5365AI601685-2.2Dual specificity phosphatase 5Dr.12062BC047814-2.1Epidermal growth factor receptor kinase substrate EPS8Dr.17286BM777144-2.0Hormone-regulated proliferation-associated 20 kDa proteinDr.9448BM156058-2.0TGF-beta-inducible early growth response protein 2Heart relatedDr.20010BQ826502-7.0ATPase, Ca++ transporting, cardiac muscle (ATP2A1)Dr.1448AL717344-3.5Fast skeletal myosin light chain 1aDr.20990AY033829 AY081167-2.4-2.1TitinMetabolismDr.24950BC053305-4.1Creatine kinase CKM3Dr.9528BC045993-3.5Pyruvate dehydrogenase kinaseDr.146AI477401-2.9Carnitine O-palmitoyltransferase IIDr.21501AI667180-2.4Short-chain acyl-CoA dehydrogenase Dr.19643AL918850-2.4FabG beta-ketoacyl -reductaseDr.15059BM530407-2.2Elongation of very long chain fatty acids (Cig30)Dr.21040BC045479-2.1Glucose-6-phosphatase, transport protein 1Dr.988AW154697-2.1Dodecenoyl-coenzyme A delta isomerase Dr.11971BG727588-2.0Carnitine O-acetyl-transferaseDr.4777AW420997-2.0Succinate-CoA ligaseDr.11252BC047826-2.0Creatine kinase, mitochondrial 1 Muscle relatedDr.21800AI883923-5.0Myosin binding protein CDr.5066AF524840-3.4Alpha-actinin 3Dr.24260NM_131619-3.0Myosin, light polypeptide 3Dr.2914BC045520-2.5Myosin light polypeptide 2; mylz2Dr.20990AY033829 AY081167-2.4-2.1TitinDr.1435AI353817-2.0Caveolin 3Dr.18657BQ479700-2.1Carbonic anhydrase IIDr.26411BQ783571-8.9Troponin IProteolysisDr.3581BM101561-8.3Chymotrypsinogen B1 Dr.3581BM101561-7.5Chymotrypsinogen B1Signal transductionDr.22841AI641080-2.4Serum deprivation response protein (SDPR)TranslationDr.7939AW281840-2.7Mitochondrial elongation factor G1Dr.1286BM036808-2.2Mitochondrial ribosomal protein L48Dr.18218AL909921-2.1Mitochondrial 28 S ribosomal protein S12 TransportDr.676BC050956-4.4ADT2, ADP,ATP carrier proteinDr.25199CD014403-2.1Calcium-binding mitochondrial carrier protein Aralar2 (Citrin) Dr.2784AI942949-2.0Solute carrier family 25 Dr.11127BG306498-3.7Synaptotagmin IDr.11127AW826278-3.2Synaptotagmin I Dr.13273BI885460-2.3GTP-binding protein rab15 Dr.22748AW280026-2.7trpn1Dr.11302BG306530-2.1ATPase (Ca++ transporting plasma membrane 2)
###end p 47
###begin p 48
Functional groups of differentially expressed genes
###end p 48
###begin p 49
###xml 0 33 0 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Proteinbiosynthesis (Translation)</italic>
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
Proteinbiosynthesis (Translation): In the group linked to proteinbiosynthesis, only three genes showed decreased expression under hypoxic conditions. All three were found to be part of the mitochondrial translational machinery. In contrast, 9 non mitochondrial genes linked to proteinbiosynthesis showed all increased expression (Table 2).
###end p 49
###begin p 50
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Metabolism</italic>
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
Metabolism: The group with metabolic genes contains 11 repressed and 28 genes with enhanced expression (Table 2). The repression majorly involves metabolic genes linked to beta-oxidation and lipid metabolism. Among the metabolic genes with enhanced expression, are pyruvate kinase and aldolase which both are key enzymes for glycolysis indicating a shift from aerobic to anaerobic metabolism induced by hypoxia.
###end p 50
###begin p 51
###xml 0 48 0 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Protection against reactive oxygen species (ROS)</italic>
Protection against reactive oxygen species (ROS): The group of genes important for protection against ROS contains 6 genes which are all enhanced under hypoxia.
###end p 51
###begin p 52
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apoptosis</italic>
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">1997</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">1998</xref>
Apoptosis: We found four genes linked to programmed cell death to be enhanced by hypoxia. Two of these, the death receptor 5 (DR5) and the BNIP3 homologue, are considered to be pro-apoptotic, whereas apoptosis inhibitor 5 and Bax inhibitor have been shown to have anti-apoptotic properties (Tewari et al. 1997; Xu and Reed 1998).
###end p 52
###begin p 53
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Growth regulation</italic>
###xml 635 645 635 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec20" ref-type="sec">Discussion</xref>
###xml 775 776 775 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
Growth regulation: In the group of genes linked to growth regulation, we found 9 genes to be repressed and 8 genes with enhanced expression. Within the group of 8 repressed genes, we found 5 antiproliferative genes: spry4 and dual specificity phosphatase 5 both inhibit mitogen-activated kinases (MAPK), SOCS3 binds and inhibits Janus kinases (JAK) and thereby prevents STAT3 activation. BTG2 which is important in the G1/S transition and TIEG2 is a transcriptional repressor with antiproliferative functions. Although some genes involved in cell proliferation, like the transcription factor c-fos were repressed by hypoxia (see also "Discussion"), the regulation of the vast majority (13 of 17) of identified genes in this group suggests stimulation of proliferation (Table 2).
###end p 53
###begin p 54
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inflammation</italic>
Inflammation: 14 genes involved in the inflammatory response were identified to be differentially regulated and all showed increased expression upon hypoxia treatment.
###end p 54
###begin p 55
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Heart-related function</italic>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 185 195 185 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec20" ref-type="sec">Discussion</xref>
Heart-related function: Several genes linked to cardiac hypertrophy, cardiomyopathy (disease of the heart muscle) and cardiac infarction were identified in this study (see Table 2 and "Discussion").
###end p 55
###begin p 56
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Muscle-related function</italic>
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 139 149 139 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec20" ref-type="sec">Discussion</xref>
Muscle-related function: Several sarcomeric genes linked to hypertrophy showed decreased expression under hypoxic conditions (Table 2 and "Discussion").
###end p 56
###begin p 57
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Development</italic>
Development: The genes in this group were all found to be upregulated by hypoxia among them the gene for notch-2 and notch-3. Notch receptors are transmembrane receptors with essential roles in development including heart development.
###end p 57
###begin p 58
###xml 0 33 0 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Transport (cellular and vascular)</italic>
Transport (cellular and vascular): A heterologous group containing the gene for embryonic hemoglobin beta e2, important for oxygen transport and hemopexin which is important for heme and iron transport and was found to be upregulated.
###end p 58
###begin p 59
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Angiogenesis</italic>
###xml 370 374 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2004</xref>
###xml 134 143 <span type="species:ncbi:7955">zebrafish</span>
Angiogenesis: It is well known that hypoxia via the hypoxia inducible factor 1alpha (HIF1alpha) pathway leads to angiogenesis. In the zebrafish heart under CCH, we observed increased expression of HIF1alpha as well as fibrinogen-alpha and -gamma. Fibrinogen-alpha has been shown to stimulate HIF1alpha and VEGF expression and thereby induces angiogenesis (Shiose et al. 2004).
###end p 59
###begin title 60
Expression changes of known hypoxia responsive genes
###end title 60
###begin p 61
###xml 269 273 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1999</xref>
###xml 437 441 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2005</xref>
###xml 540 544 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">1995</xref>
###xml 733 738 721 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2005a</xref>
###xml 1022 1026 1010 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2000</xref>
###xml 608 617 <span type="species:ncbi:7955">zebrafish</span>
###xml 864 873 <span type="species:ncbi:7955">zebrafish</span>
###xml 996 1002 <span type="species:ncbi:9986">rabbit</span>
Examples for regulation of known hypoxia responsive genes are HIF1alpha, insulin growth factor-2 (IGF-2), insulin growth factor binding protein 1 (IGFbp1) and caveolin 3. The transcription factor Hif1alpha is pivotal in the cellular response to hypoxic stress (Semenza 1999). We further observed increased expression of the egl nine homolog, a gene which was shown to be induced by hypoxia through the Hif1alpha pathway (Pescador et al. 2005). IGF-2 gene- and protein expression had been shown to be upregulated by hypoxia (Beilharz et al. 1995). It was shown that IGFbp1 also is a hypoxia-inducible gene in zebrafish embryos and it mediates hypoxia-induced embryonic growth-inhibition and developmental-retardation (Kajimura et al. 2005a). Both IGF-2 and IGFbp1 were found upregulated in our study. We observed decreased expression of caveolin 3 in the hearts of zebrafish exposed to CCH, earlier findings showed that chronic myocardial hypoxia led to decreased caveolin-3 protein expression in rabbit hearts (Shi et al. 2000). These findings indicate that the hypoxic conditions used lead to hypoxic stress in the fish heart.
###end p 61
###begin title 62
Evaluation of microarray results by quantitative real-time RT-PCR
###end title 62
###begin p 63
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 705 709 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2005</xref>
###xml 722 726 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2003</xref>
###xml 748 752 748 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2005</xref>
###xml 755 761 755 761 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 761 1233 761 1227 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="64">Verification of gene expression changes by quantitative real-time PCR. 10. selected genes, which were found to be differentially expressed on the microarrays, were further analyzed by quantitative real-time RT-PCR. Relative expression is given based on normalization to &#946;-actin. A standard curve for &#946;-actin was included in each experiment and data represents three independent experiments each done in triplicates. The primers used are given in Supplemental Table 2</p>
###xml 761 1233 761 1227 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="64">Verification of gene expression changes by quantitative real-time PCR. 10. selected genes, which were found to be differentially expressed on the microarrays, were further analyzed by quantitative real-time RT-PCR. Relative expression is given based on normalization to &#946;-actin. A standard curve for &#946;-actin was included in each experiment and data represents three independent experiments each done in triplicates. The primers used are given in Supplemental Table 2</p></caption>
###xml 1233 1233 1227 1227 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="360_2007_201_Fig4_HTML" id="MO4"/>
###xml 755 1233 755 1227 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="64">Verification of gene expression changes by quantitative real-time PCR. 10. selected genes, which were found to be differentially expressed on the microarrays, were further analyzed by quantitative real-time RT-PCR. Relative expression is given based on normalization to &#946;-actin. A standard curve for &#946;-actin was included in each experiment and data represents three independent experiments each done in triplicates. The primers used are given in Supplemental Table 2</p></caption><graphic position="anchor" xlink:href="360_2007_201_Fig4_HTML" id="MO4"/></fig>
###xml 269 278 <span type="species:ncbi:7955">zebrafish</span>
To further verify our results, we used quantitative real-time PCR for 10 of the transcripts. We confirmed the gene expression changes found in the microarray studies for these 5 up- and 5 downregulated transcripts by this independent method (Fig. 4). The downregulated zebrafish genes tested were: c-fos, phox1, creatine kinase (ckm3), nebulin, titin, and the upregulated genes tested were: metallothionein, pyruvate kinase, apoptosis inhibitor 5, igfbp1 and notch-2. The fold induction values were not always directly comparable to the array data but in all cases induction or reduction was confirmed. Quantitative differences between array data and qPCR results have been reported before (Meijer et al. 2005; Ton et al. 2003; van der Meer et al. 2005). Fig. 4Verification of gene expression changes by quantitative real-time PCR. 10. selected genes, which were found to be differentially expressed on the microarrays, were further analyzed by quantitative real-time RT-PCR. Relative expression is given based on normalization to beta-actin. A standard curve for beta-actin was included in each experiment and data represents three independent experiments each done in triplicates. The primers used are given in Supplemental Table 2
###end p 63
###begin p 64
Verification of gene expression changes by quantitative real-time PCR. 10. selected genes, which were found to be differentially expressed on the microarrays, were further analyzed by quantitative real-time RT-PCR. Relative expression is given based on normalization to beta-actin. A standard curve for beta-actin was included in each experiment and data represents three independent experiments each done in triplicates. The primers used are given in Supplemental Table 2
###end p 64
###begin title 65
###xml 141 150 <span type="species:ncbi:7955">zebrafish</span>
Assessment of microarray results for the IGF/PI3K/Akt pathway by comparing phospho-Akt levels in cardiac myocytes of normoxic versus hypoxic zebrafish hearts
###end title 65
###begin p 66
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 719 720 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 1565 1566 1565 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 1569 1570 1569 1570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1683 1689 1683 1689 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 1879 1880 1879 1880 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1893 1894 1893 1894 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2047 2048 2047 2048 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2264 2265 2264 2265 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2379 2380 2379 2380 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1689 2381 1689 2381 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="67">Effects of chronic constant hypoxia of the activation of Akt in zebrafish cardiac myocytes. Immunohistochemical staining of phospho-Akt in cardiac myocytes of zebrafish raised under hypoxic <bold>a</bold> or normoxic <bold>b</bold> conditions. Specificity is shown by the control sections obtained from normoxic fish which were not incubated with primary antibody against phospho-Akt <bold>c</bold>. For both cardiac myocytes and skeletal muscle fibers, the absorbance of the BM Purple is linearly increasing at the same relative rate with the incubation time with BM Purple AP substrate at the same relative rate <bold>d</bold>. Mean absorbances of phospho-Akt staining (+S.E.M.) from normoxic and hypoxic cardiac myocytes was not different <bold>e</bold>)</p>
###xml 1689 2381 1689 2381 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="67">Effects of chronic constant hypoxia of the activation of Akt in zebrafish cardiac myocytes. Immunohistochemical staining of phospho-Akt in cardiac myocytes of zebrafish raised under hypoxic <bold>a</bold> or normoxic <bold>b</bold> conditions. Specificity is shown by the control sections obtained from normoxic fish which were not incubated with primary antibody against phospho-Akt <bold>c</bold>. For both cardiac myocytes and skeletal muscle fibers, the absorbance of the BM Purple is linearly increasing at the same relative rate with the incubation time with BM Purple AP substrate at the same relative rate <bold>d</bold>. Mean absorbances of phospho-Akt staining (+S.E.M.) from normoxic and hypoxic cardiac myocytes was not different <bold>e</bold>)</p></caption>
###xml 2381 2381 2381 2381 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="360_2007_201_Fig5_HTML" id="MO5"/>
###xml 1683 2381 1683 2381 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="67">Effects of chronic constant hypoxia of the activation of Akt in zebrafish cardiac myocytes. Immunohistochemical staining of phospho-Akt in cardiac myocytes of zebrafish raised under hypoxic <bold>a</bold> or normoxic <bold>b</bold> conditions. Specificity is shown by the control sections obtained from normoxic fish which were not incubated with primary antibody against phospho-Akt <bold>c</bold>. For both cardiac myocytes and skeletal muscle fibers, the absorbance of the BM Purple is linearly increasing at the same relative rate with the incubation time with BM Purple AP substrate at the same relative rate <bold>d</bold>. Mean absorbances of phospho-Akt staining (+S.E.M.) from normoxic and hypoxic cardiac myocytes was not different <bold>e</bold>)</p></caption><graphic position="anchor" xlink:href="360_2007_201_Fig5_HTML" id="MO5"/></fig>
###xml 1753 1762 <span type="species:ncbi:7955">zebrafish</span>
###xml 1848 1857 <span type="species:ncbi:7955">zebrafish</span>
The IGF/PI3K/Akt pathway is activated by IGFs, which are antagonized by the IGFbp1. To test the effects of the upregulation of both IGF-2 and IGFbp1, we assayed phospo-Akt levels in cardiac myocytes and showed that phospho-Akt levels were not different between normoxic and hypoxic cells. Figure 5 shows cytoplasmic immunohistochemical staining of phospho-Akt. The antibody recognizes phosphorylated and detects the phospho-Akt1/2/3 forms. The incubation times for the primary and secondary antibody as well as the BM Purple were optimized to obtain a good signal to noise ratio. Absorbances were linearly related to the time of incubation with the primary and secondary antibodies as well as that of BM Purple. Figure 5d shows for normoxic fish the absorbance values of the phospho-Akt staining in cardiac myocytes as well as skeletal muscle fibers from the tail as a function of the incubation time with BM Purple AP substrate. The absorbance values for the heart are considerably higher than for the skeletal muscle fibers. However, for both cardiac and skeletal muscle the absorbances are linearly related with the incubation time with BM Purple AP substrate and increase at the same relative rate. This implicates that the absorbance of BM Purple after 45 min incubation with BM Purple AP substrate did not reach saturation and therefore provides a semi-quantitative estimate of the phospho-Akt content in the cardiac myocytes. Absorbances of staining for phospho-Akt in normoxic and hypoxic cardiac myocytes were not shown to be significantly different (Fig. 5E, P < 0.48), which indicates that hypoxia did not change the activation of the Akt pathway in the cardiac myocytes. Fig. 5Effects of chronic constant hypoxia of the activation of Akt in zebrafish cardiac myocytes. Immunohistochemical staining of phospho-Akt in cardiac myocytes of zebrafish raised under hypoxic a or normoxic b conditions. Specificity is shown by the control sections obtained from normoxic fish which were not incubated with primary antibody against phospho-Akt c. For both cardiac myocytes and skeletal muscle fibers, the absorbance of the BM Purple is linearly increasing at the same relative rate with the incubation time with BM Purple AP substrate at the same relative rate d. Mean absorbances of phospho-Akt staining (+S.E.M.) from normoxic and hypoxic cardiac myocytes was not different e)
###end p 66
###begin p 67
###xml 190 191 190 191 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 204 205 204 205 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 358 359 358 359 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 575 576 575 576 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 690 691 690 691 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 64 73 <span type="species:ncbi:7955">zebrafish</span>
###xml 159 168 <span type="species:ncbi:7955">zebrafish</span>
Effects of chronic constant hypoxia of the activation of Akt in zebrafish cardiac myocytes. Immunohistochemical staining of phospho-Akt in cardiac myocytes of zebrafish raised under hypoxic a or normoxic b conditions. Specificity is shown by the control sections obtained from normoxic fish which were not incubated with primary antibody against phospho-Akt c. For both cardiac myocytes and skeletal muscle fibers, the absorbance of the BM Purple is linearly increasing at the same relative rate with the incubation time with BM Purple AP substrate at the same relative rate d. Mean absorbances of phospho-Akt staining (+S.E.M.) from normoxic and hypoxic cardiac myocytes was not different e)
###end p 67
###begin title 68
Discussion
###end title 68
###begin p 69
In the aquatic environment, oxygen concentrations can often vary, and being able to adapt to changes in oxygen levels can be advantageous for the survival of aquatic animals. This might be in part the reason why some teleosts have developed the ability to withstand extreme hypoxic conditions.
###end p 69
###begin p 70
###xml 114 123 <span type="species:ncbi:7955">zebrafish</span>
In this study, we have focused on the long-term response to hypoxia in the fish heart. The hypothesis is that the zebrafish heart, in contrast to most mammalian hearts, which are characterized by relative intolerance to injury or the lack of oxygen, are able to adapt to extreme hypoxic conditions.
###end p 70
###begin p 71
###xml 473 478 473 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2000a</xref>
###xml 622 626 622 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2007</xref>
###xml 758 762 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2001</xref>
###xml 1280 1284 1280 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2002</xref>
###xml 1631 1635 1631 1635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2002</xref>
###xml 1659 1663 1659 1663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">2005</xref>
###xml 34 43 <span type="species:ncbi:7955">zebrafish</span>
###xml 1153 1162 <span type="species:ncbi:7955">zebrafish</span>
###xml 1294 1303 <span type="species:ncbi:7955">zebrafish</span>
###xml 2160 2172 <span type="species:ncbi:70862">teleost fish</span>
We showed that chronic hypoxia of zebrafish caused a smaller ventricular outflow tract, reduced lacunae and increased cardiac myocyte densities in the heart. These findings suggest that hypoxia induced an increase of the cardiac myocyte volume or at least did not result in a loss of cardiac myocytes. This is in contrast to mammals where tissue hypoxia in chronic heart failure leads to apoptosis and considerable losses of cardiac myocytes (see for review, Sabbah et al. 2000a). In mammals, compensation for this loss of cardiac myocytes occurs mainly by hypertrophy of the remaining cardiac myocytes (Ostadal and Kolar 2007), although regeneration of myocardium by proliferation of cardiac myocytes may occur also but to a limited extend (Beltrami et al. 2001). Our assay for phosho-Akt did not show any enhancement of Akt activity in response to the CCH, suggesting a lack of hypertrophic signaling via the phosphotadilinositol 3 kinase pathway. However, the density of cardiac myocyte nuclei increased by 50% during CCH, which indicates substantial proliferation of cardiac myocytes and/or nuclear hyperplasia. Recently, it has been shown that the zebrafish heart has the ability to regenerate from mechanical cardiac injury by proliferation of cardiac myocytes (Poss et al. 2002). If the zebrafish heart responds to chronic hypoxia in a similar way as to mechanical dissection, this will be beneficial in preventing apoptosis of cardiac myocytes as the diffusion distance for oxygen are not increased as during hypertrophy, which will help to prevent the development of anoxic cores in the cardiac myocytes (Des Tombe et al. 2002; van der Laarse et al. 2005). In the case that the increase in cardiac myocyte nuclear density during chronic hypoxia was due to nuclear hyperplasia and nuclear ploidy, the observed smaller ventricular outflow tract and reduced lacunae may have been the result of hypertrophy of the existing cardiac myocytes. The histological assay in this study does not clearly distinguish between hyperplasia and hypertrophy of cardiac myocytes. Future investigation of the mechanisms underlying the general morphological adaptations of teleost fish heart in response to CCH requires a nuclear stain in combination with a clear membrane stain, which allows determination of cell sizes in addition to counts of cardiac myocyte nuclei.
###end p 71
###begin p 72
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">1997</xref>
###xml 659 663 659 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2003</xref>
###xml 728 732 728 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">1993</xref>
###xml 887 891 887 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2000</xref>
###xml 234 243 <span type="species:ncbi:7955">zebrafish</span>
###xml 589 593 <span type="species:ncbi:10116">rats</span>
We were interested in the underlying gene expression changes of these adaptations. We found gene regulations in a transcriptional network of the serum response element (SRE), which are opposed to the ones described in mammals. In the zebrafish heart hypoxia repressed c-fos and phox1 expression. Both genes are important in the same transcriptional network, phox1 can transduce serum-responsive transcriptional activity to the c-fos (SRE) by interacting with serum response factor (SRF) (Simon et al. 1997). In mammals many studies showed increased expression of c-fos by hypoxia, e.g. in rats hypoxia induces c-fos expression in the LV and RV (Deindl et al. 2003) and the same held true in tissue culture cells (Webster et al. 1993). Interestingly, repression of c-fos by hypoxia has also been shown for the short-term response to anoxia in anoxia tolerant turtles (Greenway and Storey 2000). Is it possible that repression of c-fos and phox-1 are important adaptations in hypoxia tolerant animals?
###end p 72
###begin p 73
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2004</xref>
###xml 429 433 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2006</xref>
###xml 450 454 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2006</xref>
Several novel gene expression changes induced by CCH have been identified in this study (Table 2 and Supplemental Table 1). An example is the two Notch receptors, notch-2 and notch-3, whose expression were induced by CCH. Notch receptors have been shown to be important for heart patterning and differentiation (Armstrong and Bischoff 2004), cell fate determination and self renewal of stem cells (Androutsellis-Theotokis et al. 2006; Silvia Bianchi 2006) but so far have not been linked to the hypoxic response.
###end p 73
###begin p 74
###xml 254 258 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">1996</xref>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2002</xref>
###xml 641 645 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2005</xref>
###xml 1074 1078 1062 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2002</xref>
###xml 1376 1377 1364 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1428 1429 1416 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1606 1610 1594 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">2001</xref>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 684 693 <span type="species:ncbi:7955">zebrafish</span>
###xml 915 920 <span type="species:ncbi:9606">Human</span>
Several genes with links to human heart pathology were found to be upregulated in this study. Among these were two markers for myocardial infarction, complement component C9 and haptoglobin. C9 is used as a marker for myocardial infarction (Doran et al. 1996) and a polymorphism for haptoglobin predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction (Levy et al. 2002). We also observed increased expression of fetuin-alpha, a circulating calcium-regulatory glycoprotein that inhibits vascular calcification. Low fetuin-alpha levels have been associated with heart failure in mice (Merx et al. 2005). Upregulation of fetuin-alpha in the zebrafish heart could help to better tolerate CCH. Selenoprotein P (SEPP1) is a heparin-binding protein that appears to be associated with endothelial cells and has been implicated as an oxidant defense in the extracellular space. Human populations that are selenium deficient are susceptible to the development of Keshan disease, a potentially fatal form of cardiomyopathy (Nezelof et al. 2002). SEPP1 expression was found to be increased in our study indicating a potential protective mechanism against oxidative stress in the heart. This was further supported by the increased expression observed for several genes important for the protection against reactive oxygen species (ROS) (Table 2). Among them were metallothionein and glutathione S-transferase, which are both known ROS scavengers. Metallothionein has further been described to be protective against hypoxia-induced apoptosis when overexpressed (Wang et al. 2001). Our findings suggest ROS protection as an important adaptation to CCH in the fish heart.
###end p 74
###begin p 75
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2006</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 594 599 594 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2005b</xref>
###xml 734 738 734 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1996</xref>
###xml 760 764 760 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">1996</xref>
###xml 1536 1540 1536 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2006</xref>
###xml 1741 1745 1741 1745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2002</xref>
###xml 1770 1771 1770 1771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1809 1813 1809 1813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2005</xref>
###xml 1849 1853 1849 1853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2006</xref>
###xml 1869 1873 1869 1873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">2007</xref>
###xml 296 299 <span type="species:ncbi:10116">rat</span>
###xml 471 480 <span type="species:ncbi:7955">zebrafish</span>
###xml 1999 2008 <span type="species:ncbi:7955">zebrafish</span>
Furthermore, our data show for the first time that CCH simultaneously induced upregulation of IGF-2 and the insulin-like growth factor binding protein 1 (IGFbp1). In isolated cardiomyoblasts, angiotensin II stimulates IGF-2 expression which is involved in the induction of apoptotic signaling in rat hearts (Lee et al. 2006). We have observed here both angiotensin and IGF-2 upregulation (Table 2). The upregulation of IGFbp1 seems to be a general response to hypoxia in zebrafish embryos, where it mediates hypoxia-induced embryonic growth retardation and developmental delay (Kajimura et al. 2005b). IGFbp1 is a secreted protein, which binds to IGFs in the extracellular environment and prevents receptor activation (Florini et al. 1996; Stewart and Rotwein 1996). Here, IGFbp1 by binding IGF-2, may have prevented both cardioprotective as well as apoptotic effects of enhanced IGF-2 expression. To test the effects of the upregulation of both IGF-2 and IGFbp1, we assayed phospo-Akt levels in cardiac myocytes and showed that phospho-Akt levels were not different between normoxic and hypoxic cells. This suggests that either hypoxia-induced changes in mRNA expression did not occur at the protein level or the effects of increased IGF-2 expression on the IGF-1 receptor (which can be activated by IGF-2) were blunted by the upregulation of the IGFbp1. The fact that we did not observe increased phospho-Akt levels suggests a lack of hypertrophic signaling as enhanced phospho-Akt is required for cardiac hypertrophy (DeBosch et al. 2006). This may be beneficial for the heart as hypertrophy of cardiac myocytes implicates an increase in the diffusion distance for oxygen which may cause the development of anoxic cores (Des Tombe et al. 2002), release of cytochrome c (van Beek-Harmsen and van der Laarse 2005) and production of ROS (Lee et al. 2006; Powers et al. 2007) and eventually causing apoptosis of cardiac myocytes. The importance of the IGF-2/IGFbp1 signaling in the protection of the zebrafish heart and its underlying mechanisms remain to be determined.
###end p 75
###begin p 76
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2005</xref>
###xml 774 778 774 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2005</xref>
###xml 816 817 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
The gene expression changes we observed for the specific response to CCH in the fish heart were very different from the responses we observed in an earlier study in the gills (van der Meer et al. 2005). Under the same criteria as used in this study, we found that the majority of differentially regulated genes in the gills showed a decrease in gene expression (68.1% or 250 genes in total) in comparison to genes, which showed increased expression levels (31.9% or 117 genes in total). This is opposed to the heart where 69.1% of differentially regulated genes (260 genes in total) showed increased and 30.9% (116 in total) decreased expression levels. Many genes linked to protein synthesis showed a similar trend, and were downregulated in the gills (van der Meer et al. 2005) and upregulated in the heart (Table 2). The major differences observed in gene regulation between heart and gills point to very tissue specific responses to CCH. A list of genes identified in both studies, as identified by a direct comparison based on Accession numbers and old Unigenes numbers are shown in Supplemental Data 3.
###end p 76
###begin p 77
###xml 385 389 385 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2003</xref>
Teleosts have developed specific phenotypic adaptations to low oxygen, due to the natural occurrence of hypoxia in the water environment. Here, we identified the changes in gene expression as well as associated morphological changes of the fish heart to hypoxia. We observed repression of c-fos, which differs compared to the described increase in expression in mammals (Deindl et al. 2003). Other changes found like upregulation of the two Notch receptors have not been described before to the best of our knowledge. Similarly, the simultaneous increase in expression of IGF-2 and IGFbp1 has not been shown. The changes identified here can contribute to the ability of teleosts to adapt to severe hypoxia (for example, the upregulation of fetuin-alpha and sepp1 levels). Future functional studies are warranted to validate the role of the identified genes in cardiac protection to hypoxia.
###end p 77
###begin title 78
Electronic supplementary material
###end title 78
###begin p 79
Below is the link to the electronic supplementary material. 
###end p 79
###begin p 80
(XLS 76 kb)
###end p 80
###begin p 81
(DOC 33 kb)
###end p 81
###begin p 82
(DOC 57 kb)
###end p 82
###begin p 83
(XLS 52 kb)
###end p 83
###begin p 84
We would like to thank Guido van den Thillart for essential help with the hypoxia set up, Gerda Lamers for intensive help with EM microscopy. Maximilian Corredor for his help with data analysis and software, Carlo Rutjes and Patrick Niemantsverdriet for animal care. Dr. Willem van der Laarse and Dr. Siona Slob are acknowledged for their assistance in the optimization of immunohistochemistry. This work was in part supported by a European Commission 6th Framework Programme grant (contract LSHG-CT-2003-503496, ZF-Models) and a grant from the Portuguese foundation for Science and Technology (SFRH/BD/27262/2006). All experiments comply with the current laws of the Netherlands.
###end p 84
###begin title 85
References
###end title 85
###begin article-title 86
Heart valve development: endothelial cell signaling and differentiation
###end article-title 86
###begin article-title 87
###xml 113 116 <span type="species:ncbi:10116">rat</span>
Insulin-like growth factor II is induced during wound repair following hypoxic-ischemic injury in the developing rat brain
###end article-title 87
###begin article-title 88
###xml 14 19 <span type="species:ncbi:9606">human</span>
Evidence that human cardiac myocytes divide after myocardial infarction
###end article-title 88
###begin article-title 89
Physiology and pathology of notch signalling system
###end article-title 89
###begin article-title 90
Akt1 is required for physiological cardiac growth
###end article-title 90
###begin article-title 91
###xml 67 70 <span type="species:ncbi:10116">rat</span>
Effect of intermittent high altitude hypoxia on gene expression in rat heart and lung
###end article-title 91
###begin article-title 92
###xml 79 82 <span type="species:ncbi:10116">rat</span>
Calibrated histochemistry applied to oxygen supply and demand in hypertrophied rat myocardium
###end article-title 92
###begin article-title 93
Detection of myocardial infarction by immunohistological staining for C9 on formalin fixed, paraffin wax embedded sections
###end article-title 93
###begin article-title 94
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
Gene expression and phenotypic characterization of mouse heart after chronic constant or intermittent hypoxia
###end article-title 94
###begin article-title 95
Growth hormone and the insulin-like growth factor system in myogenesis
###end article-title 95
###begin article-title 96
###xml 63 84 <span type="species:ncbi:8222">Gillichthys mirabilis</span>
Hypoxia-induced gene expression profiling in the euryoxic fish Gillichthys mirabilis
###end article-title 96
###begin article-title 97
Mitogen-activated protein kinases and anoxia tolerance in turtles
###end article-title 97
###begin article-title 98
From the Cover: Insulin-like growth factor-binding protein-1 (IGFBP-1) mediates hypoxia-induced embryonic growth and developmental retardation
###end article-title 98
###begin article-title 99
Insulin-like growth factor-binding protein-1 (IGFBP-1) mediates hypoxia-induced embryonic growth and developmental retardation
###end article-title 99
###begin article-title 100
Molecular mechanisms of cardiac protection by adaptation to chronic hypoxia
###end article-title 100
###begin article-title 101
###xml 87 90 <span type="species:ncbi:10116">rat</span>
Roles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation
###end article-title 101
###begin article-title 102
Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study
###end article-title 102
###begin article-title 103
###xml 33 42 <span type="species:ncbi:7955">zebrafish</span>
###xml 92 113 <span type="species:ncbi:1781">Mycobacterium marinum</span>
Transcriptome profiling of adult zebrafish at the late stage of chronic tuberculosis due to Mycobacterium marinum infection
###end article-title 103
###begin article-title 104
###xml 110 114 <span type="species:ncbi:10090">mice</span>
Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-a-deficient mice
###end article-title 104
###begin article-title 105
Multifocal myocardial necrosis: a distinctive cardiac lesion in cystic fibrosis, lipomatous pancreatic atrophy, and keshan disease
###end article-title 105
###begin article-title 106
Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene
###end article-title 106
###begin article-title 107
###xml 22 31 <span type="species:ncbi:7955">zebrafish</span>
Heart regeneration in zebrafish
###end article-title 107
###begin article-title 108
Oxidative stress and disuse muscle atrophy
###end article-title 108
###begin article-title 109
Cell death, tissue hypoxia and the progression of heart failure
###end article-title 109
###begin article-title 110
Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1
###end article-title 110
###begin article-title 111
Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology
###end article-title 111
###begin article-title 112
Chronic myocardial hypoxia increases nitric oxide synthase and decreases caveolin-3
###end article-title 112
###begin article-title 113
Fibrinogen stimulates in vitro angiogenesis by choroidal endothelial cells via autocrine VEGF
###end article-title 113
###begin article-title 114
Protein and DNA contact surfaces that mediate the selective action of the Phox1 homeodomain at the c-fos serum response element
###end article-title 114
###begin article-title 115
###xml 37 49 <span type="species:ncbi:217509">crucian carp</span>
Maintained cardiac pumping in anoxic crucian carp
###end article-title 115
###begin article-title 116
Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors
###end article-title 116
###begin article-title 117
AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal
###end article-title 117
###begin article-title 118
###xml 27 36 <span type="species:ncbi:7955">zebrafish</span>
Gene expression profile of zebrafish exposed to hypoxia during development
###end article-title 118
###begin article-title 119
Immunohistochemical determination of cytosolic cytochrome C concentration in cardiomyocytes
###end article-title 119
###begin article-title 120
###xml 53 60 <span type="species:ncbi:8355">Xenopus</span>
###xml 88 91 <span type="species:ncbi:10116">rat</span>
Krogh's diffusion coefficient for oxygen in isolated Xenopus skeletal muscle fibers and rat myocardial trabeculae at maximum rates of oxygen consumption
###end article-title 120
###begin article-title 121
###xml 94 103 <span type="species:ncbi:7955">zebrafish</span>
Gene expression profiling of the long-term adaptive response to hypoxia in the gills of adult zebrafish
###end article-title 121
###begin article-title 122
###xml 0 9 <span type="species:ncbi:7955">Zebrafish</span>
Zebrafish cypher is important for somite formation and heart development
###end article-title 122
###begin article-title 123
Inhibition of hypoxia/reoxygenation-induced apoptosis in metallothionein-overexpressing cardiomyocytes
###end article-title 123
###begin article-title 124
Induction and nuclear accumulation of fos and jun proto-oncogenes in hypoxic cardiac myocytes
###end article-title 124
###begin article-title 125
###xml 88 93 <span type="species:ncbi:4932">yeast</span>
Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast
###end article-title 125
###begin p 126
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 126
###begin p 127
The online version of this article (doi:10.1007/s00360-007-0201-4) contains supplementary material, which is available to authorized users.
###end p 127

